Page last updated: 2024-12-05

methylene blue

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6099
CHEBI ID6872
SCHEMBL ID1351
MeSH IDM0013629

Synonyms (207)

Synonym
AC-15225
HMS2598O03
nsc-617593
methylene blue usp xii (medicinal)
basic blue 9
c.i. 52 015
methylene blue fz
methylene blue i (medicinal)
external blue 1
methylene blue zinc free
methylene blue usp (medicinal)
mitsui methylene blue
methylene blue iad
tetramethylthionine chloride
x 138
m-b tabs
sandocryl blue brl
3,7-bis(dimethylamino)phenazathionium chloride
methylthionium chloride
phenothiazin-5-ium,7-bis(dimethylamino)-, chloride
yamamoto methylene blue zf
methylene blue g
swiss blue
modr methylenova
methylene blue gz
methylene blue bb
methylene blue sp
methylene blue sg
methylene blue d
methylene blue bba
methylene blue hgg
calcozine blue zf
methylene blue bx
methylene blue zx
aizen methylene blue bh
methylene blue jfa
hidaco methylene blue salt free
leather pure blue hb
methylene blue 2bf
wln: t c666 bs ey inj euk1&1 mn1&1 &g &421
methylene blue bp
methylene blue bd
d and c blue number 1
methylene blue nf (medicinal)
yamamoto methylene blue b
3h-phenothiazine, 3-methochloride
ext d and c blue no. 1
methylene blue b
methylene blue chloride
methylene blue nz
methylene blue a
d and c blue no. 1
methylene blue bb (zinc free)
methylene blue n
methylene blue 2b
methylene blue zf
methylene blue bz
chromosmon
schultz no. 1038
3,7-bis(dimethylamino)phenothiazin-5-ium chloride
methylene blue chloride (biological stain)
methylene blue 2bn
nsc-3089
methylene blue (medicinal)
aizen methylene blue fz
methylene blue 2bp
methylene blue bpc
methylenium ceruleum
tetramethylene blue
smr000304367
MLS000719838
PRESTWICK_326
ci basic blue 9
epa pesticide chemical code 039505
ccris 833
methylthionini chloridum
urolene blue
metiltioninio cloruro [dcit]
nsc 215213
caswell no. 567
methylthioninii chloridum [inn-latin]
modr zasadita 9 [czech]
methylenum coeruleum
modr methylenova [czech]
einecs 200-515-2
chlorure de methylthioninium [inn-french]
modr rozpoustedlova 8 [czech]
cloruro de metiltioninio [inn-spanish]
methylenblau [german]
hsdb 1405
ceruleum methylenum
C00220
methylthioninium chloride
methylene blue
61-73-4
c.i. basic blue 9
phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride
c.i. 52015
3h-phenothiazine, 7-(dimethylamino)-3-(methylimino)-, 3-methochloride
nsc617593
nsc-215213
blue n, methylene
blue, swiss
blue 9, basic
blue, methylene
methylenblau
azul de metileno
cloruro de metiltioninio
bleu de methylene
CHEBI:6872 ,
chlorure de methylthioninium
methylene blue anhydrous
methylthioninii chloridum
solvent blue 8
M-3598
n-[7-(dimethylamino)-3h-phenothiazin-3-ylidene]-n-methylmethanaminium chloride
STK018918
A0574
methylene azure ii
AKOS000486124
trx0014
ci-52015
3,7-bis(dimethylamino)-5-phenothiazinium chloride
M0501
cas-61-73-4
NCGC00255351-01
dtxsid0023296 ,
dtxcid803296
tox21_302087
tox21_112497
nsc759135
pharmakon1600-01505444
S4535
metiltioninio cloruro
modr zasadita 9
rember
8nap7826ub ,
methylthioninium chloride [inn]
modr rozpoustedlova 8
phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride (1:1)
provayblue
unii-8nap7826ub
FT-0622580
AKOS015916406
lowacryl blue 9
methylthioninium chloride [mart.]
trx-0014
methylthioninium chloride proveblue
methylene blue [mi]
methylthioninium chloride [ep impurity]
methylthioninium chloride anhydrous [who-ip]
methylthioninium chloride [ema epar]
methylthioninii chloridum anhydrous [who-ip latin]
methylene blue [hsdb]
methylthioninium chloride [who-dd]
basic blue 9 [inci]
HY-14536
SCHEMBL1351
tox21_112497_1
3,7-bis(dimethylamino)-phenothiazin-5-ium chloride salt
CXKWCBBOMKCUKX-UHFFFAOYSA-M
c.i. solvent blue 8
methylthioninium chloratum
mfcd00012111
DB09241
97130-83-1
ci no 52015
M2392
1341-90-8
6476-03-5
105504-42-5
12262-49-6
basic blue 9;tetramethylthionine chloride
n-(7-(dimethylamino)-3h-phenothiazin-3-ylidene)-n-methylmethanaminium chloride
Q422134
4-(1-hydroxy-ethyl)-benzoicacid
methylene blue usp
AS-35256
152071-32-4
CCG-267696
methylene blue (c.i. 52015) biochemica
SY076497
n-(7-(dimethylamino)-3h-phenothiazin-3-ylidene)-n-methylmethanaminiumchloride
[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride
v04cg05
methylthioninii chloridum (latin)
methylthioninii chloridum anhydrous
vitableu
blu di metilene
methylthioninium chloride (ep impurity)
chlorure de methylthioninium (inn-french)
methylene blue (usp monograph)
methylene blue (ii)
methylthioninium chloride anhydrous
usepa/opp pesticide code: 039505.
colour index no. 52015
methylenum caeruleum
azul metile
methylthioninium chloride (mart.)
methylene blue (iarc)
v03ab17
desmoidpillen
collubleu
methylthioninii chloridum trihydrate
EN300-6504462
3,7-bis(dimethylamino)-5lambda4-phenothiazin-5-ylium chloride
Z1954806063

Research Excerpts

Overview

Methylene blue (MB) is a phenothiazine dye that is widely used in medicine and clinical trials for the treatment of Alzheimer's disease. It is also an important compound in textile and wood processing industries as well as in medical research for combating malaria parasites.

ExcerptReferenceRelevance
"Methylene blue is a phenothiazine dye that is widely used in medicine and clinical trials for the treatment of Alzheimer's disease. "( [Effect of methylene blue and its metabolite - azure I - on bioenergetic parameters of intact mice brain mitochondria].
Gureev, AP; Popov, VN; Potanina, DV; Samoylova, NA, 2021
)
2.45
"Methylene blue (MB) is an important compound in textile and wood processing industries as well as in medical research for combating malaria parasites. "( Intelligent modeling of dye removal by aluminized activated carbon.
Lateef, SA; Oyehan, IA; Oyehan, TA; Saleh, TA, 2022
)
2.16
"Methylene blue (MB) is a light-activated dye with demonstrated antimicrobial activity used to sterilize blood plasma."( Exploring inactivation of SARS-CoV-2, MERS-CoV, Ebola, Lassa, and Nipah viruses on N95 and KN95 respirator material using photoactivated methylene blue to enable reuse.
Harcourt, BH; Kabra, KB; Montgomery, JM; Mores, CN; Scholte, FEM; Spiropoulou, CF; Tritsch, SR, 2022
)
1.65
"Methylene blue (MB) is an exogenous contrast agent that has the potential to assist with visualization and penetration challenges in photoacoustic imaging. "( Dual-wavelength photoacoustic atlas method to estimate fractional methylene blue and hemoglobin contents.
Gonzalez, E; Lediju Bell, M, 2022
)
2.4
"Methylene blue (MB) is a dye used for histology with clinical importance and intercalates into nucleic acids. "( Improved Bladder Tumor RNA Isolation from Archived Tissues Using Methylene Blue for Normalization, Multiplex RNA Hybridization, Sequencing and Subtyping.
Angeloni, M; Bahlinger, V; Beckmann, MW; Brandl, L; Eckstein, M; Ekici, AB; Ferrazzi, F; Gloßner, L; Hartmann, A; Köhler, SA; Strick, R; Strissel, PL, 2022
)
2.4
"Methylene blue is an efficient, feasible, and safe dye for SLN mapping in early-stage gynecological cancer."( Use of methylene blue dye for sentinel lymph node mapping in early-stage gynecological cancers - An option for low resource settings.
Agrawal, S; Singh, N,
)
2.03
"Methylene blue (MB) is an effective treatment for methemoglobinemia, ifosfamide-induced encephalopathy, cyanide poisoning, and refractory vasoplegia. "( Adverse effects of methylene blue in peripheral neurons: An
Banik, RK; Horrmann, A; Johns, ME; Khasabova, IA; Mohamed, S; Simone, DA; Sohail, A; Uhelski, ML, 2022
)
2.49
"Methylene blue dye is a commonly used agent in a wide range of clinical diagnostic procedures and has been used by other investigators to perform this procedure."( Use of methylene blue dye for lymphatic basin mapping and sentinel lymph node biopsy in breast cancer patients in Enugu, Nigeria.
Ezeome, ER; Okoye, CL, 2022
)
1.9
"Methylene blue (MB) is a common multifunctional indicator, which can be applied as a quencher for electrochemiluminescence (ECL) analysis as well as a classical redox probe. "( Dual-quenching effects of methylene blue on the luminophore and co-reactant: Application for electrochemiluminescent-electrochemical ratiometric zearalenone detection.
Bi, X; Li, L; Liu, X; Luo, L; You, T, 2023
)
2.65
"Methylene blue is a promising and recommended drug for the patients undergoing the surgeries of relief obstructive jaundice during peri-operation management."( Prophylactic Administration with Methylene Blue Improves Hemodynamic Stabilization During Obstructive Jaundice-Related Diseases' Operation: a Blinded Randomized Controlled Trial.
Chen, L; Gao, X; Gu, J; Huang, J; Li, Y; Lu, K; Ma, D; Ning, J; Wang, M; Wen, J; Xiang, L; Yang, Z; Yi, B; Zhao, H, 2023
)
2.63
"Methylene blue (MB) is an alternative for combating drug-resistant malaria parasites. "( The activity of methylene blue against asexual and sexual stages of
Carlos Salazar-Alvarez, L; Clarys Baia-da-Silva, D; Costa Ferreira Neves, J; Costa Pinto Lopes, S; Dos Santos Bastos, I; Fabbri, C; Guimarães Costa, A; Marcelo Monteiro, W; Oliveira Trindade, A; Quaresma Ramos, G; Trindade Maranhão Costa, F; Vinicius Guimarães Lacerda, M, 2023
)
2.7
"Methylene blue (MB) is a conventional lymphatic tracer. "( Application of indocyanine green lymphography combined with methylene blue staining in lymphaticovenular anastomosis of lower limb vessels: A prospective study.
Guo, X; Liu, B; Ma, G; Tang, Y; Zhou, X, 2023
)
2.6
"Methylene blue is an effective treatment of refractory hypotension related to cardiac surgery requiring cardiopulmonary bypass."( Methylene Blue as an Adjunct to Treat Vasoplegia in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass: A Literature Review.
Arevalo, VN; Bullerwell, ML, 2018
)
2.64
"Methylene blue is a highly effective agent but contraindicated in severe G6PD deficiency."( Naphthalene Toxicity in Clinical Practice.
Pannu, AK; Singla, V, 2020
)
1.28
"Methylene blue is an inhibitor of MAO-A, while azure B, the major metabolite of methylene blue, and various other structural analogues retain the ability to inhibit MAO-A."( Monoamine oxidase inhibition by selected dye compounds.
de Beer, F; Petzer, A; Petzer, JP, 2020
)
1.28
"Methylene blue (MB) is an antioxidant that ameliorates ischemia-reperfusion injury in several tissues. "( Effects of Methylene Blue on Ovarian Torsion-Detorsion Injury in a Rat Model.
Erbas, O; Hortu, I; Ilgen, O; Karadadas, N; Ozceltik, G; Yigitturk, G, 2020
)
2.39
"Methylene blue is a commonly used medicine, but it is rarely used in clinical practice as a photosensitizer."( Treatment of infected wounds with methylene blue photodynamic therapy: An effective and safe treatment method.
Dong, L; He, X; Li, X; Lu, Y; Shen, X; Zhang, W; Zhao, C, 2020
)
1.56
"Methylene blue (MB) is a blue cationic thiazine dye and currently used in different medical settings. "( Methylene blue induces an analgesic effect by significantly decreasing neural firing rates and improves pain behaviors in rats.
Han, HC; Lee, SW; Moon, SW; Park, JS; Suh, HR, 2021
)
3.51
"Methylene blue (MB) is a century-old medicine, a laboratory dye, and recently shown as a premier antioxidant that combats ROS-induced cellular aging in human skins. "( Ultraviolet radiation protection potentials of Methylene Blue for human skin and coral reef health.
Arya, C; Cao, K; Kordi, JE; Mao, X; Trappio, M; Xiong, ZM, 2021
)
2.32
"Methylene blue is an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved drug with an excellent safety profile. "( Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro.
Cagno, V; Cerny, A; Cerny, E; Cerny, T; Medaglia, C; Tapparel, C; Zwygart, AC, 2021
)
3.51
"Methylene blue is a phenothiazine dye, which in combination with visible light has virucidal and bactericidal properties, disrupting the replication of a broad range of enveloped viruses and some non-enveloped viruses. "( International, prospective haemovigilance study on methylene blue-treated plasma.
Megalou, A; Noens, L; Qureshi, H; Vilariño, MD, 2017
)
2.15
"Methylene blue is a chromophore dye known for its photosensitizing properties. "( Histological Features of Methylene Blue-Induced Phototoxicity Administered in the Context of Parathyroid Surgery.
Alarcon, L; Ffolkes, L; Kurzepa, M; Maguire, CA; Ostlere, L; Samarasinghe, V; Sharma, A; Singh, M, 2017
)
2.2
"Methylene blue (MB) is an older drug that has been recently proven to exert extraordinary neuroprotective effects in several brain insults."( Methylene blue attenuates neuroinflammation after subarachnoid hemorrhage in rats through the Akt/GSK-3β/MEF2D signaling pathway.
Cao, S; Chen, G; Chen, J; Fan, L; Feng, M; Gu, C; Li, J; Li, T; Peng, Y; Shen, Y; Wang, L; Wang, Z; Xu, H; Yan, F, 2017
)
2.62
"Methylene blue (MB) is a photosensitizer used in photodynamic therapy (PDT) to treat colorectal cancer tumors and leishmaniasis infection. "( Investigation of Methylene Blue Release from Functional Polymeric Systems Using Dielectric Analysis.
Andrews, GP; Borghi-Pangoni, FB; Bruschi, ML; Jones, DS; Junqueira, MV; Yu, T, 2018
)
2.26
"Methylene blue is a redox drug with reported protective effects mainly on brain mitochondria."( Methylene blue improves mitochondrial respiration and decreases oxidative stress in a substrate-dependent manner in diabetic rat hearts.
Dănilă, MD; Duicu, OM; Muntean, DM; Petruş, A; Privistirescu, A; Raţiu, CD; Sturza, A; Wolf, A, 2017
)
2.62
"Methylene blue (MB) is a well-established drug with a long history of use, owing to its diverse range of use and its minimal side effect profile. "( From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue.
Lu, Y; Tucker, D; Zhang, Q, 2018
)
2.16
"Methylene blue is a widely used treatment for ifosfamide neurotoxicity. "( Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.
Brohl, AS; Gangadhara, S; Ludlow, S; Nanjappa, S; Snyder, M,
)
1.8
"Methylene blue (MB) is a promising prodrug to treat mitochondrial dysfunctions that is currently being used in clinical trials for Alzheimer's disease. "( Methylene blue does not bypass Complex III antimycin block in mouse brain mitochondria.
Gureev, AP; Popov, VN; Shaforostova, EA; Starkov, AA, 2019
)
3.4
"Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. "( Methylene Blue in the Treatment of Neuropsychiatric Disorders.
Alda, M, 2019
)
3.4
"Methylene blue (MB) is a synthetic phenothiazine dye that, in the last years, has generated much debate about whether it could be a useful therapeutic drug for tau-related pathologies, such as Alzheimer's disease (AD). "( Methylene Blue Blocks and Reverses the Inhibitory Effect of Tau on PMCA Function.
Berrocal, M; Caballero-Bermejo, M; Gutierrez-Merino, C; Mata, AM, 2019
)
3.4
"Methylene blue (MB) acts as a photosensitizer and after excitation by visible light (VL) produces reactive oxygen species that result in oxidative damage to DNA."( Reduced host cell reactivation of oxidatively damaged DNA in ageing human fibroblasts.
Leach, DM; Rainbow, AJ; Zacal, NJ, 2013
)
1.11
"Methylene blue is an agent thought to help reverse the effects of methemoglobinemia by facilitating the methemoglobin reductase system."( Methemoglobinemia in bronchoscopy: a case series and a review of the literature.
Bowling, M; Brown, C, 2013
)
1.11
"Methylene blue is a cationic thiazine dye useful in staining parathyroid glands during surgical resection. "( Methylene blue encephalopathy: a case report and review of published cases.
Baughman, J; Gerard, W; Shopes, E, 2013
)
3.28
"Methylene blue (MB) is a phenothiazinium dye that has shown promising results in photodynamic therapy treatment."( Molecular dynamics simulations of binding modes between methylene blue and DNA with alternating GC and AT sequences.
González, L; Nogueira, JJ, 2014
)
1.37
"Methylene blue (MB) is an approved human agent for IV and oral use, and is already being investigated for oral treatment of uncomplicated malaria."( Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria.
Berman, J; Im-Erbsin, R; Li, Q; Obaldia, N; Ohrt, C; Xie, L, 2014
)
1.43
"Methylene blue (MB) is a well-known photosensitizer used mostly for antimicrobial photodynamic therapy (APDT). "( Urea enhances the photodynamic efficiency of methylene blue.
Baptista, MS; Coutinho-Neto, MD; Junqueira, HC; Maciel, C; Nuñez, SC; Ribeiro, MS; Yoshimura, TM, 2015
)
2.12
"Methylene blue (MB) is a century-old drug with a newly discovered protective function in the ischemic stroke model."( Methylene blue-induced neuronal protective mechanism against hypoxia-reoxygenation stress.
Choudhury, GR; Li, W; Liu, R; Ryou, MG; Winters, A; Yang, SH; Yuan, F, 2015
)
2.58
"Methylene blue (MB) is a medication commonly used to treat methemoglobinemia, reducing methemoglobin to hemoglobin. "( A Novel Use of Methylene Blue in the Pediatric ICU.
Benner, K; Brown, B; Hayes, L; Prabhakaran, P; Rutledge, C, 2015
)
2.21
"Methylene blue (MB) is a substance from the phenothiazine class often used as a PS."( Functional Polymeric Systems as Delivery Vehicles for Methylene Blue in Photodynamic Therapy.
Borghi-Pangoni, FB; Bruschi, ML; Ferreira, SB; Hioka, N; Junqueira, MV; Rabello, BR, 2016
)
1.4
"Methylene blue (MB) is a good candidate for the PDT drug, because the dye is an effective photosensitizer, can be easily synthesized, and is already being used in other clinical fields."( Nano-formulation of a photosensitizer using a DNA tetrahedron and its potential for in vivo photodynamic therapy.
Ahn, DR; Bang, D; Kim, KR, 2016
)
1.16
"Methylene blue is a phenothiazine agent, that possesses a diversity of biomedical and biological therapeutic purpose, and it has also become the lead compound for the exploitation of other pharmaceuticals such as chlorpromazine and the tricyclic antidepressants. "( Measuring the bioactivity and molecular conformation of typically globular proteins with phenothiazine-derived methylene blue in solid and in solution: A comparative study using photochemistry and computational chemistry.
Ding, F; Peng, W; Peng, YK; Xie, Y, 2016
)
2.09
"Methylene blue USP (MB) is a FDA-grandfathered drug used in clinics to treat methemoglobinemia, carbon monoxide poisoning and cyanide poisoning that has been shown to increase fMRI evoked blood oxygenation level dependent (BOLD) response in rodents. "( Methylene blue modulates functional connectivity in the human brain.
Altmeyer, WB; Barrett, DW; Duong, TQ; Franklin, CG; Gonzalez-Lima, F; Gutierrez, JE; Heyl, BL; Lancaster, JL; Li, J; Malloy, KE; Rodriguez, P; Singh, AP; Zhou, W, 2017
)
3.34
"Methylene blue (MB) is an FDA-grandfathered drug with memory-enhancing effects at low doses, but opposite effects at high doses. "( Methylene Blue Facilitates Memory Retention in Zebrafish in a Dose-Dependent Manner.
Caramillo, EM; Echevarria, DJ; Gonzalez-Lima, F, 2016
)
3.32
"Methylene blue is a cationic thiazine dye with redox-cycling properties and a selective affinity for the nervous system."( Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2.
Howland, RH, 2016
)
2.6
"Methylene blue (MB) is an effective neuroprotectant in many neurological disorders. "( Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response.
Bian, G; Guo, L; Kong, P; Li, B; Sun, Y; Sun, Z; Wang, J; Zhao, C, 2016
)
3.32
"As methylene blue is a vital dye that is absorbed by damaged tissue but not undamaged epidermis, it can be used to assess wound closure."( Methylene Blue Assay for Estimation of Regenerative Re-Epithelialization In Vivo.
Dickie, R; Milyavsky, M, 2017
)
2.41
"Methylene blue (MB) acts as a photosensitizer and after excitation by visible light (VL) produces reactive oxygen species that result in oxidatively damaged DNA. "( UV-inducible base excision repair of oxidative damaged DNA in human cells.
Kassam, SN; Rainbow, AJ, 2009
)
1.8
"Methylene blue (MB) is a widely studied agent currently under investigation for its properties relating to photodynamic therapy (PDT). "( Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics.
Chen, Y; Ji, J; Li, Y; Shen, P; Zheng, W; Zhong, J, 2008
)
1.79
"Methylene blue is a dark green crystal. "( [Late methylene blue appearance in urine after local treatment of cutaneous fistula in hip osteomyelitis as a first sign of renal failure].
Cvetković, BR; Cvetković, VR; Milenković, D; Rosić, ZV, 2008
)
2.27
"Methylene blue (MB) is a safe, low cost, and common blue dye remaining a popular choice for sentinel lymph node (SLN) mapping. "( Sentinel lymph node mapping using near-infrared fluorescent methylene blue.
Chu, M; Wan, Y, 2009
)
2.04
"Methylene blue (MB) is a diaminophenothiazine with potent antioxidant and unique redox properties that prevent morphologic degenerative changes in the mouse retina induced by rotenone, a specific mitochondrial complex I inhibitor. "( Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy.
Gonzalez-Lima, F; John, JM; Lee, J; Rojas, JC, 2009
)
3.24
"Methylene blue (MB) is a phenothiazine dye that is widely used in clinical practice and can be administered intravenously."( The sonodynamic antitumor effect of methylene blue on sarcoma180 cells in vitro.
Chida, S; Kawamura, K; Komori, C; Okada, K; Suzuki, T, 2009
)
1.35
"Methylene blue is an effective near-infrared fluorophore that provides direct visualization of coronary arteriography and cardiac perfusion. "( Real-time assessment of cardiac perfusion, coronary angiography, and acute intravascular thrombi using dual-channel near-infrared fluorescence imaging.
Chen, FY; Flaumenhaft, R; Frangioni, JV; Graham, GJ; Laurence, RG; Tanaka, E, 2009
)
1.8
"Methylene blue perfusion is a convenient and effective method to identify subtle incompleteness of specimen and can improve the detection of lymph node."( [Integrity evaluation of resected mesentery specimen after total mesorectal excision by methylene blue perfusion via superior rectal artery].
Fu, CG; Ji, QF; Lou, Z; Mei, ZB; Meng, RG; Wang, LL; Zhang, W, 2010
)
1.3
"Methylene blue is an FDA approved compound with a variety of pharmacologic activities. "( Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish.
Haass, C; Hruscha, A; Paquet, D; Schmid, B; van Bebber, F, 2010
)
3.25
"Methylene blue is a selective inhibitor of guanylate cyclase, a second messenger involved in nitric oxide-mediated vasodilation."( Methylene blue for the treatment of septic shock.
Flynn, JD; Hatton, KW; McMahon Horner, D; Paciullo, CA, 2010
)
2.52
"Methylene blue (MB) is a vital dye to allow better visualization and marker of parathyroid glands. "( In vitro assessment of the effect of methylene blue on voltage-gated sodium channels and action potentials in rat hippocampal CA1 pyramidal neurons.
Yang, Z; Zhang, T; Zhang, Y; Zhao, J, 2010
)
2.08
"Methylene blue allergy is a well-known entity associated with food or lymph node location. "( Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue.
Delhoume, M; Laudy, JS; Nathan, N; Nubret, K; Orsel, I; Sellami, M, 2011
)
2.06
"USP methylene blue (MB) is a diaminophenothiazine drug with antioxidant and metabolic-enhancing properties."( Beneficial network effects of methylene blue in an amnestic model.
Gonzalez-Lima, F; Riha, PD; Rojas, JC, 2011
)
1.14
"Methylene blue (MB) is an inhibitor of inducible NO synthase and an NO scavenger that has been shown to attenuate reperfusion hypotension."( The effect of methylene blue during orthotopic liver transplantation on post reperfusion syndrome and postoperative graft function.
Fukazawa, K; Pretto, EA, 2011
)
1.45
"Methylene blue (MB) is a drug with a long history and good safety profile, and with recently-described features desirable in a treatment for ALS."( Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Lougheed, R; Turnbull, J, 2011
)
2.15
"Methylene blue (MB) is a cationic dyestuff, which is particularly resistant to biodegradation. "( Removal of methylene blue from water by gamma-MnO2.
Chen, CY; Hu, CY; Kuan, WH, 2011
)
2.2
"Methylene blue (MB) is a redox dye that increases COX content and activity in vitro and in vivo suggesting that MB could prevent and treat LSFC."( Low-concentration methylene blue maintains energy production and strongly improves survival of Leigh syndrome French Canadian skin fibroblasts.
Bouchard, L; Côté, I; Larouche, PL; Legault, J; Morin, C; Pichette, A; Robinson, BH, 2011
)
1.42
"Methylene blue is a vasoactive chemical that has been shown to provide hemodynamic stability in the treatment of refractory septic shock. "( Local cutaneous necrosis secondary to a prolonged peripheral infusion of methylene blue in vasodilatory shock.
Dumbarton, TC; Gorman, SK; Green, R; Loubani, O; Minor, S; White, F, 2012
)
2.05
"Methylene blue (MB) is a near-infrared fluorophore that provides a stable visual map of skin perfusion after intravenous injection. "( Intraoperative prediction of postoperative flap outcome using the near-infrared fluorophore methylene blue.
Ashitate, Y; Choi, HS; Frangioni, JV; Hutteman, M; Laurence, RG; Lee, BT; Lunsford, E; Oketokoun, R, 2013
)
2.05
"Methylene blue injection is a low-cost screening technique, simple to perform on an outpatient basis and in the case of suprasphincteric fistulas also a simple diagnostic technique is sufficient to allow the closure of the fistula."( [Identification of internal fistolous orifice: evolution of methylene blue technique with a mini-probe].
Andreuccetti, J; Crispino, P; Gaj, F; Trecca, A, 2012
)
2.06
"Methylene blue is a useful therapy for catecholamine-resistant vasoplegic shock. "( The response to methylene blue in patients with severe hypotension during liver transplantation.
Berman, GW; Campsen, J; Cheng, SS; Fiegel, MJ; Hendrickse, A; Mandell, MS; Merritt, GR; Teitelbaum, I; Wachs, M; Zimmerman, M, 2012
)
2.17
"Methylene blue is a neuroprotective compound that can protect RGCs from toxic insults. "( Methylene blue protects primary rat retinal ganglion cells from cellular senescence.
Daudt, DR; Mueller, B; Park, YH; Wen, Y; Yorio, T, 2012
)
3.26
"Methylene blue is an intraoperative adjunct for localization of enlarged parathyroid glands. "( Systematic review of intravenous methylene blue in parathyroid surgery.
Balasubramanian, SP; Chadwick, DR; Harrison, BJ; Patel, HP, 2012
)
2.1
"Methylene blue (MB+) is a well-known dye in medicine and has been discussed as an easily applicable drug for topical treatment in photodynamic therapy (PDT). "( Nonlinear dynamics of intracellular methylene blue during light activation of cell cultures.
Akgün, N; Beck, G; Heckelsmiller, K; Kunzi-Rapp, K; Rück, A; Schick, E; Steiner, R, 1997
)
2.01
"Methylene blue (MB) is a powerful reducing agent that is widely used in clinical practice as well as for metabolic studies of the erythrocyte. "( Exposure of erythrocytes to methylene blue shows the active role of catalase in removing hydrogen peroxide.
Ferraris, AM; Gaetani, GF; Mangerini, R; Racchi, O; Rapezzi, D; Rolfo, M, 2002
)
2.05
"Methylene blue is a basic dye commonly used in histologic microbiologic, and tissue staining. "( Methylene blue: dangerous dye for neonates.
Albert, M; Gilchrist, BF; Lessin, MS, 2003
)
3.2
"Methylene blue is a vital dye that is used in the treatment of methaemoglobinaemia. "( Urinary discoloration after rectal instillation of methylene blue dye.
Chng, HC; Yap, KP, 2003
)
2.01
"Methylene blue is a noxious product, especially in neonates."( Methemoglobinemia and hemolysis after enteral administration of methylene blue in a preterm infant: relevance for pediatric surgeons.
Allegaert, K; Devlieger, H; Lerut, T; Miserez, M; Naulaers, G; Vanhole, C, 2004
)
1.28
"Methylene blue (MB) is a phenothiazinium photosensitizer with promising applications in the photodynamic therapy (PDT) for anticancer treatment. "( The binding properties of photosensitizer methylene blue to herring sperm DNA: a spectroscopic study.
Tang, GQ; Zhang, LZ, 2004
)
2.03
"Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumoral activity. "( Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy.
Capella, MA; Kirszberg, C; Rumjanek, VM, 2005
)
3.21
"Methylene blue is a safe and easy-to-use drug employed in human therapy."( Trypanocidal activity of methylene blue. Evidence for in vitro efficacy and in vivo failure.
Boda, C; Bouteille, B; Breton, JC; Courtioux, B; Enanga, B, 2006
)
1.36
"Methylene blue is a reduction-oxidation agent that can act as a powerful antioxidant and also as an enhancer of the electron transport chain, preventing formation of mitochondrial oxygen free radicals and promoting oxygen consumption."( Methylene blue prevents neurodegeneration caused by rotenone in the retina.
Gonzalez-Lima, F; Rojas, JC; Zhang, X, 2006
)
2.5
"Methylene blue (MB) is a thiazine dye with cationic and lipophilic properties that acts as an electron transfer mediator in the mitochondria. "( Methylene blue prevents methylmalonate-induced seizures and oxidative damage in rat striatum.
Coelho, RC; de Carvalho Myskiw, J; Ferreira, AP; Fighera, MR; Fiorenza, NG; Furian, AF; Mello, CF; Oliveira, MS; Petry, JC; Royes, LF, 2007
)
3.23
"Methylene blue (MB) is a metabolic enhancer that has been demonstrated to improve memory retention when given post-training in low doses in a variety of tasks in rats, including inhibitory avoidance, spatial memory (in both normal and metabolically-impaired subjects), object recognition, and habituation to a familiar environment. "( The brain metabolic enhancer methylene blue improves discrimination learning in rats.
Gonzalez-Lima, F; Maldonado, MA; McCollum, D; Riha, PD; Wrubel, KM, 2007
)
2.07
"Methylene blue is an effective tracer to detect SLNs in patients with early stage cervical cancer. "( Sentinel lymph node detection using methylene blue in patients with early stage cervical cancer.
Liang, LZ; Wei, M; Xiong, Y; Yan, XJ; Yuan, SH; Zeng, YX; Zhang, HZ, 2007
)
2.06
"Methylene blue acts as an antioxidant in this experimental system and may reduce intraabdominal adhesion formation by enhancing peritoneal fibrinolytic activity following surgery."( Intraperitoneal administration of methylene blue attenuates oxidative stress, increases peritoneal fibrinolysis, and inhibits intraabdominal adhesion formation.
Aarons, CB; Becker, JM; Cohen, PA; Gower, AC; Heydrick, SJ; Reed, KL; Stucchi, AF, 2007
)
2.06
"Methylene blue injection is a novel and highly effective method that will improve lymph node preparation in colorectal cancer."( [Lymph node preparation in colorectal cancer. Ex vivo methylene blue injection as a novel technique to improve lymph node visualization].
Anthuber, M; Arnholdt, H; Jähnig, H; Kerwel, T; Märkl, B, 2008
)
1.32
"Methylene blue is an inhibitor of guanylyl cyclase, which increases systemic vascular resistance and reverses shock in animal studies."( Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue.
Evora, PR; Simon, MR, 2007
)
1.27
"Methylene blue (MB) is a less expensive and readily available alternative dye."( Methylene blue dye--a safe and effective alternative for sentinel lymph node localization.
Abdel-Rahman, AT; Akberali, S; Carpenter, R; Gattuso, JM; Mostafa, A; Varghese, P,
)
2.3
"Methylene blue is a competitive inhibitor of the glutathione reductase of Plasmodium falciparum and is used in combination with other antimalarial drugs leading to a renaissance of methylene blue in malaria therapy. "( Cation exchange resins as pharmaceutical carriers for methylene blue: binding and release.
Burhenne, J; Gut, F; Haefeli, WE; Schiek, W; Walter-Sack, I, 2008
)
2.04
"Methylene blue is an effective, safe and easy way to localize and identify abnormal parathyroid glands, thereby improving the results and shortening the operating time."( Intraoperative identification of parathyroids by means of methylene blue.
Derom, A; Derom, F; Janzing, H; Van den Brande, F; Wallaert, P,
)
1.1
"Methylene blue (MB) is a soluble guanylate cyclase inhibitor, and known as an endothelium-derived relaxing factor (EDRF) inhibitor in vitro. "( Effect of methylene blue on blood pressure in rats.
Alican, I; Karahan, F; Oktay, S; Onat, F; Ozkutlu, U; Yegen, BC, 1993
)
2.13
"Methylene blue (MB) is a thiazine dye used in the treatment of methemoglobinemia. "( [Methylene blue as an endocrine modulator: interactions with thyroid hormones].
Schreiber, V, 1995
)
2.64
"Methylene blue (MB) is a widely used putative inhibitor of nitric oxide (NO)-dependent responses, particularly in cell culture and vascular ring studies. "( Methylene blue restores vasodilation to bradykinin after inhibition of nitric oxide production in the isolated dog lung.
Ehrhart, IC; Endredi, J; Hofman, WF; Shapiro, MB,
)
3.02
"Methylene blue (MB) is a thiazine dye used in the treatment of methemoglobinemia. "( Methylene blue--an endocrine modulator.
Haluzík, M; Nedvídková, J; Schreiber, V, 1995
)
3.18
"Methylene blue is a commonly used dye in diagnostic procedures such as fistula detection, delineation of body tissues during surgery and for checking the patency of fallopian tubes. "( Pulmonary edema following intrauterine methylene blue injection.
Kashyap, L; Mohan, V; Saxena, A; Trikha, A, 1996
)
2.01
"Methylene blue is a poor tattoo agent, but its occasional use continues, and pathologists should recognize the resulting reaction."( Endoscopic tattoo agents in the colon. Tissue responses and clinical implications.
Gottfried, MR; Lane, KL; Vallera, R; Washington, K, 1996
)
1.02
"Methylene blue (MB) is a thiazine dye that, although not regulated for use with edible fish, may sometimes be used as a chemotherapeutic agent in the aquaculture industry. "( Determination of methylene blue in channel catfish (Ictalurus punctatus) tissue by liquid chromatography with visible detection.
Hurlbut, JA; Long, AR; Pfenning, AP; Plakas, SM; Roybal, JE; Turnipseed, SB,
)
1.91
"Methylene blue is a thiazine dye, which has been used in the clinical medicine as disinfection agent and in treatment of methemoglobinemia. "( [The effect of an NO-synthase inhibitor, methylene blue, on the function of certain endocrine glands].
Haluzík, M; Jahodová, J; Nedvídková, J; Schreiber, V, 1997
)
2.01
"Methylene blue dye is a new tool to evaluate in vivo cyto-histological tubal damage, and is a useful and simple method to provide a prognosis of salpingean function."( Methylene blue dyeing of cellular nuclei during salpingoscopy, a new in-vivo method to evaluate vitality of tubal epithelium.
Marconi, G; Quintana, R, 1998
)
2.46
"Methylene blue (MB) is a chromophore with absorption peaks in the 600-700 nm region whose use has not been reported in laser-assisted vascular anastomoses."( Methylene blue based protein solder for vascular anastomoses: an in vitro burst pressure study.
Bell, PR; Birch, JF; Mandley, DJ; Trotter, PJ; Wilkinson, F; Williams, SL; Worrall, DR, 2000
)
2.47
"Methylene blue (MB+) is a well-known dye in medicine and has been discussed as an easily applicable drug for the topical treatment during photodynamic therapy (PDT). "( Methylene blue mediated photodynamic therapy in experimental colorectal tumors in mice.
Beck, G; Genze, F; Orth, K; Rück, A, 2000
)
3.19
"Methylene blue is a common ingredient in products used to extend the life of bait fish."( Heinz-body hemolytic anemia associated with ingestion of methylene blue in a river otter.
Narurkar, NS; Phalen, DN; Thomas, JS, 2002
)
1.28
"Methylene blue infusion is a safe effective method of localizing abnormal parathyroid glands."( Parathyroid identification by methylene blue infusion.
Airan, MC; Gordon, DL; Seidman, LH; Thomas, W, 1975
)
1.26
"Methylene blue infusion is a safe method of more rapidly identifying parathyroid tissue."( Parathyroid identification by methylene blue infusion.
Bambach, CP; Reeve, TS, 1978
)
1.27
"Methylene blue is a highly ionized and a rapidly eliminated drug which can combine well with tissues at higher concentration maintained for several hours and can easily pass through the blood-brain barrier."( [Antitumor effect of methylene blue in vivo].
Lai, BT, 1989
)
1.32

Effects

Methylene blue plasma has a very acceptable safety profile with a rate of serious adverse reactions of 0·5/10 000 units. Methyleneblue dye has an important role in lymphatic mapping for sentinel lymph node surgery.

Methylene blue trihydrate has a variety of biomedical and biologically therapeutic applications. It has only recently been noted to cause severe central nervous system toxicity.

ExcerptReferenceRelevance
"Methylene blue (MB) has a protective effect on cognitive decline caused by chronic hypoperfusion, but the specific mechanism is not clear. "( Effect of Methylene Blue and PI3K-Akt Pathway Inhibitors on the Neurovascular System after Chronic Cerebral Hypoperfusion in Rats.
Li, R; Li, Y; Liu, M; Nie, Z; Wang, X; Zhang, W, 2020
)
2.4
"Methylene blue plasma has a very acceptable safety profile with a rate of serious adverse reactions of 0·5/10 000 units."( International, prospective haemovigilance study on methylene blue-treated plasma.
Megalou, A; Noens, L; Qureshi, H; Vilariño, MD, 2017
)
2.15
"Methylene blue has a similar chemical structure and exhibits similar physicochemical properties as toluidine blue."( Methylene Blue as a Diagnostic Aid in the Early Detection of Potentially Malignant and Malignant Lesions of Oral Mucosa.
Arpita, R; Krishna, B; Lejoy, A; Venkatesh, N, 2016
)
2.6
"Methylene blue trihydrate has a variety of biomedical and biologically therapeutic applications. "( Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies).
, 2008
)
2.05
"Methylene blue trihydrate has a variety of biomedical and biologically therapeutic applications. "( Toxicity and carcinogenicity studies of methylene blue trihydrate in F344N rats and B6C3F1 mice.
Auerbach, SS; Bristol, DW; Chhabra, RS; Hébert, CD; Peckham, JC; Travlos, GS, 2010
)
2.07
"Methylene blue dye has an important role in lymphatic mapping for sentinel lymph node surgery. "( Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors.
Degnim, AC; Lovely, J; Shah-Khan, MG, 2012
)
2.22
"Methylene blue (MB) has a similar mode of action as chloroquine (CQ) and has moreover been shown to selectively inhibit the Plasmodium falciparum glutathione reductase."( Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine.
Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, PE; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Schiek, W; Schirmer, RH; Tapsoba, T; Walter-Sack, I; Witte, S, 2006
)
2.5
"Methylene blue has an acute pressor effect in patients with septic shock."( [Inhibition of the nitric oxide pathway in refractory septic shock].
Andresen, M; Bugedo, G; Castillo, L; Dagnino, J; Dougnac, A; Espejo, J; Hernández, G; Letelier, LM, 1996
)
1.74
"Methylene blue (MB) has experienced a renaissance mainly as a component of drug combinations against Plasmodium falciparum malaria. "( Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
Akoachere, MB; Becker, K; Buchholz, K; Dandekar, T; Eubel, JK; Gromer, S; Schirmer, RH, 2008
)
2.13
"Methylene blue has been in medicinal use for centuries and is best known as an antidotal treatment for acquired methemoglobinemia (MetHB). "( Methylene Blue: An Antidote for Methemoglobinemia and Beyond.
Liebelt, EL; Pushparajah Mak, RS, 2021
)
3.51
"Methylene blue (MB) has been in clinical use for a century and proved especially useful as a photosensitizer for photodynamic disinfection (PDI)."( Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation.
Arnaut, LG; Coelho, MF; da Cunha, JS; de Almeida, LP; Lobo, CS; Lourenço, JV; Núñez, J; Pereira, D; Rodrigues-Santos, P; Sousa, DL; Trêpa, JCD, 2022
)
1.68
"Methylene blue (MB) has been used to treat methemoglobinemia. "( Safety and usefulness of fluorescence imaging using methylene blue as a fluorophore in a Japanese population with hepatobiliary and pancreatic diseases: A phase I study.
Abe, S; Akamatsu, N; Arita, J; Fukuda, K; Hasegawa, K; Kaneko, J; Kawaguchi, Y; Kobayashi, Y; Maki, H, 2023
)
2.6
"Methylene blue (MB) has been used to increase blood pressure in septic shock, acting on the activity of guanylate cyclase and nitric oxide synthase."( Effect of methylene blue on hemodynamic response in the early phase of septic shock: A case series.
Auxiliadora-Martins, M; Basile-Filho, A; Becari, C; Donadel, MD; Dos Reis Sepeda, C; Evora, PRB; Gallo, GB; Jordani, MC; Luis-Silva, F; Martins-Filho, OA; Menegueti, MG; Mestriner, F; Peres, LM; Petroski-Moraes, BC; Sato, L, 2023
)
2.76
"Methylene blue (MB) has been tested as a rescue therapy for patients with refractory septic shock. "( Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.
Aguilera-González, P; Aguirre-Avalos, G; Chávez-Peña, Q; Gómez-Partida, CA; Hernández, G; Ibarra-Estrada, M; Kattan, E; López-Pulgarín, JA; Mijangos-Méndez, JC; Ortiz-Macías, IX; Rico-Jauregui, U; Sandoval-Plascencia, L, 2023
)
2.69
"Methylene blue has been extensively studied in the fields of biomedicine and biosensing due to its excellent singlet oxygen yield, redox properties, and good DNA affinity."( Synthesis and DNA Cleavage Activity of Cationic Methylene-Blue-Backboned Polymers.
Cai, X; Feng, F; Zhang, X; Zhang, Y, 2023
)
1.63
"Methylene blue (MB) has anti-inflammatory properties, however, its underlying molecular mechanism remains elusive. "( Methylene blue targets PHD3 expression in murine microglia to mitigate lipopolysaccharide-induced neuroinflammation and neurocognitive impairments.
Che, J; Chen, W; Deng, Y; Dong, J; He, Z; Jiang, X; Ou, G; Sun, Y; Zhang, J, 2023
)
3.8
"Methylene blue (MB) has been shown to exhibit therapeutic effects on diabetes-related diseases."( Evaluation of topical methylene blue nanoemulsion for wound healing in diabetic mice.
Cao, W; Chen, B; Gao, Y; Jiang, Y; Jiang, Z; Li, S; Mo, R; Tan, Q; Tian, M; Xu, B; Zhao, D, 2023
)
1.95
"Methylene blue has multiple antiviral properties against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2). "( Interaction of Methylene Blue with Severe Acute Respiratory Syndrome Coronavirus 2 Envelope Revealed by Molecular Modeling.
Fedorov, V; Kholina, E; Khruschev, S; Kovalenko, I; Meerovich, G; Strakhovskaya, M; Vasyuchenko, E, 2023
)
2.71
"Methylene blue (MB) has a protective effect on cognitive decline caused by chronic hypoperfusion, but the specific mechanism is not clear. "( Effect of Methylene Blue and PI3K-Akt Pathway Inhibitors on the Neurovascular System after Chronic Cerebral Hypoperfusion in Rats.
Li, R; Li, Y; Liu, M; Nie, Z; Wang, X; Zhang, W, 2020
)
2.4
"Methylene blue-plasma (MBP) has been used for over 20 years, but its efficacy in this setting remains controversial."( Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.
Álvarez, I; Amunárriz, C; Arroyo, JL; García, JM; Martínez, E; Muñoz, C; Romón, I, 2020
)
2.72
"Methylene blue staining has been used as an intra-operative tool to improve tissue visualisation and preserve facial nerve integrity."( The use of methylene blue to assist with parotid sialadenectomy in dogs.
Bird, FG; Brissot, HN; Camarasa, JJ; Campmany, M; Gordo, I; Vallefuoco, R, 2020
)
1.67
"Methylene blue has potential as a treatment for overdoses."( Efficacy of methylene blue in a murine model of amlodipine overdose.
Baccanale, CL; de Castro Brás, LE; Eccleston, L; Meggs, WJ; O'Rourke, D; Pittman, P; Sloan, T; St Antoine, JC; Verzwyvelt, SM, 2021
)
1.72
"Methylene blue (MB) has recently been proposed as a new chemical probe to colorimetrically verify the presence of hydroxyl radicals and was applied to the microbubble technique in this report. "( Effect of acidic conditions on decomposition of methylene blue in aqueous solution by air microbubbles.
Fujiwara, N; Minamoto, C; Minamoto, Y; Nakayama, S; Shigekawa, Y; Tada, K; Yano, J; Yokoyama, T, 2021
)
2.32
"Methylene blue has been the treatment of choice because of its effectiveness for both prevention and rescue therapy."( Use of Intravenous Hydroxocobalamin without Methylene Blue for Refractory Vasoplegic Syndrome After Cardiopulmonary Bypass.
Finamore, M; Peyko, V, 2021
)
1.6
"Methylene blue has been used as a kind of efficient and cheap commercial photosensitizer in APDT."( Surfactin-methylene blue complex under LED illumination for antibacterial photodynamic therapy: Enhanced methylene blue transcellular accumulation assisted by surfactin.
Li, S; Weng, Y; Xu, L; Yu, D; Zhang, H; Zhao, J; Zhuo, Y, 2021
)
1.75
"Methylene blue plasma has a very acceptable safety profile with a rate of serious adverse reactions of 0·5/10 000 units."( International, prospective haemovigilance study on methylene blue-treated plasma.
Megalou, A; Noens, L; Qureshi, H; Vilariño, MD, 2017
)
2.15
"Methylene blue (MB) has been used to treat refractory hypotension in a variety of settings."( Methylene blue for postcardiopulmonary bypass vasoplegic syndrome: A cohort study.
Caridi-Scheible, M; Chen, E; Hammer, B; Mazzeffi, M; Paciullo, C; Ramsay, J,
)
3.02
"Methylene blue (MB) has NO blocking and antioxidant effects."( Methylene blue reduces progression of burn and increases skin survival in an experimental rat model.
Évora, PRB; Faria, FM; Farina, JA; Oliveira, CC; Rosique, MJ; Rosique, RG, 2017
)
2.62
"Methylene blue (MB), which has antioxidant, anti-inflammatory, neuroprotective, and mitochondria protective effects, has been widely used as a dye and medication. "( Methylene blue inhibits NLRP3, NLRC4, AIM2, and non-canonical inflammasome activation.
Ahn, H; An, BS; Hong, EJ; Kang, SG; Kim, PH; Ko, HJ; Lee, E; Lee, GS; Yoon, SI, 2017
)
3.34
"Methylene blue (MB) has become a popular therapy for cardiac vasoplegia despite a paucity of prospective data to direct its use."( Methylene Blue for Vasoplegic Syndrome.
Booth, AT; Mehaffey, JH; Melmer, PD; Tribble, B; Tribble, C, 2017
)
2.62
"Methylene blue (MB) has been reported to attenuate brain and renal ischemia-reperfusion injury."( Methylene Blue Protects the Isolated Rat Lungs from Ischemia-Reperfusion Injury by Attenuating Mitochondrial Oxidative Damage.
Chen, JL; Pang, QF; Sheng, Q; Tian, WF; Wang, ZQ; Weng, P; Yuan, JJ; Zeng, S; Zhang, XT, 2018
)
2.64
"Methylene blue (MB) has been systematically investigated for its protective effects against refractory hypotension and mitochondrial dysfunction."( Methylene blue alleviates endothelial dysfunction and reduces oxidative stress in aortas from diabetic rats.
Duicu, OM; Muntean, DM; Privistirescu, AI; Roșca, MG; Sima, A; Sturza, A; Timar, R, 2018
)
2.64
"Methylene blue (MB) has been advocated for the treatment of shock refractory to standard measures. "( Methylene Blue for Refractory Shock in Polytraumatized Patient: A Case Report.
Carlotti, APCP; Carmona, F; Evora, PRB; Godinho, M; Scarpelini, S; Teixeira, GD; Volpon, LC, 2018
)
3.37
"Methylene Blue (MB) has been widely used in antimicrobial Photodynamic Therapy (aPDT), however, the mechanisms of action (Type I or Type II) are defined by its state of aggregation. "( Controlling methylene blue aggregation: a more efficient alternative to treat Candida albicans infections using photodynamic therapy.
Aquino, S; da Collina, GA; da Silva, DFT; Freire, F; Pavani, C; Prates, RA; Santos, TPDC; Sobrinho, NG; Tempestini Horliana, ACR, 2018
)
2.3
"Methylene blue (MB) has been shown to slow down the progression of the Alzheimer's disease (AD) and other tauopathies; however distribution of MB into the brain is limited due its high hydrophilicity. "( Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies.
Groshev, A; Grover, A; Jinwal, UK; Sutariya, VB; Zhang, J, 2014
)
2.12
"Methylene blue (MB) has unique energy-enhancing and antioxidant properties and is FDA-approved drug to treat methemoglobinemia and cyanide poisoning. "( Neuroprotective efficacy of methylene blue in ischemic stroke: an MRI study.
Du, F; Duong, TQ; Huang, S; Rodriguez, P; Shen, Q; Watts, LT, 2013
)
2.13
"Methylene blue (MB) has known energy-enhancing and antioxidant properties."( Methylene blue is neuroprotective against mild traumatic brain injury.
Chemello, J; Duong, TQ; Fernandez, A; Huang, S; Long, JA; Shen, Q; Talley Watts, L; Van Koughnet, S, 2014
)
2.57
"Methylene blue has been used to identify and preserve lymphatic vessels, and venography has been a standard component of sclerotherapy and percutaneous retrograde techniques."( Intravenous methylene blue venography during laparoscopic paediatric varicocelectomy.
Cervellione, RM; Keene, DJ, 2014
)
1.5
"Methylene blue (MB) has recently been considered for new therapeutic applications. "( Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is mediated by dual inhibition of GSK3β downstream of PKA.
Hwang, SJ; Kim, SG; Lee, CG; Wu, HM, 2014
)
2.09
"As methylene blue (MB) has been recently proposed to preserve blood pressure in case of vasoplegic syndrome and shock, an entity directly related to systemic inflammation, we aimed to elucidate the effect of MB on the expression of adhesion-molecules in endothelial-cells."( Methylene blue modulates adhesion molecule expression on microvascular endothelial cells.
Beiras-Fernandez, A; Guo, F; Lupinski, M; Meybohm, P; Moritz, A; Stock, UA; Werner, I, 2014
)
2.47
"Methylene blue (MB) has been used with some success as a treatment for the vasoplegia of vasopressor-refractory septic shock. "( Impact of methylene blue in addition to norepinephrine on the intestinal microcirculation in experimental septic shock.
Dumbarton, TC; Farah, N; Lehmann, C; Maxan, A; Minor, S; Nantais, J; Zhou, J, 2014
)
2.25
"Methylene blue (MB) has been used in the identification of abnormal parathyroid glands in surgery for hyperparathyroidism. "( The value and role of low dose methylene blue in the surgical management of hyperparathyroidism.
Bewick, J; Pfleiderer, A, 2014
)
2.13
"Methylene blue (MB) has been shown to be safe and effective against falciparum malaria in Africa and to have pronounced gametocytocidal properties."( Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso.
Berens-Riha, N; Bountogo, M; Bousema, T; Breitkreutz, J; Coulibaly, B; Drakeley, C; Kieser, M; Klose, C; Meissner, PE; Mockenhaupt, FP; Müller, O; Nebié, E; Pritsch, M; Schirmer, RH; Sié, A; Sirima, SB; Wieser, A, 2015
)
2.09
"Methylene blue has been selected as a cationic dye for its removal from various environmental sources using pH-sensitive biopolymeric hydrogels."( Investigation of citric acid-glycerol based pH-sensitive biopolymeric hydrogels for dye removal applications: A green approach.
Franklin, DS; Guhanathan, S, 2015
)
1.14
"Methylene blue (MB) has been used in laboratories and clinics since the 1890s."( Methylene Blue Reduces Acute Cerebral Ischemic Injury via the Induction of Mitophagy.
Di, Y; Fan, M; He, YL; Huang, X; Liu, SH; Wu, KW; Wu, LY; Zhao, T; Zhao, YQ; Zhu, LL, 2015
)
2.58
"The Methylene blue has been chosen as a model cationic dye."( pH-sensitive Itaconic acid based polymeric hydrogels for dye removal applications.
Franklin, DS; Guhanathan, S; Sakthivel, M, 2016
)
0.92
"Methylene blue (MB) has received much attention in the perioperative and critical care literature because of its ability to antagonize the profound vasodilation seen in distributive (also referred to as vasodilatory or vasoplegic) shock states. "( Methylene Blue: Magic Bullet for Vasoplegia?
Fischer, GW; Hosseinian, L; Levin, MA; Weiner, M, 2016
)
3.32
"Methylene blue has been considered as one of the major water contaminated pollutants."( Efficacy of SnO2 nanoparticles toward photocatalytic degradation of methylene blue dye.
Elango, G; Roopan, SM, 2016
)
1.39
"Methylene blue and thiamine have been occasionally successful as treatment."( The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
HaDuong, JH; Yeo, KK, 2016
)
1.16
"Methylene blue has been safely used for the localization of parathyroid glands during parathyroidectomy, and only a few adverse effects have been documented. "( Methylene blue and parathyroid adenoma localization: Three new cases of a rare cutaneous complication.
Lieberman, ED; Pytynia, KB; Thambi, R, 2016
)
3.32
"Methylene blue (MB) has been used for additional blood pressure support in patients who develop severe, refractory vasoplegia; however, MB can induce serotonin syndrome, especially when used in conjunction with other serotonergic agents. "( Serotonin Syndrome Following Methylene Blue Administration for Vasoplegic Syndrome.
Hencken, L; Ly, N; Morgan, JA; To, L, 2016
)
2.17
"Methylene blue (MB) has been widely applied in the clinical area and is currently being used in aquaculture as biocide. "( Methylene blue toxicity in zebrafish cell line is dependent on light exposure.
Costa, SR; da Silva Júnior, FM; Monteiro, Mda C; Sandrini, JZ, 2016
)
3.32
"Methylene blue has a similar chemical structure and exhibits similar physicochemical properties as toluidine blue."( Methylene Blue as a Diagnostic Aid in the Early Detection of Potentially Malignant and Malignant Lesions of Oral Mucosa.
Arpita, R; Krishna, B; Lejoy, A; Venkatesh, N, 2016
)
2.6
"Methylene blue (MB), which has mitochondria-protective properties, was infused via an osmotic pump into the anterior muscle compartment of one hind limb of late pre- symptomatic SOD1-G93A mice for ≥3weeks."( Preservation of neuromuscular function in symptomatic SOD1-G93A mice by peripheral infusion of methylene blue.
Barrett, EF; Barrett, JN; Nonner, D; Talbot, JD; Wicomb, K; Zhang, Z, 2016
)
1.37
"Methylene blue (MB) has been implicated to be neuroprotective in a variety of neurodegenerative diseases by restoring mitochondrial function."( Methylene blue improves streptozotocin-induced memory deficit by restoring mitochondrial function in rats.
Li, L; Li, PJ; Lu, HL; Qin, L; Song, YJ; Yang, RL, 2017
)
2.62
"Methylene blue trihydrate has a variety of biomedical and biologically therapeutic applications. "( Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies).
, 2008
)
2.05
"Methylene blue has been used for the rapid reversal of circulatory shock refractory to fluid administration, inotropic agents, and vasoconstrictors. "( Blue dye, green heart.
Rodriguez, ER; Tan, CD,
)
1.57
"Methylene blue has multiple indications for use, but recently it has been shown to be useful in treating refractory hypotension. "( Methylene blue for refractory hypotension: a case report.
Weissgerber, AJ, 2008
)
3.23
"Methylene blue (MB) has recently been reevaluated for malaria treatment. "( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
2.08
"Methylene blue (MB) has been shown to photoinduce the direct inactivation of Gram-positive bacteria Staphylococcus aureus (S. "( The role of reactive oxygen species in Staphylococcus aureus photoinactivation by methylene blue.
Alouini, Z; Boudabbous, A; Jemli, M; Sabbahi, S, 2008
)
2.01
"Methylene blue has been successfully used for the prevention and treatment of vasoplegia syndrome (VS) in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)."( Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review.
Holt, DW; McRobb, CM, 2008
)
2.51
"Methylene blue (MB) dye has been used for lymphatic mapping/sentinel lymphadenectomy (LM/SL) in staging of melanoma and breast cancer. "( Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy.
Axelrod, P; Bleicher, RJ; Kloth, DD; Robinson, D, 2009
)
2.06
"Methylene blue has been found to be a potent inhibitor of monoamine oxidase (MAO), and several cases of serotonin toxicity have been reported recently following its administration."( Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.
Gillman, PK; Stanford, BJ; Stanford, SC, 2010
)
1.32
"Methylene blue has been used to help facilitate parathyroid surgery for over 30 years. "( Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use.
Delfiner, J; Fernandez, J; Pollack, A; Pollack, G, 2009
)
2.1
"Methylene blue trihydrate has a variety of biomedical and biologically therapeutic applications. "( Toxicity and carcinogenicity studies of methylene blue trihydrate in F344N rats and B6C3F1 mice.
Auerbach, SS; Bristol, DW; Chhabra, RS; Hébert, CD; Peckham, JC; Travlos, GS, 2010
)
2.07
"Methylene blue has only recently been noted to cause severe central nervous system toxicity. "( CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.
Gillman, PK, 2011
)
2.12
"Methylene blue (MB) has been experimentally proven neuroprotective in a porcine model of global ischemia-reperfusion in experimental cardiac arrest."( Effect of methylene blue on the genomic response to reperfusion injury induced by cardiac arrest and cardiopulmonary resuscitation in porcine brain.
Martijn, C; Wiklund, L, 2010
)
1.48
"Methylene blue (MB) has been advocated for the treatment of refractory hemodynamic instability in patients with septic shock. "( Prolonged methylene blue infusion in refractory septic shock: a case report.
Dumbarton, TC; Green, R; Minor, S; Yeung, CK, 2011
)
2.21
"Methylene blue (MB) has been shown to prevent fibrosis formation in various tissues."( The effect of methylene blue on peridural fibrosis formation after laminectomy in rats: an experimental novel study.
Fareghbal, S; Farrokhi, MR; Farrokhi, N; Vasei, M, 2011
)
1.45
"Methylene blue has significant advantages with respect to product cost, absence of anaphylactic reactions, and lack of interference with pulse oximetry."( Occurrence of prolonged injection site mass with methylene blue but not isosulfan blue after the sentinel node procedure.
Bouton, ME; Komenaka, IK; Shirah, GR, 2011
)
1.34
"Methylene blue also has the ability to scavenge nitric oxide, as well as inhibit nitric oxide synthase."( Methylene blue in the treatment of refractory shock from an amlodipine overdose.
Hoffman, RS; Jang, DH; Nelson, LS, 2011
)
2.53
"Methylene blue (MB) has been shown to act at multiple cellular and molecular targets and as a result possesses diverse medical applications. "( Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase.
Harvey, BH; Petzer, A; Petzer, JP; Wegener, G, 2012
)
2.13
"Methylene blue has been used not only as a diagnostic agent, but also as an agent in the treatment of ifosfamide-induced encephalopathy (IIE) for several years. "( Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy.
Fisher, DC; McDonnell, AM; Rybak, I; Wadleigh, M, 2012
)
2.06
"Methylene blue dye has an important role in lymphatic mapping for sentinel lymph node surgery. "( Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors.
Degnim, AC; Lovely, J; Shah-Khan, MG, 2012
)
2.22
"Methylene blue (MB), has been shown to modulate aggregation of amyloidogenic disease proteins."( Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Agrawal, N; Aron, R; Finkbeiner, S; Glabe, C; Lau, A; Lotz, GP; Marsh, JL; Muchowski, PJ; Necula, M; Sontag, EM; Thompson, LM; Tran, A; Yang, G, 2012
)
2.54
"Methylene blue, which has been shown to increase oxygen consumption in vitro, was used to restore mitochondrial electron transport in order to facilitate memory consolidation."( Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats.
Callaway, NL; Gonzalez-Lima, F; McCollum, D; Riha, PD; Wrubel, KM, 2002
)
2.48
"Methylene blue has been used to selectively stain areas of specialized intestinal metaplasia in Barrett's esophagus. "( Does methylene blue detect intestinal metaplasia in Barrett's esophagus?
Breyer, HP; Edelweiss, MI; Maguilnik, I; Silva De Barros, SG, 2003
)
2.28
"Methylene blue has intrinsic antimalarial activity and it can act as a chloroquine sensitizer. "( Methylene blue as an antimalarial agent.
Becher, H; Becker, K; Coulibaly, B; Eubel, J; Kouyaté, B; Merkle, H; Müller, O; Scheiwein, M; Schiek, W; Schirmer, RH; Stich, A; Zich, T, 2003
)
3.2
"Methylene Blue (MB) has well-established photochemical properties and has been used in a variety of photochemical applications including photodynamic therapy. "( Binding, aggregation and photochemical properties of methylene blue in mitochondrial suspensions.
Baptista, MS; Belisle, E; Gabrielli, D; Kowaltowski, AJ; Severino, D, 2004
)
2.02
"Methylene blue has been used to treat hypovolemic states. "( Methylene blue enhancement of resuscitation after refractory hemorrhagic shock.
Chitwood, WR; Ghiassi, S; Kim, VB; Nifong, LW; Rotondo, MF; Scott, CM; Sun, YS, 2004
)
3.21
"Methylene blue, which has been thought to reverse the condition, was administered in 26 cases."( Evaluating risk factors for the development of ifosfamide encephalopathy.
David, KA; Picus, J, 2005
)
1.05
"Methylene blue has been advocated as an adjunct to conventional vasoconstrictors in such situations."( Vasoplegic syndrome--the role of methylene blue.
Shanmugam, G, 2005
)
1.33
"Methylene blue (MB) has a similar mode of action as chloroquine (CQ) and has moreover been shown to selectively inhibit the Plasmodium falciparum glutathione reductase."( Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine.
Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, PE; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Schiek, W; Schirmer, RH; Tapsoba, T; Walter-Sack, I; Witte, S, 2006
)
2.5
"Methylene blue (MB) has been used in intravital staining of various tissues for a long time."( [The assessment of intravital staining of parotic gland using methylene blue in the surgery of benign gland tumors--preliminary report].
Kopeć, T; Szczepański, M; Szyfter, W; Zeromski, J, 2006
)
1.3
"The methylene blue method has been widely used for analysis of sulfide for more than 100 years. "( Methylene blue derivatization then LC-MS analysis for measurement of trace levels of sulfide in aquatic samples.
Hintelmann, H; Small, JM, 2007
)
2.34
"Methylene blue (MB) has been used clinically for about a century to treat numerous ailments. "( Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways.
Ames, BN; Atamna, H; Boyle, K; Kato, H; Newberry, J; Nguyen, A; Schultz, C, 2008
)
3.23
"Methylene blue has been frequently used as an inhibitor of soluble guanylyl cyclase. "( Novel actions of methylene blue.
Brunner, F; Mayer, B; Schmidt, K, 1993
)
2.07
"Methylene blue has an acute pressor effect in patients with septic shock."( [Inhibition of the nitric oxide pathway in refractory septic shock].
Andresen, M; Bugedo, G; Castillo, L; Dagnino, J; Dougnac, A; Espejo, J; Hernández, G; Letelier, LM, 1996
)
1.74
"Methylene blue (MB) has been intermittently used in manic depressive illness over the past century. "( Anxiolytic and antidepressant properties of methylene blue in animal models.
Cağlayan, B; Eroğlu, L, 1997
)
2
"Methylene blue (MB) has been used as a vasopressor in sepsis and acute liver failure."( The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation.
Baumann, J; Bellamy, MC; Gedney, JA; Koelzow, H; Snook, NJ, 2002
)
1.4
"Methylene blue fading has the potential to act as a switch against over exposure and a visual indicator of solder activation."( Methylene blue soldered microvascular anastomoses in vivo.
Bell, PR; Birch, JF, 2002
)
2.48
"Methylene blue and inosine have been shown to stimulate glycolytic metabolism in the erythrocytes, increasing the concentration of 2.3-diphosphoglycerate (2,3-DPG), which is necessary for hemoglobin function, by regulating oxidative metabolism and providing a five-carbon nutrient for glycolysis, respectively. "( Preservation of erythrocytes using metabolic regulators and mutrients. V. Inosine and methylene blue.
Dawson, RB; Hershey, RT; Myers, CS, 1978
)
1.92
"The methylene blue test has fewer variables, and fits easily into a urodynamic routine."( An analysis of rapid pad testing and the history for the diagnosis of stress incontinence.
Papa Petros, PE; Ulmsten, U, 1992
)
0.76
"Methylene blue (MB) has recently been introduced to inactivate viruses in single donor fresh frozen plasma (FFP) units. "( [Initial experiences with methylene blue virus inactivated fresh frozen plasma: results of a clinical and in vitro study].
Neumeyer, H; Wieding, JU, 1992
)
2.03
"Both methylene blue and CoCl2 have been found to accelerate the ageing of collagen in normal lizards."( Effect of methylene blue and cobaltous chloride on the alloxan-induced changes in collagen characteristics in the skin of garden lizard Calotes versicolor.
Behera, HN; Mishra, G, 1989
)
1.13
"Methylene blue (MB) has been suggested as a therapeutic alternative for heparin reversal in patients sensitive to protamine. "( Methylene blue enhances lateral association of fibrin resulting in rapid gelation and thick fiber formation.
Carr, ME; Powers, PL, 1989
)
3.16

Actions

Methylene blue can inhibit the growth of Ehrlich ascitic tumor, L1210 leukemia and P388 leukemia in mice. It can metabolize into leukomethylene blue, which is colorless in urine.

ExcerptReferenceRelevance
"Methylene blue can increase the number of LNs harvested in CRC, reduce the incidence of fewer than 12 LNs harvested, and ensure the accuracy of LN staging."( Methylene blue can increase the number of lymph nodes harvested in colorectal cancer: a meta-analysis.
Meng, W; Shen, Y; Wang, Z; Wei, M; Xiao, J; Yang, X, 2023
)
3.8
"The methylene blue displays a reversible change in the complex refractive index throughout a reduction-oxidation transition, which generates an optical signal that can be electrochemically modulated and detected at high sensitivity."( Detection of influenza virus by electrochemical surface plasmon resonance under potential modulation.
Ghithan, JH; Jones, KB; Keynton, RS; Mendes, SB; Moreno, M; Nunn, BM; O'Toole, MG; Qatamin, AH; Zamborini, FP, 2019
)
0.99
"Methylene blue could inhibit mRNA transcription and protein expression of iNOS in lung of septic rat, but failed to reduce the degree of lung injury in sepsis."( [Effect of methylene blue on changes in inducible nitric oxide synthase in lung of rats with sepsis].
Dai, C; Wang, Y; Yu, X, 2016
)
1.55
"Methylene blue's ability to increase cytochrome c oxidase and protect RGCs against these noxious stimuli supports its suggested mechanism of action, which is to preserve the electron transport chain."( Methylene blue protects primary rat retinal ganglion cells from cellular senescence.
Daudt, DR; Mueller, B; Park, YH; Wen, Y; Yorio, T, 2012
)
2.54
"Methylene blue can inhibit the growth and acid production metabolism of Streptococcus matans and acid production metabolism of i-PGM."( [Inhibition effect of methylene blue on the acids production of Streptococcus mutans].
Chu, BF; Huang, LZ; Li, ZG; Liu, HC; Shen, SJ; Wang, CL; Zhao, M, 2005
)
2.09
"Methylene blue was found to inhibit thiamine transport competitively (Ki = 0.63 microM) in baker's yeast. "( Inhibition of thiamine transport in baker's yeast by methylene blue.
Iwashima, A; Nishimura, H; Nishino, H, 1980
)
1.95
"Methylene blue was shown to cause membrane damage comparable with the effect of rose bengal and toluidine blue."( Protective effect of amphotericin B against lethal photodynamic treatment in yeast.
Lazarova, G; Tashiro, H, 1995
)
1.01
"Methylene blue appears to inhibit nitric oxide-stimulated soluble guanylyl cyclase and has been widely used for inhibition of cGMP-mediated processes. "( Inhibition of nitric oxide synthesis by methylene blue.
Brunner, F; Mayer, B; Schmidt, K, 1993
)
2
"Methylene blue can metabolize into leukomethylene blue, which is colorless in urine."( Nonvisualization of intravenous methylene blue in patients with clinically normal renal function.
Joel, AB; Mordkin, RM; Mueller, MD; Pahira, JJ, 2001
)
1.32
"The methylene blue produced an increase in the bladder activity and a decrease in the urethral smooth muscle relaxant response induced with bladder contraction."( Effect of methylene blue on the vesicourethral function in the rats.
Fujieda, N; Harada, T; Kawahara, T; Kudo, T; Nishizawa, O; Noto, H; Shimoda, N; Suzuki, K; Suzuki, T; Tsuchida, S, 1992
)
1.17
"Methylene blue did not inhibit EDRF activity in any model, despite causing increased pulmonary vascular tone and responsiveness to various constrictor agents."( Comparison of the hemodynamic effects of nitric oxide and endothelium-dependent vasodilators in intact lungs.
Archer, SL; Cowan, N; DeMaster, EG; Nelson, DP; Rist, K; Weir, EK, 1990
)
1
"Methylene blue can inhibit the growth of Ehrlich ascitic tumor, L1210 leukemia and P388 leukemia in mice. "( [Antitumor effect of methylene blue in vivo].
Lai, BT, 1989
)
2.04

Treatment

Methylene blue treatment did not alter Caspase-6 levels, assessed by RT-PCR, western blot and immunohistochemistry. Treatment increased sperm count (p < .001) and motility compared to the cisplatin group.

ExcerptReferenceRelevance
"Methylene blue-treated convalescent plasma did not prevent progression from mild to severe illness and did not reduce viral load in outpatients with COVID-19. "( High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Alemany, A; Amado Simon, R; Ancochea, À; Àngel Rodriguez-Arias, M; Ara, J; Baro, B; Bassat, Q; Blanco, I; Blanco, J; Bonet Papell, G; Bonet, M; Cantoni, J; Capdevila-Jáuregui, M; Clotet, B; Contreras, E; Corbacho-Monné, M; Costes, G; Farré, M; Fernández Rivas, G; Forcada Arcarons, A; Galvan-Femenia, I; Garcia Garcia, V; Grifols, JR; Llopis Roca, F; Malchair, P; Marks, M; Millan, A; Millat-Martinez, P; Mitjà, O; Otero, A; Ouchi, D; Piccolo Ferreira, F; Pradenas, E; Prat, N; Puig, J; Ramírez-Morros, A; Rodríguez Codina, J; Rodriguez Cortez, O; Ruibal Suarez, JC; Ruiz-Comellas, A; San José, A; Torrano-Soler, P; Vidal-Alaball, J; Videla, S; Zarauza Pellejero, A, 2022
)
2.55
"Methylene blue treatment demonstrated an attenuation of the development, but had no effect on the expression of morphine CPP."( Molecular chaperone heat shock protein 70 inhibitors suppress conditioned place preference induced by morphine exposure in male rats.
Bernardi, RE; Gong, Q; Li, YL; Liang, H; Liang, JH; Wei, S, 2022
)
1.44
"Methylene blue photochemical treatment (100 µM methylene blue, 30 minutes of 12,500-lux red light exposure) of murine norovirus-contaminated masks reduced infectious viral titers by over four orders of magnitude on surgical mask surfaces."( Of masks and methylene blue-The use of methylene blue photochemical treatment to decontaminate surgical masks contaminated with a tenacious small nonenveloped norovirus.
Dams, L; de Jaeger, S; Fries, A; Harcourt, BH; Haubruge, E; Heyne, B; Lendvay, TS; Ludwig-Begall, LF; Razafimahefa, RM; Thiry, E; Wielick, C; Willaert, JF, 2022
)
2.53
"Methylene blue treatment did not alter Caspase-6 levels, assessed by RT-PCR, western blot and immunohistochemistry, but inhibited fluorescently-labelled Caspase-6 activity in acute brain slice intact neurons."( Methylene blue inhibits Caspase-6 activity, and reverses Caspase-6-induced cognitive impairment and neuroinflammation in aged mice.
Beauchet, O; Flores, J; LeBlanc, AC; Noël, A; Sjöström, PJ; Zhou, L, 2019
)
2.68
"Methylene blue treatment increased the sperm count (p < .001), viability (p < .001) and motility (p < .001) compared to the cisplatin group."( The ameliorative effects of methylene blue on testicular damage induced by cisplatin in rats.
Amiri, P; Gholami Jourabi, F; Hashemi, H; Heidarianpour, A; Yari, S, 2021
)
1.64
"Methylene blue has been the treatment of choice because of its effectiveness for both prevention and rescue therapy."( Use of Intravenous Hydroxocobalamin without Methylene Blue for Refractory Vasoplegic Syndrome After Cardiopulmonary Bypass.
Finamore, M; Peyko, V, 2021
)
1.6
"Methylene blue treatment does not reduce the Hb-NO or MetHb levels in intoxicated animals while administration of α-tocopherol acetate reduces substantially lipid peroxidation."( Investigation of in vivo toxicity of hydroxylamine sulfate and the efficiency of intoxication treatment by α-tocopherol acetate and methylene blue.
Prodanchuk, GM; Prodanchuk, MG; Tsakalof, AK; Tsatsakis, AM, 2013
)
1.32
"Methylene blue treated plasma showed reduced coagulation factor (CF) activity and protein levels. "( Quantitative evaluation of plasma after methylene blue and white light treatment in four Chinese blood centers.
Changqing, L; Chunhui, Y; Guohui, B; Hong, Y; Juanjuan, W; Mingyuan, W; Wuping, L; Xiaopu, X; Xinsheng, Z; Zherong, B, 2013
)
2.1
"Methylene blue treatment and 7 days of storage at 4 °C activated the protein C pathway, whereas storage at room temperature and storage after methylene blue treatment decreased the functional capacity of the protein C pathway."( Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation.
Greinacher, A; Hron, G; Kellner, S; Selleng, K; Thiele, T; Warkentin, TE; Wasner, C; Westphal, A, 2016
)
1.36
"Methylene blue treatment reduced these parameters."( Methylene blue prevents retinal damage in an experimental model of ischemic proliferative retinopathy.
Contartese, DS; Dorfman, VB; Fernández, JC; Inserra, PI; Larrayoz, IM; Loidl, CF; López-Costa, JJ; Martínez, A; Martínez-Murillo, R; Rey-Funes, M; Rolón, F, 2016
)
2.6
"Methylene blue (MB) treatment of plasma is known to reduce the activity of clotting factors, but its effect on thrombin generation and clot formation is not well documented."( Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate.
Cardigan, R; Cookson, P; Luddington, R; Philpot, K, 2009
)
2.06
"Methylene blue is the treatment of choice in symptomatic patients."( Methemoglobinemia: life-threatening hazard of multiple drug ingestions.
Garayúa, JE; Ramírez Rivera, J,
)
0.85
"Methylene blue treatment increased heart rate, cardiac index, mean arterial, pulmonary artery, pulmonary artery occlusion and central venous pressures, systemic vascular resistance, ventricular stroke work indices and O(2) delivery and uptake, and decreased lactate levels."( A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock.
Binnekade, JM; Daemen-Gubbels, CR; de Jong, M; Groeneveld, AB; Juffermans, NP; Vervloet, MG, 2010
)
1.39
"Methylene blue treatment reduced cerebral tissue nitrite/nitrate content (p < .05) and the number of inducible and neuronal nitric oxide synthase-activated cortical cells during administration (p < .01)."( Methylene blue protects the cortical blood-brain barrier against ischemia/reperfusion-induced disruptions.
Martijn, C; Miclescu, A; Sharma, HS; Wiklund, L, 2010
)
2.52
"Methylene blue-treated fresh-frozen plasma (MB-FFP) is mainly used in Europe. "( Anaphylactic reaction after methylene blue-treated plasma transfusion.
Castro, S; Chollet-Martin, S; Dewachter, P; Le Beller, C; Lillo-le-Louet, A; Mouton-Faivre, C; Nicaise-Roland, P, 2011
)
2.11
"Methylene blue light treatment (MBLT) is efficient in inactivating viruses in plasma. "( The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices.
Andreu, G; Depasse, F; Samama, MM; Seghatchian, J; Sensebé, L, 2005
)
2.11
"The methylene blue pretreatment induced the decrease of tracheal and lung tissue smooth muscle contraction amplitude increased by exogenous irritant--toluene. "( Inhibition of guanylyl cyclase in the airways hyperreactivity.
Antosova, M; Nosalova, G; Strapkova, A; Turcan, T, 2005
)
0.89
"Methylene blue (MB) treated plasma has been in clinical use for 15 years. "( Updates on pathogen inactivation of plasma using Theraflex methylene blue system.
Reichenberg, S; Seghatchian, J; Walker, WH, 2008
)
2.03
"Methylene blue pretreatment produced approximately 5-fold shifts to the right of both nitroglycerin and nitroprusside relaxation curves."( Nitroglycerin tolerance and cyclic GMP generation in the longitudinal smooth muscle of the guinea-pig ileum.
Burkman, AM; Fertel, RH; Keith, RA; Sokoloski, TD, 1983
)
0.99
"In methylene blue-treated rings isoproterenol- and forskolin-induced relaxation were prevented in both endothelium-intact and -denuded rings, but the inhibitory effect of methylene blue were significantly more in rings with endothelium than in those without."( beta-Adrenoceptor activates endothelium-dependent release of nitric oxide in rat aorta.
Daniel, EE; Kwan, CY; Zheng, XF, 1995
)
0.81
"Methylene blue treatment prevented the increase in plasma AA concentration in oestradiol benzoate-treated rats."( Adenohypophyseal ascorbic acid: influences of oestradiol and methylene blue.
Haluzík, M; Nedvídková, J; Schreiber, V, 1995
)
1.25
"Methylene blue-treated plasma and the cryoprecipitates obtained from it may be effective for replacement therapy in cases of von Willebrand disease and deficiencies of factor XIII and fibrinogen, but the clinical studies are needed to verify that possibility."( Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma.
Aznar, JA; Molina, R; Montoro, JM, 1999
)
2.01
"Methylene blue phototreatment effectively inactivates cell-free viruses in plasma while maintaining coagulation activities. "( Elimination of both cell-free and cell-associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system.
Abe, H; Hirayama, J; Ikebuchi, K; Ikeda, H; Owada, T; Yamada-Ohnishi, Y, 2000
)
1.97
"Methylene blue treatment resulted in methemoglobin formation and oxidative damage to red blood cells, leading to a regenerative anemia and a variety of tissue and biochemical changes secondary to erythrocyte injury."( Hematological effects in F344 rats and B6C3F1 mice during the 13-week gavage toxicity study of methylene blue trihydrate.
Chhabra, RS; Hejtmancik, MR; Kurtz, PJ; Persing, RL; Ryan, MJ; Toft, JD, 2002
)
1.25
"Methylene blue treatment increases GSH levels and PBG-synthetase activity in erythrocytes while liver and kidney GSH and GSSG levels remain constant."( Porphobilinogen synthetase activity response to increased levels of reduced glutathione produced by methylene blue, in blood, liver and kidney.
Castro Mendoza, HJ; de la Piedra, C; González Isabel, C; Jerez, E, 1979
)
1.2
"Treatment with methylene blue photosensitizer, PBM, and aPDT induced the initial microbial reduction, but aPDT was more effective 48 h after treatment."( Use of photodynamic therapy and photobiomodulation as alternatives for microbial control on clinical and subclinical mastitis in sheep.
da Silva Souza, KL; de Jesus Beloti, L; Frias, DFR; Neto, WMR; Núñez, SC; Silva, LO, 2022
)
1.06
"Treatment with methylene blue was initiated but did not result in complete resolution of cyanosis."( Methaemalbumin: a diagnostic surrogate for methaemoglobinaemia and treatment with red cell exchange in a patient with thalassaemia.
Fuenzy, AI; Lau, VI; Noga, T; Prus-Czarnecka, Z, 2023
)
1.25
"Co-treatment with methylene blue ameliorated the neurotoxic effects of CuO-NPs; therefore, MB evidently had a powerful modulatory effect against the neurotoxicity of nano-Cu oxide via its antioxidant and mitochondrial protection properties."( Protective effect of methylene blue against copper oxide nanoparticle-induced neurobehavioral toxicity.
El Okle, OS; Goma, AA; Tohamy, HG, 2021
)
1.26
"Treatment with methylene blue will result in reversal of methemoglobinemia and clinical recovery in most cases but needs to be used at appropriate doses in carefully selected individuals."( Evaluation and management of acquired methemoglobinemia associated with topical benzocaine use.
Ashraf, Z; Taleb, M; Tinkel, J; Valavoor, S, 2013
)
0.73
"Pretreatment with Methylene Blue (MB), a Tau aggregation inhibitor and a redox cycler, reduced hyperthermia-induced Tau oligomerization as well as nucleic acid damage."( Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo.
Binder, L; Bonnefoy, E; Buée, L; Chauderlier, A; Chouala, MS; Delattre, L; Galas, MC; Humez, S; Kayed, R; Lefebvre, B; Marciniak, E; Sultan, A; Tardivel, M; Violet, M, 2015
)
0.74
"Treatment with methylene blue markedly reduced activities of serum transaminase, gamma glutamine transferase and bilirubin levels as compared to bile-duct ligated rats without methylene blue."( Effects of methylene blue in reducing cholestatic oxidative stress and hepatic damage after bile-duct ligation in rats.
Aksu, B; Aktas, C; Civelek, S; Guzel, A; Kanter, M; Umit, H; Uzun, H, 2010
)
1.09
"Treatment with methylene blue did not alter per se any of the behavioral responses measured in the ETM, but blocked the effect promoted by SNP."( Role of ventral hippocampal nitric oxide/cGMP pathway in anxiety-related behaviors in rats submitted to the elevated T-maze.
Calixto, AV; De Lima, TC; Duarte, FS; Duzzioni, M; Faria, MS; Nascimento Häckl, LP, 2010
)
0.7
"Treatment with methylene blue, an antioxidant markedly reduced neuronal damage, leakage of albumin, overexpression of GFAP and damage to myelin following cardiac arrest."( Cardiac arrest-induced regional blood-brain barrier breakdown, edema formation and brain pathology: a light and electron microscopic study on a new model for neurodegeneration and neuroprotection in porcine brain.
Miclescu, A; Sharma, HS; Wiklund, L, 2011
)
0.71
"Treatment with methylene blue was initiated immediately."( Benzocaine-induced methaemoglobinaemia: a case study.
Bittmann, S; Krüger, C,
)
0.47
"Treatment with methylene blue should be guided by the whole clinical picture rather than by the MetHb level alone."( Symptomatic-low grade methemoglobinemia because of dapsone: a multiple hit hypothesis.
Klein, R; Skold, A,
)
0.47
"Pre-treatment with methylene blue enhanced the antianxiety effect of thymoquinone in both unstressed and stressed mice."( Thymoquinone produced antianxiety-like effects in mice through modulation of GABA and NO levels.
Dhingra, D; Gilhotra, N, 2011
)
0.69
"Pre-treatment with methylene blue enhanced the inhibitory effect of L-arginine and sodium nitroprusside on myometrial spontaneous contractions."( Effects of L-arginine and sodium nitroprusside on the spontaneous contractility of human non-pregnant uterus.
Ayoubi, JM; Dilaï, N; Fanchin, R; Hoffmann, P; Pons, JC; Stanke-Labesque, F, 2003
)
0.64
"Treatment with methylene blue should be considered in patients with anaphylactic hypotension that has not responded to other interventions."( Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue.
Evora, PR; Simon, MR, 2007
)
0.89
"Pretreatment with methylene blue (10(-5) M) increased both the amplitude and the duration of the contractile response in these tissues."( Endogenous vasodilators modulate pulmonary vascular anaphylaxis.
Adams, GK; Kelly, LJ; Undem, BJ, 1994
)
0.61
"Pretreatment with methylene blue in Group II also resulted in significant pulmonary artery vasoconstriction to even the 10(-6) mol/liter acetylcholine infusion (10.4 +/- 7.8% in Group II vs."( Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension.
Bagley, CW; Cycan, A; Fields, J; Mohanty, PK; Pandian, NG; Porter, TR; Taylor, DO, 1993
)
0.61
"Treatment with methylene blue and LNMA significantly potentiated 5-HT-induced contraction."( Relaxant effect of nitric oxide and prostacyclin on serotonin-induced vasocontraction of human umbilical artery.
Nakano, Y; Okatani, Y; Sagara, Y; Watanabe, K, 1996
)
0.63
"Pretreatment with methylene blue (10(-5) M) did not significantly influence the regional difference in the action of nicorandil."( Regional differences in the vasorelaxant effects of nicorandil and amlodipine on isolated porcine coronary arteries.
Bagger, JP; Frøbert, O; Mikkelsen, EO; Tankó, LB, 1998
)
0.62
"pretreatment with methylene blue (MB) (30 microg), a guanylyl cyclase inhibitor, significantly reduced the effects of microinjections of SNP (3 and 5 microg), however, this did not modify the stimulatory action of SIN-1 (30 microg) on plasma prolactin levels of conscious male rats."( Methylene blue inhibits stimulatory effect of sodium nitroprusside but not of 3-morpholino sydnonimine on prolactin secretion in freely moving male rats.
González, MC; Llorente, E, 1998
)
2.07
"Treatment with methylene blue significantly suppressed the drop of body weight and the increase in blood glucose and glycated hemoglobin concentrations in the diabetic group."( Treatment with the NO-synthase inhibitor, methylene blue, moderates the decrease in serum leptin concentration in streptozotocin-induced diabetes.
Haluzik, M; Nedvídková, J; Skrha, J, 1999
)
0.91
"Pretreatment with methylene blue completely blocked the febrile response."( Fever: an integrated response of the central nervous system to oxidative stress.
Maulik, G; Riedel, W, 1999
)
0.63
"Treatment with methylene blue was not significantly predictive of histological damage; the colour of the testis before detorsion was not correlated with histological damage."( The effect of methylene blue on histological damage after spermatic cord torsion in a rat model.
Greenstein, A; Matzkin, H; Schreiber, L, 2001
)
1.01
"Pretreatment with methylene blue (10(-5) M) or nitroglycerin (3 x 10(-8) M) inhibited or potentiated, respectively, the relaxing action of melatonin."( The mode of vasorelaxing action of melatonin in rabbit aorta.
Oe, H; Satake, N; Sawada, T; Shibata, S, 1991
)
0.6
"Treatment with methylene blue or mechanical endothelial damage increased the contractile work of basilar arteries stimulated by PGF2 alpha and reduced the affinity of the dihydropyridines in such precontracted vessels."( The influence of endothelium on the action of PGF2 alpha and some dihydropyridine-type calcium antagonists in porcine basilar arteries.
Fricke, U; Klaus, W; Kojda, G; Werner, G,
)
0.47
"Pretreatment with methylene blue (10(-5) M) also caused a significant reduction of the SNP-induced relaxations in the precontracted thoracic ducts."( Acetylcholine-induced release of endothelium-derived relaxing factor from lymphatic endothelial cells.
Ohhashi, T; Takahashi, N, 1991
)
0.6
"Treatment with methylene blue slowed the development of relaxation and, in the presence of cimetidine, depressed the magnitude of relaxation."( Mechanism underlying responses to histamine of isolated monkey and human cerebral arteries.
Toda, N, 1990
)
0.62

Toxicity

Methylene blue has been shown to be safe and effective against falciparum malaria in Africa. It was found that the methylene blue dye at doses differing by several orders of magnitude from those that are toxic for humans is not toxic.

ExcerptReferenceRelevance
"Because methylene blue exhibits germicidal, oxidation, and reduction properties, the authors asked whether this agent causes adverse effects on gametes, embryos, and/or secretions of the reproductive tract."( Adverse effects of methylene blue on human sperm motility, components of human reproductive tract fluids, and mouse embryo cleavage.
Accetta, CR; Anderson, TL; Coddington, CC; Hodgen, GD; Kruger, T; Swanson, J, 1989
)
1.04
" It allows a quantitative evaluation of the whole toxic effect (cytostasis and cytolysis) of activated macrophages on adherent tumour cells."( A simple photometric microassay for the quantitative evaluation of macrophage-mediated cytotoxicity on adherent cancer cells.
Jeannin, JF; Leclerc, A; Martin, F; Olsson, NO,
)
0.13
"The risk of adverse consequences of virus-inactivation procedures for plasma and cellular blood components must be less than the risk of transfusion-associated viral disease."( Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation.
Cifone, MA; Dodd, RY; Murli, H; Myhr, B; Wagner, SJ, 1995
)
0.56
"To describe photosensitization after prenatal exposure to a toxic amount of methylene blue and to alert pediatricians that, in a review of the literature, photosensitization (which this dye is capable of) has not been reported as a complication of prenatal exposure."( Methylene blue-induced phototoxicity: an unrecognized complication.
Gilbert, S; Magilner, D; Porat, R, 1996
)
1.97
" In addition to this newly observed complication, the patient had other previously described toxic effects."( Methylene blue-induced phototoxicity: an unrecognized complication.
Gilbert, S; Magilner, D; Porat, R, 1996
)
1.74
" Methylene blue also attenuated the toxic effects of all the tested compounds."( [Toxicity and hypotensive effect of L-arginine oxoborolidinone and its modulation by methylene blue. Comparison with L-arginine, nitrite, and nitrate].
Araujo Alvarez, JM; Bravo Avila, ME; Bustamante Quezada, A; Trujillo Ferrara, JG,
)
1.27
" This approach may offer a safe alternative to conventional antimicrobial treatment."( Cytotoxic effects of antimicrobial photodynamic therapy on keratinocytes in vitro.
Corry, D; Greenman, J; Purcell, WM; Zeina, B, 2002
)
0.31
" The most toxic MVOC was 1-decanol which was as effective as MMS in all test systems."( On the cytotoxicity of some microbial volatile organic compounds as studied in the human lung cell line A549.
Kreja, L; Seidel, HJ, 2002
)
0.31
" Therefore, standard dosages of MB appear to be safe in G6PD-deficient African populations with predominantly class III G6PD deficiency."( Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso.
Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, P; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Sanon, M; Schiek, W; Schirmer, H; Walter-Sack, I; Witte, S; Wüst, K, 2005
)
0.59
"40%, and FS 10% appeared to be safe as determined by no cytotoxic effects on rabbit corneal endothelial cells in culture."( Comparison of dyes for cataract surgery. Part 1: cytotoxicity to corneal endothelial cells in a rabbit model.
Chang, YS; Chen, YT; Hsiao, JH; Tseng, SH; Tseng, SY, 2005
)
0.33
" The primary outcome was the incidence of severe haemolysis or other serious adverse events (SAEs)."( Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841].
Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, PE; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Sanon, M; Schiek, W; Schirmer, H; Tapsoba, T; Walter-Sack, I; Witte, S, 2005
)
0.69
"No differences in the incidence of SAEs and other adverse events were observed between children treated with CQ-MB (including 24 cases of G6PD deficiency) compared to children treated with CQ."( Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841].
Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, PE; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Sanon, M; Schiek, W; Schirmer, H; Tapsoba, T; Walter-Sack, I; Witte, S, 2005
)
0.69
"MB is safe for the treatment of uncomplicated falciparum malaria, even in G6PD deficient African children."( Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841].
Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, PE; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Sanon, M; Schiek, W; Schirmer, H; Tapsoba, T; Walter-Sack, I; Witte, S, 2005
)
0.69
" We suggest that the mechanism of toxicity was a direct effect of methylene blue, although an adverse interaction with serotonin re-uptake inhibitors could not be excluded."( Methylene blue toxicity following infusion to localize parathyroid adenoma.
Majithia, A; Stearns, MP, 2006
)
2.01
" When tested up to toxic dose levels, S-59 was negative in the mouse bone marrow micronucleus assay and the rat hepatocyte unscheduled DNA synthesis (UDS) test."( The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment.
Gatehouse, D; Kirkland, D; Speit, G; Tice, RR, 2007
)
0.34
" Adverse reactions were 1 : 8500 with treated and 1 : 2177 with untreated units."( Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience.
Anagnostopoulos, N; Gorgolidis, G; Hantziara, S; Katsea, P; Kavallierou, L; Politis, C; Richardson, C; Triantaphylou, V; Tsoutsos, D; Ziroyannis, P, 2007
)
0.56
" The possibility of using PA for water disinfection depends on the ratio of safe and effective concentrations."( [Comparative toxicity of photosensitizers in varying destruction].
Beliaeva, NN; Golovach, EN; Kuznetsova, NA; Poliakova, EE; Sinitsina, OO; Sycheva, LP; Zholdakova, ZI,
)
0.13
" Reported adverse reaction to isosulfan blue/patent blue V varied from minor to severe anaphylactic reactions (1-3%) requiring vigorous resuscitation."( Methylene blue dye--a safe and effective alternative for sentinel lymph node localization.
Abdel-Rahman, AT; Akberali, S; Carpenter, R; Gattuso, JM; Mostafa, A; Varghese, P,
)
1.57
" No drug-related serious adverse events and no deaths occurred."( Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Coulibaly, B; Klose, C; Kouyaté, B; Mansmann, U; Meissner, P; Mockenhaupt, FP; Müller, O; Schirmer, RH; Sié, A; Walter-Sack, I; Zoungrana, A, 2008
)
0.66
"An increasing number of clinical observations suggest adverse neurologic outcome after methylene blue (MB) infusion in the setting of parathyroid surgery."( Adverse effects of methylene blue on the central nervous system.
Briner, A; Dayer, AG; Gascon, E; Kiss, JZ; Klauser, P; Licker, MJ; Morel, DR; Muller, D; Vutskits, L, 2008
)
0.9
" A potential side effect is neurotoxicity, often manifesting as confusion, hallucination, or seizure."( Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH, 2008
)
0.35
" It has been noted to cause skin necrosis, but its more mild adverse effects from intraparenchymal breast injections are not well characterized."( Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy.
Axelrod, P; Bleicher, RJ; Kloth, DD; Robinson, D, 2009
)
0.62
" It was found that the methylene blue dye at doses differing by several orders of magnitude from those that are toxic for humans is able to suppress completely the SOS response induced by UV with a wavelength of 300--400 nm in Escherichia coli."( [Methylene blue as a supressor of the genotoxic effect of ultraviolet radiation with a wavelength of 300-400 nm].
Cherviakov, GG; Chistiakov, VA; Kolenko, MA; Sazykina, MA; Usatov, AV, 2009
)
1.57
" We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia."( Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.
Gillman, PK; Stanford, BJ; Stanford, SC, 2010
)
0.6
" This is an extremely useful and relatively safe technique that has been underreported in the otolaryngology literature."( Utility and safety of methylene blue demarcation of preauricular sinuses and branchial sinuses and fistulae in children.
Dickson, JM; Ludemann, JP; Riding, KH, 2009
)
0.67
" Its use has been widely considered both safe and cost effective."( Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use.
Delfiner, J; Fernandez, J; Pollack, A; Pollack, G, 2009
)
0.66
"The data suggest that there is a safe therapeutic window whereby PDT can inactivate endodontic pathogens without affecting host cell viability."( Endodontic antimicrobial photodynamic therapy: safety assessment in mammalian cell cultures.
Battaglino, RA; Fontana, CR; Kent, R; Morse, LR; Pagonis, TC; Soukos, NS; Xu, Y; Young, MJ, 2009
)
0.35
"Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide."( Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity.
Garna, A; Giovanis, P; Giusto, M; Marcante, M; Nardi, K,
)
0.4
"A serious adverse effect that can limit the utility of ifosfamide is neurotoxicity, known as ifosfamide-induced encephalopathy (IIE)."( Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity.
Marshall, H; McQuary, A; Richards, A, 2011
)
0.73
"Marking with blue dye injection is a safe and low cost method for localization of non palpable breast lesions that are detectable by Ultrasound."( Marking non-palpable breast masses with injected methylene blue dye, an easy, safe and low cost method for developing countries and resource-limited areas.
Akramossadat, S; Asieh, O; Fereshte, E; Golshan, M; Ladan, F; Nasrinossadat, A; Reza, C, 2011
)
0.62
" Only non-serious adverse events occurred."( Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers.
Danese, S; Di Stefano, AF; Jas, V; Moro, L; Radicioni, MM; Repici, A, 2012
)
1.82
" These data support strongly that AFL is safe and sufficient for transcutaneous delivery of drugs and vaccines."( Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology.
Anderson, RR; Chen, X; Kositratna, G; Manstein, D; Shah, D; Wu, MX, 2012
)
0.38
" These results support the idea of a safe production of recombinant proteins using adenoviral vectors."( Biosafety evaluation of recombinant protein production in goat mammary gland using adenoviral vectors: preliminary study.
Espinoza, AS; Moltó, MP; Pedroso, MS; Pose, AG; Rodríguez, ES; Zamora, PA, 2012
)
0.38
" Our results indicate that methylene blue can rescue toxic phenotypes associated with mutant TDP-43 and FUS including neuronal dysfunction and oxidative stress."( Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio.
Ciura, S; Drapeau, P; Kabashi, E; Maios, C; Parker, JA; Patten, SA; Therrien, M; Vaccaro, A, 2012
)
2.12
"Methylene blue (MB) has been shown to be safe and effective against falciparum malaria in Africa and to have pronounced gametocytocidal properties."( Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso.
Berens-Riha, N; Bountogo, M; Bousema, T; Breitkreutz, J; Coulibaly, B; Drakeley, C; Kieser, M; Klose, C; Meissner, PE; Mockenhaupt, FP; Müller, O; Nebié, E; Pritsch, M; Schirmer, RH; Sié, A; Sirima, SB; Wieser, A, 2015
)
2.09
" We observed no procedural complications or adverse events."( Efficacy, Safety, and Predictors of Intradiscal Methylene Blue Injection for Discogenic Low Back Pain: Results of a Multicenter Prospective Clinical Series.
Geurts, JW; Kallewaard, JW; Kessels, A; van Kleef, M; van Santbrink, H; Willems, P, 2016
)
0.69
" The verdict of the toxicity assay rendered the treated permeate as biologically safe for discharge or reuse in industrial and domestic purposes."( Optimization and modelling of synthetic azo dye wastewater treatment using Graphene oxide nanoplatelets: Characterization toxicity evaluation and optimization using Artificial Neural Network.
Banerjee, P; Das, P; Mukhopadhayay, A; Sau, S, 2015
)
0.42
" After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)."( Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial.
Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018
)
0.75
"Serotonin syndrome (SS) is a potentially serious side effect of serotonergic drugs."( Serotonin Toxicity and Urinary Analgesics: A Case Report and Systematic Literature Review of Methylene Blue-Induced Serotonin Syndrome.
K Schultz, S; Warren, MW; Zuschlag, ZD, 2018
)
0.7
" Therefore, PDT seems to be a safe method in the treatment of periodontal infections without significant side effects."( Photodynamic Therapy has no Adverse Effects In Vitro on Human Gingival Fibroblasts and Osteoblasts.
Azaripour, A; Azaripour, M; Noorden, CJFV; Willershausen, B; Willershausen, I, 2018
)
0.48
"Noninvasive, safe and cost-effective cell viability assay is important in many fields of biological research such as cell culture and counting."( Noninvasive and safe cell viability assay for Paramecium using natural pigment extracted from food.
Tokunaga, E; Yamashita, K, 2020
)
0.56
"Preoperative CT-guided methylene blue/collagen solution injection offers a safe and highly effective technique for marking subpleural lung nodules undergoing VATS or RATS."( Methylene Blue/Collagen Mixture for CT-Guided Presurgical Lung Nodule Marking: High Efficacy and Safety.
Adam, B; Aoun, HD; Baciewcz, F; Beydoun, R; Heath, KE; Littrup, PJ; Prus, M, 2020
)
2.31
"Under the same parameters, the combined group and PDT have good germicidal efficacy, but PDT has fewer adverse reactions and less damage."( [Comparison of the effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy on caries prevention].
Yao, LP; Yu, XH; Zhang, L, 2020
)
0.79
" However, the safety of MB is being questioned since serious adverse events (AEs) such as hemodynamic instability, hemolysis, and serotonin syndrome were reported."( Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review.
Baijens, LWJ; Kremer, B; Maxim, A; Pilz, W; Simon, SR; Tariq, B, 2021
)
0.91
" These findings indicate that it is safe to use small amounts of MB as a food dye during swallowing examinations."( Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review.
Baijens, LWJ; Kremer, B; Maxim, A; Pilz, W; Simon, SR; Tariq, B, 2021
)
0.91
" It was proven to be safe and reliable in clinical trials of HIV treatment."( Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
Cheng, L; Jiang, M; Jin, C; Liu, F; Lu, X; Wu, H; Wu, N; Yao, H; Yu, B; Zhang, J; Zhou, X, 2021
)
2.06
" In both acute and chronic tests, the degraded dye had a stronger toxic effect when compared to the untreated dye."( When treatment increases the contaminant's ecotoxicity: A study of the Fenton process in the degradation of methylene blue.
Carlos, TD; Cavallini, GS; Gravato, C; Pallini, A; Pereira Dornelas, AS; Pereira, DH; Sarmento, RA; Vieira, MM, 2021
)
0.83
" Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9 (PHQ-9) were used to evaluate the pre-operation and post-operation states of the patients, and adverse events were recorded."( Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome.
Fang, H; Liao, L; Su, D; Wang, M; Wang, X; Yang, H; Yang, Y; Yu, X; Zhang, J; Zhang, W, 2022
)
0.99
"Ultrasound-guided intra-articular MB injection is a safe and effective therapy for patients with LFJS."( Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome.
Fang, H; Liao, L; Su, D; Wang, M; Wang, X; Yang, H; Yang, Y; Yu, X; Zhang, J; Zhang, W, 2022
)
0.99
"Our findings justify the use of methylene blue and carbon nanoparticles in reverse lymphatic mapping, as they can increase the efficiency of collecting "target lymph nodes" and minimize the iatrogenic injury in the donor area while having no significant adverse effects on the survival condition of transplanted lymph nodes."( Methylene blue and carbon nanoparticles had no significant adverse effects on the survival and function of lymph nodes after non-vascularized transplantation in a mouse model.
Chen, L; Dong, D; Liu, C; Liu, T; Wang, H; Yuan, M, 2022
)
2.45
" Given the concern for Ag NPs' cytotoxicity for adverse health effect, cytotoxicity measurement in HEK 293T cell lines were performed."( Evaluation of silver nanoparticles attached to methylene blue as an antimicrobial agent and its cytotoxicity.
Banga, S; Brooks, A; Er, AO; Hakimov, S; Harness, B; Hurley, J; Kylychbekov, S; Neupane, S, 2022
)
0.98
" CONCLUSIONS Anticholinergic toxidrome may explain the neurological adverse effects associated with high doses of methylene blue."( Anticholinergic Toxidrome as a Possible Explanation for Methylene Blue Toxicity.
Aldeghaither, S; Deschênes, PJF; Samoukovic, G, 2023
)
1.37

Pharmacokinetics

ExcerptReferenceRelevance
" Therefore, in order to investigate the distributive profile for MB as compared with that for CDP, pharmacokinetic parameters for MB and CDP were estimated from plasma concentration--time data following simultaneous intravenous administration by a bolus injection and by a contrast rate infusion in rabbits."( Dose dependency of apparent volumes of distribution for methylene blue in rabbits.
Kozaki, A; Watanabe, J, 1981
)
0.51
"Using an in vitro pharmacokinetic model, area under the curve (AUC) estimates from an osmotic continuous-withdrawal device were compared to AUC estimates by a conventional trapezoidal method."( In vitro evaluation of a continuous-sampling device for pharmacokinetic parameter estimation.
Chocas, EC; Paap, CM, 1993
)
0.29
" In most clinical pharmacokinetic studies, the phenomenon of autoinduction has been observed, but the mechanism is not completely understood."( Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Beijnen, JH; de Kraker, J; Groen, HJ; Jansen, RL; Keizer, HJ; Kerbusch, T; Schellens, JH; van Putten, JW, 2001
)
0.31
" The developed analytical method was successfully applied to the pharmacokinetic study of MB and AZB in rats."( Simultaneous quantification of methylene blue and its major metabolite, azure B, in plasma by LC-MS/MS and its application for a pharmacokinetic study.
Ha, DJ; Kim, SJ; Koo, TS, 2014
)
0.69

Compound-Compound Interactions

Methylene blue combined with aprotinin on intraperitoneal adhesion. Primaquine and methylene blue are gametocytocidal drugs that can be combined with artemisinin-based combination therapy (ACT) to reduce malaria transmission.

ExcerptReferenceRelevance
" A combination with fluorescence labeling (FITC-dextran uptake) of macrophage-like cells, allowed us to demonstrate 1) the complete, regular distribution of both cell populations along the entire small intestine, and 2) the constant, intimate associations between interstitial cells of Cajal and macrophage-like cells."( Selective double staining of interstitial cells of Cajal and macrophage-like cells in small intestine by an improved supravital methylene blue technique combined with FITC-dextran uptake.
Mikkelsen, HB; Thuneberg, L; Wittrup, IH, 1988
)
0.48
"To study the effect of methylene blue combined with aprotinin on intraperitoneal adhesion."( [Clinical study of the effect of methylene blue combined with aprotinin on intraperitoneal adhesion].
Cao, TS; Liu, RH; Sun, XM, 2005
)
0.92
" vulgaris in the presence of MB or NFR combined with H2O2 results in the decomposition of both the algal species and the photosensitizer."( Photosensitized destruction of Chlorella vulgaris by Methylene Blue or Nuclear Fast Red combined with hydrogen peroxide under visible light irradiation.
McCullagh, C; Robertson, PK, 2006
)
0.58
"MB-AQ is a promising alternative drug combination against malaria in Africa."( Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Coulibaly, B; Klose, C; Kouyaté, B; Mansmann, U; Meissner, P; Mockenhaupt, FP; Müller, O; Schirmer, RH; Sié, A; Walter-Sack, I; Zoungrana, A, 2008
)
0.66
"Indirect computed tomography lymphography (CT-LG) combined with blue dye injection can locate the sentinel lymph node (SLN) in tongue carcinoma."( Localization of the sentinel lymph node in tongue VX2 carcinoma via indirect CT lymphography combined with methylene blue dye injection.
Hoffman, MR; Rieves, A; Sha, Y; Shen, N; Shu, Y; Wu, H; Xi, X; Ying, H; Zhou, L, 2010
)
0.57
"To localize the SLN in tongue VX2 carcinoma using indirect CT-LG combined with methylene blue injection."( Localization of the sentinel lymph node in tongue VX2 carcinoma via indirect CT lymphography combined with methylene blue dye injection.
Hoffman, MR; Rieves, A; Sha, Y; Shen, N; Shu, Y; Wu, H; Xi, X; Ying, H; Zhou, L, 2010
)
0.8
" Serotonin toxicity is reviewed, using the lessons inherent in the methylene blue story and experience, to illustrate how the mechanisms and potency of serotonergic drugs interact to determine severity."( CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.
Gillman, PK, 2011
)
0.92
" Our current study examines whether the method of radiocolloid combined with methylene dye localization (RCML) has an advantage over WL."( Radiocolloid in combination with methylene dye localization, rather than wire localization, is a preferred procedure for excisional biopsy of nonpalpable breast lesions.
Fan, W; Fu, JH; He, JH; Tang, J; Wang, X; Wu, YP; Xie, XM; Xie, ZM; Yang, MT, 2011
)
0.37
"This study aimed to determine if Photodynamic Antimicrobial Chemotherapy (PACT) was effective in the treatment of Burkholderia cepacia complex infection and whether a synergistic effect was evident if PACT was used in combination with antibiotics."( Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection.
Cassidy, CM; Donnelly, RF; Elborn, JS; Magee, ND; Tunney, MM, 2012
)
0.38
"The main objective of this study is to test the efficacy of magnesium oxide combined with two tissue conditioners (Viscogel and GC Soft), in inhibiting the growth of Candida albicans."( The effectiveness of magnesium oxide combined with tissue conditioners in inhibiting the growth of Candida albicans: an in vitro study.
Bhat, AM; Kanathila, H; Krishna, PD,
)
0.13
" Results : The inhibition effect of magnesium oxide 1% combined with tissue conditioners (VGC and GCC) is not significant in both the groups."( The effectiveness of magnesium oxide combined with tissue conditioners in inhibiting the growth of Candida albicans: an in vitro study.
Bhat, AM; Kanathila, H; Krishna, PD,
)
0.13
"Magnesium oxide in combination with tissue conditioners are effective against Candida albicans; GC soft with magnesium oxide showed a better result than Viscogel with magnesium oxide; Increasing the concentration of magnesium oxide increases the zone of inhibition of Candida albicans."( The effectiveness of magnesium oxide combined with tissue conditioners in inhibiting the growth of Candida albicans: an in vitro study.
Bhat, AM; Kanathila, H; Krishna, PD,
)
0.13
"The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei."( The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine.
Aldana, I; Bertani, S; Deharo, E; Garavito, G; Quiliano, M; Valentin, A, 2012
)
0.97
"The study demonstrated the synergistic photoactivated antimicrobial effects of CDots in combination with other photosensitizers."( Synergistic photoactivated antimicrobial effects of carbon dots combined with dye photosensitizers.
Bond, AE; Coleman, M; Dong, X; Pan, N; Sun, YP; Tang, Y; Yang, L, 2018
)
0.48
" This study sought to assess the efficacy of laser fluorescence alone and in combination with photosensitizers for detection of demineralized smooth-surface lesions of permanent teeth."( Evaluation of laser fluorescence in combination with photosensitizers for detection of demineralized lesions.
Bargrizan, M; Fekrazad, R; Kalhori, KA; NouhzadehMalekshah, S, 2019
)
0.51
" Primaquine (PQ) and methylene blue (MB) are gametocytocidal drugs that can be combined with artemisinin-based combination therapy (ACT) to reduce malaria transmission, including resistant strains."( Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial.
Compaoré, G; Coulibaly, B; D Alessandro, U; Jahn, A; Kieser, M; Klose, C; Krisam, J; Lu, G; Meissner, P; Mendes Jorge, M; Mockenhaupt, FP; Müller, O; Nebie, E; Ouermi, L; Sié, A, 2019
)
1.07
" indocyanine green fluorescence (ICG), combined with blue dye in patients with breast cancer."( Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer.
Jiang, Y; Li, Y; Lin, Y; Liu, H; Mao, F; Shen, S; Sun, Q; Xiao, M; Zhang, J; Zhang, X; Zhou, Y; Zhu, Q, 2019
)
0.51
"To compare the anti-caries effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy (MB-PDT)."( [Comparison of the effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy on caries prevention].
Yao, LP; Yu, XH; Zhang, L, 2020
)
1.01
" The efficacy of Indocyanine green (ICG) combined with methylene blue (group A) and fluorescein combined with methylene blue (group B) in SLNB of breast cancer was compared, complications were observed at the same time."( Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer.
Chu, J; Ding, Y; Gao, N; Li, L; Lin, XN; Liu, JQ; Xu, WH; Yang, AQ, 2021
)
1.13
"Using the Murine Hepatitis Virus (MHV) A59 coronavirus as a SARS-CoV-2 animal surrogate, we validated that methylene blue (MB) in combination with sunlight exposure is a robust, fast, and low-cost decontamination method for PPE that should be added to the toolbox of practical pandemic preparedness."( Methylene blue in combination with sunlight as a low cost and effective disinfection method for coronavirus-contaminated PPE.
Gordon, PMK; Heyne, B; Vos, KA, 2022
)
2.38
"The analgesic effect of IV self-controlled analgesia combined with ropivacaine is quick, but the maintenance time is short."( Methylene Blue Combined with Ropivacaine for Intercostal Nerve Block After Autologous Costal Cartilage Removal in Juvenile Patients.
Chen, Z; Liu, Y; Lu, X; Ren, J; Sun, P, 2022
)
2.16
"To observe the effect of methylene blue combined with ropivacaine intercostal nerve block on postoperative analgesia after autologous costal cartilage augmentation rhinoplasty."( Application of methylene blue combined with ropivacaine intercostal nerve block in postoperative analgesia of autologous costal cartilage augmentation rhinoplasty.
Guoyu, J; Tao, W; Xi, Y, 2022
)
1.38
" In the experimental group methylene blue was combined with ropivacaine intercostal nerve block as patient controlled intravenous analgesia (PCIA), and the control group was ropivacaine intercostal nerve block combined with PCIA."( Application of methylene blue combined with ropivacaine intercostal nerve block in postoperative analgesia of autologous costal cartilage augmentation rhinoplasty.
Guoyu, J; Tao, W; Xi, Y, 2022
)
1.37
"Intercostal nerve block with methylene blue combined with ropivacaine can achieve good postoperative analgesic effects in augmentation rhinoplasty with autologous costal cartilage."( Application of methylene blue combined with ropivacaine intercostal nerve block in postoperative analgesia of autologous costal cartilage augmentation rhinoplasty.
Guoyu, J; Tao, W; Xi, Y, 2022
)
1.37
"Our 3DVT based on CT-LG data combined with methylene blue in ESLNB ensures a high identification rate of SLNs with low false-negative rates."( Three-dimensional visual technique based on CT lymphography data combined with methylene blue in endoscopic sentinel lymph node biopsy for breast cancer.
Luo, Y; Ou, C; Wang, B; Wang, Y; Ye, J; Yu, J; Zhang, P, 2022
)
1.21
"In this work, we develop a mussel-inspired biosorbent combined with graphene oxide for removal of organic dyes in water sources."( Mussel - Inspired biosorbent combined with graphene oxide for removal of organic pollutants from aqueous solutions.
An, NHT; Dat, NT; Linh, ND; Manh, NB; Thu, VT; Trieu, MH, 2023
)
0.91
" We evaluated the application of indocyanine green (ICG) lymphography combined with MB staining in lower limb lymphaticovenular anastomosis (LVA)."( Application of indocyanine green lymphography combined with methylene blue staining in lymphaticovenular anastomosis of lower limb vessels: A prospective study.
Guo, X; Liu, B; Ma, G; Tang, Y; Zhou, X, 2023
)
1.15
" ICG lymphography combined with MB staining has the advantages of real-time visualization and accurate localization."( Application of indocyanine green lymphography combined with methylene blue staining in lymphaticovenular anastomosis of lower limb vessels: A prospective study.
Guo, X; Liu, B; Ma, G; Tang, Y; Zhou, X, 2023
)
1.15
"This study aimed to evaluate the feasibility of applying carbon nanoparticles (CNs) to visualize clip-marked metastatic nodes in combination with indocyanine green (ICG) and methylene blue (MB) as sentinel lymph node (SLN) tracers for targeted axillary dissection (TAD) after neoadjuvant therapy (NAT)."( Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
Fan, L; Hua, B; Li, Y; Ren, XT; Yang, X, 2023
)
1.31
"This study investigated the effect of fiberoptic ductoscopy (FDS) combined with methylene blue staining immediately after FDS procedure on pathological nipple discharge diseases."( A retrospective study of ductoscopy combined with immediate methylene blue staining in nipple discharge diseases.
Wang, HL; Yang, WS; Zhang, FF; Zhang, Y, 2023
)
1.38

Bioavailability

A chyle leak may also result in blue staining of the drain output. This is not an immediate phenomenon, and rather, based on the bioavailability of methylene blue this would take a minimum of 1 hour. The dye is absorbed into mesenteric lymphatics and travels via the thoracic duct.

ExcerptReferenceRelevance
"Sodium salicylate improves the rectal absorption of drugs which exhibit molecular self-association; it is suggested that salicylate may improve drug bioavailability by altering the drug self-association pattern."( Prevention of molecular self-association by sodium salicylate: effect on methylene blue.
Fisher, P; Touitou, E, 1986
)
0.5
" Bioisosteric replacement of the carboxylic function by tetrazole to increase bioavailability and to maintain comparable acidity led to improved antimalarial properties as well, but only with the cyanoethyl-protected tetrazoles."( 5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials.
Bauer, H; Biot, C; Davioud-Charvet, E; Schirmer, RH, 2004
)
0.32
"To evaluate the bioavailability and bioactivity of human growth hormone (hGH) delivered transdermally through microchannels (MCs) in the skin created by radio-frequency (RF) ablation."( Transdermal delivery of human growth hormone through RF-microchannels.
Gershonowitz, A; Levin, G; Phillip, M; Rudaev, S; Sacks, H; Sherman, A; Stern, M; Zivin, I, 2005
)
0.33
" Creation of MCs in the outer layers of the skin enabled efficient delivery of hGH, with a bioavailability of 75% (rats) or 33% (GPs) relative to subcutaneous (s."( Transdermal delivery of human growth hormone through RF-microchannels.
Gershonowitz, A; Levin, G; Phillip, M; Rudaev, S; Sacks, H; Sherman, A; Stern, M; Zivin, I, 2005
)
0.33
" With the aim of excluding treatment failures due to low bioavailability, we have investigated the absolute bioavailability of MB given as an aqueous oral formulation and its interaction with chloroquine (CQ)."( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
0.63
" The absolute bioavailability was 72."( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
0.63
"The absolute bioavailability of MB is high."( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
0.63
" The absolute bioavailability was also investigated after the intake of 2L of bowel cleansing preparation in 2h and by comparing the dose of 200mg with a single iv dose of 100mg in the same subjects."( Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers.
Danese, S; Di Stefano, AF; Jas, V; Moro, L; Radicioni, MM; Repici, A, 2012
)
1.82
" By decreasing particle sizes nanosuspensions enhance dissolution rate and bioavailability of the active pharmaceutical ingredient."( Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics.
Geissler, S; Hill, A; Mäder, K; Weigandt, M, 2012
)
0.38
" A chyle leak may also result in blue staining of the drain output; however, this is not an immediate phenomenon, and rather, based on the bioavailability of methylene blue this would take a minimum of 1 hour, and more likely up to 4 hours, as the dye is absorbed into mesenteric lymphatics and travels via the thoracic duct."( Determining between chyle leak and anastomotic leak after esophageal reconstruction: the utility of methylene blue dye.
Fairbank, S; Huang, T; Kapila, S; Rozen, WM; Wu, T, 2012
)
0.79
" In this study, we aimed to prepare novel hydrophobic glutathione coated PLGA nanoparticles to improve bioavailability of MB in the brain."( Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies.
Groshev, A; Grover, A; Jinwal, UK; Sutariya, VB; Zhang, J, 2014
)
0.68
" Concurrent administration of P-gp inhibitors and P-gp substrate drugs may also result in alterations in the bioavailability of some antimalarials."( The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation.
Crowe, A; Page-Sharp, M; Senarathna, SM, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The optimum condition for methylene blue adsorption was found at pH 8 with an adsorbent dosage of 3g/L and an initial concentration of 400mg/L. The dose-response curve of CpCr(NO)2Cl was displaced to the right by hemoglobin, as well as methyleneBlue.

ExcerptRelevanceReference
" The applicability of this method for rapid and accurate evaluation of fibrinolytic activity was demonstrated by dose-response curves with purified plasmin, plasmin generated by urokinase in human plasma and euglobulin."( A method using fibrin-fixed Blue Dextran for determining the plasmin and plasmin inhibitor activities in human plasma.
Fujii, S; Kosugi, T; Mori, H; Otsuka, A; Sakurai, E; Sone, K; Sumi, H; Tamura, Y, 1978
)
0.26
" This effect is studied with respect to dose-response and time-response relationships, the influence of concentrations of bilirubin and albumin, and the oxygen consumption."( Photodegradation of bilirubin as enhanced by photosensitizers in vitro.
Jährig, D; Jährig, K; Meisel, P, 1978
)
0.26
" Dose-response relations to norepinephrine, endothelium-dependent dilators (acetylcholine, histamine, and A23187), and nitroglycerin were done."( Depression of endothelium-dependent relaxation in aorta from rats with Brugia pahangi lymphatic filariasis.
Kaiser, L; Lamb, VL; Tithof, PK; Williams, JF, 1991
)
0.28
" The dose-response curve of SNP was shifted to the right, and the relaxation to verapamil was slightly reduced."( Endothelium-derived relaxing factor influences renal vascular resistance.
Förstermann, U; Frölich, JC; Radermacher, J, 1990
)
0.28
" A full dose-response relationship could not be constructed for proendothelin, but the highest dose used (4 nmol) increased the perfusion pressure by 15."( Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat.
Douglas, SA; Hiley, CR, 1990
)
0.28
" Methylene blue also caused 10 fold and 100 fold rightward shifts in the dose-response curves of MY-5445 and vinpocetine, respectively."( Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Brazdil, R; Diocee, BK; Jordan, R; Souness, JE, 1989
)
1.19
" Captopril (10(-6) M) and SnoCap (10(-6) M) equally inhibited contraction to angiotensin I, inducing a 50-fold shift in the dose-response curve."( S-nitrosocaptopril. II. Effects on vascular reactivity.
Andon, N; Cooke, JP; Loscalzo, J, 1989
)
0.28
"The currently recommended dosage regimen for methylene blue (intermittent bolus dose) in the treatment of methaemoglobinaemia caused by dapsone is often inadequate."( Management of dapsone poisoning complicated by methaemoglobinaemia.
Dawson, AH; Whyte, IM,
)
0.39
" Cimetidine shifted the dose-response curve for histamine to the right, but chlorpheniramine did not alter the response."( Mechanisms of histamine-induced relaxation in isolated monkey and dog coronary arteries.
Toda, N, 1986
)
0.27
" From these data it appears that as conditions may warrant, the dosage of methylene blue may be safely increased up to at least 15 mg/kg in therapy of severe methemoglobinemias."( Methylene blue: effects and disposition in sheep.
Burrows, GE, 1984
)
1.94
" retrograde method was studied at flow rates and dosage volumes typically used in neonatal intensive-care units."( Flow dynamics of a retrograde i.v. drug infusion system.
Gauger, LJ; Gibboney, ER; Nordin, BJ, 1984
)
0.27
" While methylene blue in judicious dosage will reduce the content of methaemoglobin after aniline exposure, it may not eliminate visible cyanosis."( Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia.
Harvey, JW; Keitt, AS, 1983
)
0.98
" In vitro, the dose-response curves of norepinephrine in isolated intact aortic and mesenteric rings form the exercise trained-SHR were significantly lower than those from the untrained-SHR."( Chronic exercise enhances endothelium-mediated dilation in spontaneously hypertensive rats.
Ding, YA; Lee, YM; Sheu, JR; Yang, JH; Yen, MH, 1995
)
0.29
" A rapid, transient relaxation was observed during the cumulative dose-response and a new plateau of equilibrium was seen following an increase in developed force after the last dose of SP."( Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries.
Arden, WA; Fiscus, RR; Gross, DR; Lanzo, S; Maley, RH; Salley, RK, 1994
)
0.29
" When the endothelium was removed, however, the dose-response curves of both groups of rats were shifted to the left with an increase in maximum responses and they were no longer significantly different (max."( Effect of swimming on vascular reactivity to phenylephrine and KC1 in male rats.
Jansakul, C, 1995
)
0.29
" Methylene Blue (which blocks production of cGMP by EDRF-NO) and Nw-nitro-L-arginine (which inhibits EDRF-NO synthesis), both shifted 5-HT dose-response curves to the left and completely abolished the differences in sensitivity to the agonist."( Nitric oxide and superoxide anions in vascular reactivity of renovascular hypertensive rats.
Bellver, A; Celentano, MM; de la Riva, IJ; Rosón, MI; Vega, GW, 1995
)
1.2
" Utilizing the dorsal hand vein technique, dose-response curves to bradykinin (maximum dose = 513 ng/min) were constructed in veins preconstricted with the alpha-adrenergic agonist phenylephrine in healthy young volunteers."( Mechanism of bradykinin-induced venodilation in humans.
Blaschke, TF; Dachman, WD; Ford, GA; Hoffman, BB, 1993
)
0.29
" Nitroprusside, atriopeptin II and 8-Br-cGMP all increased renin release but the dose-response relationships were biphasic."( Cyclic GMP-linked pathway for renin secretion.
Abu-Kishk, RA; D'Aloia, MA; Lush, DJ; Noble, AR; Williams, BC, 1994
)
0.29
" Pyo (10 microM) surmountably inhibited aortic responses to GTN, isosorbide dinitrate, SIN-1, and SNAP with a characteristic rightward shift of the dose-response curve; the apparent EC50 of these drugs for relaxation of phenylephrine-contracted aorta was increased 18-, 4-, 13-, and 15-fold, respectively."( Inhibition of nitrovasodilators by pyocyanin and methylene blue is dissociated from nitric oxide formation.
Bozinovski, J; Brien, JF; Marks, GS; Nakatsu, K, 1994
)
0.54
" Six-minute pretreatment with 50 nmol of the nitric oxide synthase inhibitor L-NG-nitroarginine (NNR) significantly inhibited CD-produced hot-plate and tail-flick antinociception as evidenced by 6-fold shifts to the right of the CD dose-response curves."( Pharmacologic evidence that spinal muscarinic analgesia is mediated by an L-arginine/nitric oxide/cyclic GMP cascade in rats.
Iwamoto, ET; Marion, L, 1994
)
0.29
" Rings of femoral artery from heartworm-infected and noninfected control dogs were suspended in muscle baths, and dose-response relationships to endothelium-dependent (methacholine) and -independent (sodium nitroprusside) vasodilators were done."( Dirofilaria immitis: depression of endothelium-dependent relaxation of canine femoral artery seen in vivo does not persist in vitro.
Kaiser, L; Lamb, VL; Mupanomunda, M; Schwartz, AJ; Schwartz, NR; Tithof, PK; Williams, JF, 1994
)
0.29
" In healthy volunteers full dose-response curves were constructed by infusing histamine, before and after administration of an H1 or H2 antagonist or both antagonists, into dorsal hand veins preconstricted with the alpha-adrenergic agonist phenylephrine."( Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes.
Bedarida, G; Blaschke, TF; Dachman, WD; Hoffman, BB, 1994
)
0.29
"Nitric oxide synthase(NOS) inhibitor,N omega-nitro-L-arginine methyl ester (L-NAME, 10-300 mg/kg) and L-NG-monomethyl-arginine (L-NMMA, 30-300 mg/kg) suppressed the swellings of adjuvant-injected paw of rats (25-54%) at day 2 and 8 when dosed intraperitoneally and orally for 4 days from day -1 to day 2 after adjuvant."( Nitric oxide and superoxide radical are involved in both initiation and development of adjuvant arthritis in rats.
Oyanagui, Y, 1994
)
0.29
" A dose-response study was conducted to find a concentration of H2O2 which increased CF without influencing left ventricular developed (LVDP) or end-diastolic (LVEDP) pressures."( The role of nitric oxide in the cardiac effects of hydrogen peroxide.
Skjelbakken, T; Vaage, J; Valen, G, 1996
)
0.29
"25 to 30 mg kg-1 significantly increased the percentage of open arm entries and exhibited an inverted U-shaped dose-response curve."( Anxiolytic and antidepressant properties of methylene blue in animal models.
Cağlayan, B; Eroğlu, L, 1997
)
0.56
"Uncertainty of the transport of reactive chemicals to the lung is a major concern when using intranasal dosing of animals."( The importance of the diluent for airway transport of toluene diisocyanate following intranasal dosing of mice.
Ebino, K; Karol, MH; Lemus, R, 1999
)
0.3
" The dose-response curve, however, had an inverted U shape."( Anxiolytic effect of methylene blue microinjected into the dorsal periaqueductal gray matter.
de-Oliveira, RW; Guimarães, FS, 1999
)
0.62
" The dose-response curve of CpCr(NO)2Cl was displaced to the right by hemoglobin, as well as methylene blue, showing involvement of the NO/cGMP pathway."( Vasodilator effects of organotransition-metal nitrosyl complexes, novel nitric oxide donors.
Legzdins, P; Pang, CC; Poon, JS; Wang, YX, 2000
)
0.53
"A dose-response relationship was found between the measured absorption of the solder and the burst pressure of the anastomoses formed."( Methylene blue based protein solder for vascular anastomoses: an in vitro burst pressure study.
Bell, PR; Birch, JF; Mandley, DJ; Trotter, PJ; Wilkinson, F; Williams, SL; Worrall, DR, 2000
)
1.75
", commercially available laxatives, and dosage forms with PMAA-based enteric-coatings (Eudragit L)."( Leakage of enteric (Eudragit L)-coated dosage forms in simulated gastric juice in the presence of poly(ethylene glycol).
Breitkreutz, J, 2000
)
0.31
" This tumour model can be of use in further studies to optimize particle size and dosage for embolization as well as to evaluate the effect of different anti-neoplastic drugs, slowly released by controlled degradation of dextran microspheres."( The VX2 carcinoma in the rabbit auricle as an experimental model for intra-arterial embolization of head and neck squamous cell carcinoma with dextran microspheres.
Bernsen, MR; Bosman, F; Dullens, HF; Franssen, O; Hennink, WE; Slootweg, PJ; van Es, RJ, 1999
)
0.3
"A new oral dosage form for controlled and complete release of drug after a predetermined lag time is described."( Channeling agent and drug release from a central core matrix tablet.
Fini, A; González-Rodríguez, ML; Merino, S; Pérez-Martínez, JI; Rabasco, AM, 2001
)
0.31
" The methods have been applied to the determination of the three compounds in a commercial dosage form."( Determination of phenolphthalein and methylene blue by first derivative spectrophotometry and potassium nitrate by direct spectrophotometry in a pharmaceutical formulation.
Aşik, S; Dölen, E; Yalçin, G,
)
0.4
" Antibiotic dosed solid CLMs were placed on agar plates streaked with Escherichia coli and incubated."( Local pharmaceutical release from a new hydrogel implant.
Chen, J; Felsen, D; Petratos, PB; Poppas, DP, 2002
)
0.31
" The aim of this study was to understand the kinetics of urea and methylene blue instilled into the inner ear space through the RWM and to establish a method for determining the optimal dosage for the treatment of inner ear disorders."( Estimation of perilymph concentration of agents applied to the round window membrane by microdialysis.
Hunter, BA; Juhn, SK; Lee, S; Odland, RM, 2003
)
0.56
"Inner ear microdialysis may be a useful method for establishing a therapeutic dosage for ototoxic agents used in the treatment of inner ear disorders."( Estimation of perilymph concentration of agents applied to the round window membrane by microdialysis.
Hunter, BA; Juhn, SK; Lee, S; Odland, RM, 2003
)
0.32
" A clinically relevant increase in systemic vascular resistance and a decrease in norepinephrine dosage were observed in 51 patients within 1 hour after methylene blue infusion."( Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?
Fischer, S; Hagl, C; Haverich, A; Knobloch, K; Kofidis, T; Leyh, RG; Simon, AR; Strüber, M; Wachsmann, B, 2003
)
1.96
" The optimum experimental conditions were investigated in detail, including the selection of measuring wave-length and catalytic reactive medium, the dosage of indicator and oxidizer, the influence of temperature and reactive time, and the interference of co-existent ions with the assay."( [Determination of nitrate and nitrite by catalytic spectrophotometry of potassium bromate-methylene blue system].
Deng, J; Xu, JS; Yuan, YL, 2002
)
0.54
" Color removal efficiencies increased rapidly with Fe/Cu dosage and reaction time, respectively, at initial time and slowly to stable values."( Discoloration of methylene blue and wastewater from a plant by a Fe/Cu bimetallic system.
Ding, ZG; Gao, TY; Liu, J; Ma, LM; Xu, WY; Zhou, RF, 2004
)
0.66
" This introductory review will initiate a series of papers on the occasion of Ehrlich's 150th birthday and the 'World Conference on Dosing of Antiinfectives: Dosing the Magic Bullets', which is going to be held in Nürnberg, Germany, from September 9 to 11, 2004 (see www."( The return of Ehrlich's 'Therapia magna sterilisans' and other Ehrlich concepts?. Series of papers honoring Paul Ehrlich on the occasion of his 150th birthday.
Sörgel, F, 2004
)
0.32
" Intraperitoneal injection of 20% water solution of L-arginine in dosage 200 mg per 100 g of an animal body mass have had aggravated an acute pancreatitis course; intravenous injection of 1% water solution of methylene blue in dosage 1 mg per 100 g of an animal body mass caused pancreatoprotective effect."( [Role of nitric oxide and lipid peroxidation in pathogenesis of acute experimental pancreatitis].
Fedorovich, AA; Krivoruchko, IA, 2005
)
0.52
" Although Azure B is a significant impurity in methylene blue trihydrate, the amount of Azure B seen in urine samples collected from rodents dosed with methylene blue trihydrate is significantly greater than the amount seen in rodent urine spiked directly with methylene blue."( Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and B6C3F1 mouse urine.
Gaudette, NF; Lodge, JW,
)
0.73
" The adsorption potential of JPW was observed to be dependent on various parameters such as type of dye, initial dye concentration, pH and dosage of adsorbent."( Use of jute processing wastes for treatment of wastewater contaminated with dye and other organics.
Banerjee, S; Dastidar, MG, 2005
)
0.33
" However, dosing regimens and protocols need to be clearly defined before widespread routine use."( Vasoplegic syndrome--the role of methylene blue.
Shanmugam, G, 2005
)
0.61
"A capillary electrophoresis method for the determination of the dye methylene blue (tetramethylthionine, MB) in human urine depending on liquid/liquid-extraction and diode array detection has been developed, validated, and applied to samples of healthy individuals, who had been dosed with methylene blue within clinical studies."( Analysis of methylene blue in human urine by capillary electrophoresis.
Borwitzky, H; Burhenne, J; Haefeli, WE, 2005
)
0.94
"In this study, adsorption kinetics of a cationic dye, methylene blue, onto clay from aqueous solution with respect to the initial dye concentration, temperature, pH, mixing rate and sorbent dosage were investigated."( The adsorption kinetics of the cationic dye, methylene blue, onto clay.
Açikyildiz, M; Bayrak, R; Doğar, C; Gürses, A; Karaca, S; Yalçin, M, 2006
)
0.84
" The influence of factors as EDLs, solution volume and TiO(2) catalyst dosage on the decomposition of MB in the PCD/EDLs process was also investigated."( Photocatalytic degradation of methylene blue in TiO2 aqueous suspensions using microwave powered electrodeless discharge lamps.
Hong, J; Liu, YZ; Sun, C; Yang, SG, 2006
)
0.62
" The effect of system variables such as concentration, temperature, pH, contact time, adsorbent dosage and particle size was studied."( Adsorptive removal of basic dyes from aqueous phase onto activated carbon of used tea leaves: a kinetic and thermodynamic study.
Rastogi, K; Singh, DK, 2004
)
0.32
" contact time, solution pH, biosorbent dosage and initial dye concentration."( Kinetic and equilibrium studies of methylene blue biosorption by Posidonia oceanica (L.) fibres.
Mahjoub, B; Ncibi, MC; Seffen, M, 2007
)
0.62
" The adsorption of methylene blue onto dehydrated wheat bran (DWB) was investigated at temperatures (25-45 degrees C), initial methylene blue (MB) concentrations (100-500 mg L(-1)) and adsorbent dosage at the given contact time for the removal of dye."( Removal of methylene blue from aqueous solution by dehydrated wheat bran carbon.
Dursun, G; Ozer, A, 2007
)
1.06
" The operating variables studied were initial dye concentration, initial solution pH, adsorbent dosage and contact time."( Mass transfer, kinetics and equilibrium studies for the biosorption of methylene blue using Paspalum notatum.
Kumar, KV; Porkodi, K, 2007
)
0.57
" The effects of shaking time, biosorbent dosage and pH on adsorption capacity were studied."( Methylene blue biosorption from aqueous solutions by yellow passion fruit waste.
Dias, SL; Lima, EC; Mazzocato, AC; Pavan, FA, 2008
)
1.79
" Dose-response experiments in single cell neuronal cultures revealed that a 2-h-long exposure to MB at non-cell-death-inducing concentrations could still induce significant retraction of dendritic arbor."( Adverse effects of methylene blue on the central nervous system.
Briner, A; Dayer, AG; Gascon, E; Kiss, JZ; Klauser, P; Licker, MJ; Morel, DR; Muller, D; Vutskits, L, 2008
)
0.67
" Dosed rats developed methemoglobinemia and a regenerative Heinz body anemia."( Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies).
, 2008
)
0.61
" Batch kinetics and isotherm studies were carried out under varying experimental conditions of contact time, initial methylene blue concentration, adsorbent dosage and pH."( Adsorptive removal of methylene blue by tea waste.
Islam, MA; Mahmud, S; Rukanuzzaman, M; Uddin, MT, 2009
)
0.88
" The effects of shaking time, adsorbent dosage and pH on adsorption capacity were studied."( Applications of Brazilian pine-fruit shell in natural and carbonized forms as adsorbents to removal of methylene blue from aqueous solutions--kinetic and equilibrium study.
Calvete, T; Cardoso, NF; Lima, EC; Royer, B; Simon, NM; Vaghetti, JC; Veses, RC, 2009
)
0.57
" Batch adsorption tests were performed at 25 degrees C and the effects of particle size, contact time, adsorbent dosage and pH were investigated."( Activated carbons from waste biomass: an alternative use for biodiesel production solid residues.
Franca, AS; Nunes, AA; Oliveira, LS, 2009
)
0.35
" The influence of different DNA extraction procedures for 8-oxodG and 8-oxodA levels was assessed in DNA extracted from rat livers following dosing with carbon tetrachloride."( Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry.
Farmer, PB; Gescher, AJ; Kaur, B; Sharma, RA; Singh, R; Steward, WP; Teichert, F; Verschoyle, RD; Vives, M, 2009
)
0.35
" It is concluded that PEO in combination with PVP yields a non disintegrating type bioadhesive dosage form which is suitable for gastroretentive applications."( Evaluation of polyethylene oxide compacts as gastroretentive delivery systems.
Alfredson, T; Anne, P; Birudaraj, R; Jasti, B; Killion, R; Li, X; Mahalingam, R; Stefanidis, D, 2009
)
0.35
" Then they were used as adsorbent for the removal of methylene blue from aqueous solutions under varying conditions of initial concentration, carbon dosage and pH."( Preparation and characterization of activated carbon from cotton stalk by microwave assisted chemical activation--application in methylene blue adsorption from aqueous solution.
Dai, J; Deng, H; Tao, G; Yang, L, 2009
)
0.81
" Adrenaline caused inhibition of rhythmic activity at a dosage that increased the rate of isolated sinus venosus."( Inherent rhythmicity and interstitial cells of Cajal in a frog vein.
Ghose, D; Jose, L; Manjunatha, S; Rao, JP; Rao, MS, 2008
)
0.35
" Batch adsorption tests were performed at 25 degrees C and the effects of particle size, contact time, adsorbent dosage and initial solution pH were investigated."( Microwave assisted thermal treatment of defective coffee beans press cake for the production of adsorbents.
Alves, CC; Franca, AS; Nunes, AA; Oliveira, LS, 2010
)
0.36
" In rats survival of all dosed groups was similar to that of the vehicle controls, whereas mice exhibited a dose-dependent increase in survival."( Toxicity and carcinogenicity studies of methylene blue trihydrate in F344N rats and B6C3F1 mice.
Auerbach, SS; Bristol, DW; Chhabra, RS; Hébert, CD; Peckham, JC; Travlos, GS, 2010
)
0.63
"One titrimetric and two spectrophotometric methods which are simple, sensitive and rapid are described for the assay of salbutamol sulphate (SBS) in bulk drug and in tablet dosage forms using N-bromosuccinimide (NBS) and two dyes, rhodamine-B and methylene blue, as reagents."( Rapid titrimetric and spectrophotometric methods for salbutamol sulphate in pharmaceuticals using N-bromosuccinimide.
Basavaiah, K; Ramakrishna, V; Somashekar, BC, 2007
)
0.52
"We present a novel PDMS-based microinjection system in a microfluidic format with precise electroosmotic dosage control."( Microinjection in a microfluidic format using flexible and compliant channels and electroosmotic dosage control.
Noori, A; Selvaganapathy, PR; Wilson, J, 2009
)
0.35
" The toxicity of MB, however, limits parenteral (subcutaneous) administration of the dye to dosage levels which are much less effective than the maximum tolerated oral levels."( THE ANTIRICKETTSIAL EFFECT OF THIONINE DYES : I. THE USE OF METHYLENE BLUE AND TOLUIDINE BLUE TO COMBAT EXPERIMENTAL TSUTSUGAMUSHI DISEASE (SCRUB TYPHUS).
Fox, JP; Peterson, OL, 1947
)
0.47
"1) Heparin and ACE inhibitors are risk factors; 2) In the recommended doses it is safe (the lethal dose is 40 mg/kg); 3) The use of MB does not cause endothelial dysfunction; 4) The MB effect appears in cases of nitric oxide (NO) up-regulation; 5) MB is not a vasoconstrictor, by blocking of the GMPc system it releases the AMPc system, facilitating the norepinephrine vasoconstrictor effect; 6) The most used dosage is 2 mg/kg as IV bolus followed by the same continuous infusion because plasmatic concentrations strongly decays in the first 40 minutes; 7) There is a possible 'window of opportunity' for the MB's effectiveness."( Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties.
Alves Junior, L; Bassetto, S; Evora, PM; Evora, PR; Menardi, AC; Reis, CL; Ribeiro, PJ; Rodrigues, AJ; Vicente, WV,
)
1.57
" The experiments conducted at different dye concentrations (12 and 20 ppm), catalyst loading, pH and H2O2 dosage (1-10 ml l(-1)), revealed that the degradation rate is strongly influenced by respective experimental parameters."( Titamium oxide (TiO2) assisted photocatalytic degradation of methylene blue.
Madhu, GM; Pai, KV; Raj, MA, 2009
)
0.59
" The effects of pH, catalyst dosage ([ZnO]) and initial concentration of MB ([MB]) on the photocatalytic degradation efficiency of MB were investigated."( Microwave-assisted preparation, characterization and photocatalytic properties of a dumbbell-shaped ZnO photocatalyst.
Dong, SY; Feng, JL; Sun, JH; Sun, SP; Wu, QH; Yang, LY, 2010
)
0.36
" It has been observed that the optimum pH is 8 and adsorbent dosage required is 4 g/L for 97% removal of methylene blue (100 mg/L)."( Removal of basic dye (methylene blue) from aqueous solution by adsorption using Musa paradisica: a agricultural waste.
Shrivastava, VS; Sonawane, GH, 2009
)
0.88
" The tested MB was completely decolorized in Na-OL-1 suspension by the fraction dosing of H(2)O(2) (556."( Decolorization of methylene blue in layered manganese oxide suspension with H2O2.
Hu, C; Hu, X; Nie, Y; Zhang, L, 2011
)
0.7
" The effect factors including pH, contact time, temperature and dosage on the adsorption properties of methylene blue onto graphene were investigated."( Adsorption of methylene blue from aqueous solution by graphene.
Du, Q; Jiao, Y; Li, Y; Liu, T; Sun, J; Wang, K; Wang, Z; Wu, D; Xia, Y; Yang, G; Zhang, W; Zhu, H, 2012
)
0.95
" The parameters affecting MB adsorption included pH, initial concentration of MB, reaction temperature, particle size and dosage of WPWS."( Removal of methylene blue from aqueous solution using wine-processing waste sludge.
Chen, YM; Li, HH; Li, YS; Liu, CC; Wang, MK, 2012
)
0.77
" The performance of the MSN(AP) was tested by the adsorption of MB in a batch system under varying pH (2-11), adsorbent dosage (0."( Amino modified mesostructured silica nanoparticles for efficient adsorption of methylene blue.
Hameed, BH; Jalil, AA; Jusoh, NW; Jusoh, R; Kamarudin, NH; Karim, AH; Sidik, SM; Triwahyono, S, 2012
)
0.61
" Initial dye concentration and adsorbent dosage were found as significant factors for the adsorption of MB dye."( Adsorption of methylene blue dye from aqueous solution by sugar extracted spent rice biomass.
Han, JI; Kim, I; Ur Rehman, MS, 2012
)
0.74
" The hazardous dyes MG and MB removal studied under the various conditions like contact time, dye concentration, temperature, pH and adsorbent dosage to examine the adsorption characteristics of the newly synthesized mesoporous AlPO(4) molecular sieves."( Hazardous dyes removal from aqueous solution over mesoporous aluminophosphate with textural porosity by adsorption.
Devi, MR; Kannan, C; Muthuraja, K, 2013
)
0.39
" In a human GBM xenograft model, a single daily dosage of MB does not activate AMP-activated protein kinase signaling, and no tumor regression was observed."( Reversing the Warburg effect as a treatment for glioblastoma.
Bigner, DD; Choudhury, GR; Ghorpade, A; Keir, ST; Li, W; Liu, R; Poteet, E; Ryou, MG; Simpkins, JW; Tang, L; Wen, Y; Winters, A; Yan, H; Yang, SH; Yuan, F, 2013
)
0.39
"0), contact time (1-60 min), sorbent dosage (0."( Improved biosorption potential of Thuja orientalis cone powder for the biosorptive removal of Basic Blue 9.
Akar, T; Balk, YY; Tuna, O; Tunali Akar, S, 2013
)
0.39
" The effects of pH, contact time, temperature and dosage on the adsorption properties of methylene blue onto calcium alginate immobilized graphene oxide composites were investigated."( Methylene blue adsorption on graphene oxide/calcium alginate composites.
Du, Q; Li, Y; Liu, T; Sun, J; Wang, Y; Wang, Z; Wu, S; Xia, L; Xia, Y, 2013
)
2.05
" The effects of variables such as pH, initial dye concentration, adsorbent dosage (g), temperature and sonication time (min) on MB removal were studied and using central composite design (CCD) and the optimum experimental conditions were found with desirability function (DF) combined response surface methodology (RSM)."( Optimization of the ultrasonic assisted removal of methylene blue by gold nanoparticles loaded on activated carbon using experimental design methodology.
Asghari, A; Daneshfar, A; Ghaedi, M; Roosta, M; Sahraei, R, 2014
)
0.65
"A simple, rapid, sensitive, and accurate extractive spectrophotometric method has been developed for the determination of seven nonsteroidal anti-inflammatory drugs (NSAIDs)--namely diclofenac sodium, ibuprofen, indomethacin, ketoprofen, ketorolac tromethamine, mefenamic acid, and naproxen-in pure forms as well as their pharmaceutical dosage forms (tablets, capsules, effervescent granules, syrups, oral drops, ampules, eye drops, gels, and suppositories)."( Extractive spectrophotometric determination of some nonsteroidal anti-inflammatory drugs using methylene blue.
El-Kommos, ME; Hakiem, AF; Mohamed, NA,
)
0.35
" Sensitive, rapid, and fully validated electrochemical and RP-LC methods for the determination of IRT in its dosage form were presented in details."( Analytical application of polymethylene blue-multiwalled carbon nanotubes modified glassy carbon electrode on anticancer drug irinotecan and determination of its ionization constant value.
Akmese, B; Can, A; Dogan-Topal, B; Karadas, N; Ozkan, SA; Sanli, S, 2013
)
0.68
" The effects of factors including pH, contact time, temperature, and dosage on the adsorption properties of MB onto graphene and modified graphene were investigated."( [Adsorption properties of modified graphene for methylene blue removal from wastewater].
Luo, HJ; Wang, C; Wang, H; Wang, YW; Wu, Y; Zhang, ZL, 2013
)
0.65
" We find that 6 weeks of methylene blue dosing in the water from 16 months to 17."( Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.
Carlson, GA; Friedman, T; Hyman, BT; Pitstick, R; Polydoro, M; Roe, A; Spires-Jones, TL, 2014
)
2.15
" The adsorption capacity increased with increasing the initial dye concentration and pH, while it decreased with increasing the adsorbent dosage and temperature, indicating an exothermic process."( Study of Methylene Blue adsorption on keratin nanofibrous membranes.
Aluigi, A; Jannoke, L; Rombaldoni, F; Tonetti, C, 2014
)
0.82
" The influence of solution pH, initial dye concentration, contact time and adsorbent dosage was examined in batch mode and optimum conditions was set as pH=7."( Artificial neural network-genetic algorithm based optimization for the adsorption of methylene blue and brilliant green from aqueous solution by graphite oxide nanoparticle.
Ghaedi, AM; Ghaedi, M; Tashkhourian, J; Teimuori, M; Zeinali, N, 2014
)
0.63
" The decolorization efficiency of MWs for methylene blue (MB) azo dye was examined as a function of pH, stirring time, MW dosage and initial concentration of the MB solution."( Facile decolorization of methylene blue with flower-like manganese wads.
Huang, C; Wei, B; Yang, A; Zhang, Z, 2014
)
0.97
" Administration of MB increases the expression of E-selectin and VCAM-1 depending on the dosage and time of exposure."( Methylene blue modulates adhesion molecule expression on microvascular endothelial cells.
Beiras-Fernandez, A; Guo, F; Lupinski, M; Meybohm, P; Moritz, A; Stock, UA; Werner, I, 2014
)
1.85
" The PPy/Fe3O4 capsule shell used as a support was constructed in one-step, which not only dramatically simplified the preparation process, but also easily controlled the magnetic properties of the catalysts through adjusting the dosage of FeCl2·4H2O."( A simple way to prepare Au@polypyrrole/Fe3O4 hollow capsules with high stability and their application in catalytic reduction of methylene blue dye.
Cui, F; Cui, T; Wang, H; Wu, J; Xu, L; Yao, T, 2014
)
0.61
" The effects of initial MB concentration (100-900mgL(-1)), contact time (15-315min), the pH of the solution (3-10), temperature (298-318K), adsorbent dosage (0."( Removal of methylene blue from aqueous solutions by chemically modified bamboo.
Guo, JZ; Li, B; Liu, L; Lv, K, 2014
)
0.79
" Batch adsorption studies were carried out to investigate the effects of the initial pH of the solution, the dosage of adsorbent, the contact time and temperature on the adsorption of methylene blue."( [Adsorption of methylene blue from aqueous solution onto magnetic Fe3O4/ graphene oxide nanoparticles].
Chang, Q; Hu, MX; Huang, J; Jiang, GD; Tang, HQ, 2014
)
0.95
"16 K), biosorbent dosage (1-10 g L(-1)), contact time (0-1,440 min), agitation speed (0-150 rpm) and dye concentration (25-2,500 mg L(-1))."( Biosorption of methylene blue by de-oiled algal biomass: equilibrium, kinetics and artificial neural network modelling.
Chokshi, K; Ghosh, A; Ghosh, T; Maurya, R; Mishra, S; Paliwal, C; Pancha, I; Shrivastav, A, 2014
)
0.76
" As a regenerable adsorbent, negligible difference in regeneration efficiency was observed when a higher Oxone(®) dosage was employed but a better efficiency was obtained at a lower MACC loading."( Performance of magnetic activated carbon composite as peroxymonosulfate activator and regenerable adsorbent via sulfate radical-mediated oxidation processes.
Dong, Z; Lim, TT; Lua, SK; Oh, WD, 2015
)
0.42
" The optimum condition for methylene blue adsorption on the adsorbent was found at pH 8 with an adsorbent dosage of 3g/L and an initial concentration of 400mg/L, and the removal percentage reached above 90%."( Preparation and adsorption property of xylan/poly(acrylic acid) magnetic nanocomposite hydrogel adsorbent.
Jing, Z; Liu, B; Sun, XF; Wang, H, 2015
)
0.71
" Effects of various conditions such as initial concentration of methylene blue (MB), initial pH, contact time, dosage of biosorbent, and stirring rate were also investigated for the adsorption process."( Potential biosorbent derived from Calligonum polygonoides for removal of methylene blue dye from aqueous solution.
Abd El-Salam, NM; Khan, AS; Khan, H; Khan, MI; Man, Z; Muhammad, N; Nasrullah, A, 2015
)
0.89
" Then the dependency of dyes removal percentage in their ternary solution on the level and magnitude of variables such as sonication time, initial dyes concentrations and adsorbent dosage was fully investigated and optimized by central composite design (CCD) under response surface methodology (RSM) as well as by regarding desirability function (DF) as a good and general criterion."( Simultaneous ultrasound-assisted ternary adsorption of dyes onto copper-doped zinc sulfide nanoparticles loaded on activated carbon: optimization by response surface methodology.
Asfaram, A; Bazrafshan, AA; Ghaedi, M; Goudarzi, A; Hajati, S, 2015
)
0.42
"The reassessed and reaffirmed concepts were 1) MB is safe in the recommended doses (the lethal dose is 40 mg/kg); 2) MB does not cause endothelial dysfunction; 3) The MB effect appears in cases of NO up-regulation; 4) MB is not a vasoconstrictor, by blocking the cGMP pathway it releases the cAMP pathway, facilitating the norepinephrine vasoconstrictor effect; 5) The most used dosage is 2 mg/kg as IV bolus, followed by the same continuous infusion because plasma concentrations sharply decrease in the first 40 minutes; and 6) There is a possible "window of opportunity" for MB's effectiveness."( Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised.
Alves Junior, L; Bassetto, S; Evora, PR; Ferreira, CA; Menardi, AC; Rodrigues, AJ; Scorzoni Filho, A; Vicente, WV,
)
0.37
" Decolorization efficiencies were also affected by initial pH value, initial concentration of methylene blue, dosage of PAA-Fe NPs, and degradation temperature."( [Enhanced reductive decoloration of methylene blue by polyacrylic acid modified zero-valent iron nanoparticles].
He, J; Liu, KQ; Wang, P; Wang, XY, 2015
)
0.91
" Effective generation of singlet oxygen was achieved with a low photosensitizer dosage (0."( In vitro investigation of methylene blue-bearing, electrostatically assembled aptamer-silica nanocomposites as potential photodynamic therapeutics.
Ding, TS; Hsu, HY; Huang, XC; Luo, YL, 2015
)
0.72
" In this paper, we have developed a novel hybrid agar-polydimethylsiloxane (PDMS) microfluidic device for single- and multi-concentration chemical dosing and on-chip oviposition screening of free-flying adult stage Drosophila."( An integrated hybrid microfluidic device for oviposition-based chemical screening of adult Drosophila melanogaster.
Hilliker, AJ; Leung, JC; Rezai, P, 2016
)
0.43
" The enhancement of the magnetic field achieved by increases in the initial dye concentration, and a decrease in the biochar dosage and solution pH, were more significant compared with those caused by other conditions."( Effect of a magnetic field on the adsorptive removal of methylene blue onto wheat straw biochar.
Li, G; Liu, L; Zhang, C; Zhang, S; Zhao, W; Zhu, L; Zhu, W, 2016
)
0.68
" The effect of various parameters such as pH, contact time and initial dye concentration, sorption isotherm and adsorbent dosage were studied."( Experimental Design Approach for Methylene Blue Dye Removal in Aqueous Environment by Nitrilotriacetic Modified Banana Pith.
Lee, SL; Liew, SW; Ong, ST, 2016
)
0.72
" Adsorption parameters such as initial pH of the dye solution and adsorbent dosage were also optimized."( Peroxide-assisted microwave activation of pyrolysis char for adsorption of dyes from wastewater.
Nair, V; Vinu, R, 2016
)
0.43
" Results indicated that MB produced hormetic dose-response effects on memory."( Methylene Blue Facilitates Memory Retention in Zebrafish in a Dose-Dependent Manner.
Caramillo, EM; Echevarria, DJ; Gonzalez-Lima, F, 2016
)
1.88
" The adsorption experiments were carried out under different conditions of initial dye concentration (50-100 mg/L) adsorbent dosage (0."( Adsorption of methylene blue using modified adsorbents from drinking water treatment sludge.
El-Daim El Taher, MA; Fadlalla, SM; Nageeb Rashed, M, 2016
)
0.79
" Solution pH, initial dye concentration and adsorbent dosage were studied as independent variables at five levels each, respectively."( Lotus seedpod as a low-cost biomass for potential methylene blue adsorption.
He, Q; Wang, H; Yang, K; Zhang, J; Zheng, L; Zhou, J; Zou, Z, 2016
)
0.69
" In order to obtain the maximum removal of MB dye from wastewater, the adsorption experimental parameters such as initial dye concentration, contact time, solution pH and adsorbent dosage were optimized by trial and error approach."( Computation of adsorption parameters for the removal of dye from wastewater by microwave assisted sawdust: Theoretical and experimental analysis.
A, S; C, R; P, SK; P, SR; S, S, 2017
)
0.46
" Therefore, the aim of this study was to review available data regarding mechanisms, dosing strategies, and side effects of MB, with a focus on its applications for vasoplegia in cardiac surgery."( Methylene Blue for Vasoplegic Syndrome.
Booth, AT; Mehaffey, JH; Melmer, PD; Tribble, B; Tribble, C, 2017
)
1.9
"A strategy combining covalent conjugation of photosensitizers to a peptide ligand directed to the melanocortin 1 (MC1) receptor with the application of sequential LED light dosage at near-IR wavelengths was developed to achieve specific cytotoxicity to melanocytes and melanoma (MEL) with minimal collateral damage to surrounding cells such as keratinocytes (KER)."( Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy.
Bigliardi, PL; Bigliardi-Qi, M; Burkett, BA; Eberle, AN; Krishnan-Kutty, V; Pant, A; Rout, B; Srinivas, R, 2017
)
0.46
" Effect of pH, dye concentration, adsorbent dosage and temperature were studied."( A comparison of mango seed kernel powder, mango leaf powder and Manilkara zapota seed powder for decolorization of methylene blue dye and antimicrobial activity.
Muthuramu, KL; Sundararaman, B, 2016
)
0.64
" The adsorption parameters including the initial pH value, dosage of biosorbents, contact time, and initial MB concentration were investigated to find the optimum adsorption conditions."( Microwave-Hydrothermal Treated Grape Peel as an Efficient Biosorbent for Methylene Blue Removal.
Jiang, C; Lin, Z; Ma, L; Zou, Z, 2018
)
0.71
" The conditions affecting the photocatalytic degradation, including the dosage of photocatalyst, the initial concentration of MB, pH value, and hardness of water were systematically evaluated."( Doping Ag/AgCl in zeolitic imidazolate framework-8 (ZIF-8) to enhance the performance of photodegradation of methylene blue.
Fan, G; Guo, L; Lin, R; Luo, J; Snyder, SA; Zheng, X, 2018
)
0.69
" The effects of the dosage of catalyst, initial solution pH and the amount of hydrogen peroxide on the removal of MB were investigated."( Catalytic performances of Ni/Fe layered double hydroxides fabricated via different methods in Fenton-like processes.
Tian, B; Wang, Q; Wang, X, 2018
)
0.48
" The blocking drug used was an MB compound preparation, and several indexes were recorded, including pain visual analogue scores (VAS), dosage of oral analgesic required, plasma interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and cortisol levels, basic viability, selfassessment, and satisfaction."( Clinical Study of Ultrasound-Guided Methylene Blue Thoracic Paravertebral Nerve Block for the Treatment of Postherpetic Neuralgia.
Mei, L; Wang, W; Zhao, P, 2019
)
0.79
" The patients' degree of pain and dosage of oral analgesic required were reduced, basic patient viability was improved, and patients reported higher degrees of satisfaction."( Clinical Study of Ultrasound-Guided Methylene Blue Thoracic Paravertebral Nerve Block for the Treatment of Postherpetic Neuralgia.
Mei, L; Wang, W; Zhao, P, 2019
)
0.79
" The effects of adsorption conditions such as adsorption time, initial concentration of MB and dosage of SSP on the detoxification of MB were examined."( Adsorption behaviors of methylene blue on sunflower stem pith.
Jing, G; Liu, X; Sun, Y; Wang, B, 2019
)
0.82
" The effects of temperature, solution pH, initial dye concentration, and adsorbent dosage on the adsorption of methylene blue using the obtained hydrochar were also investigated and the conditions necessary for the maximum removal and adsorption capacity were determined."( Hydrothermal carbonization of acerola (Malphigia emarginata D.C.) wastes and its application as an adsorbent.
Barrozo, MAS; Duarte, CR; Nogueira, GDR, 2019
)
0.73
" Adjusting the copper ferrite dosage in the composite as well as presence of fatty acids as benign materials surrounding nanoparticles led to decline the cytotoxicity of the fabricated samples."( Facile fabrication of cytocompatible polyester fiber composite incorporated via photocatalytic nano copper ferrite/myristic-lauric fatty acids coating with antibacterial and hydrophobic performances.
Bashiri Rezaie, A; Mahmoudi Rad, M; Montazer, M, 2019
)
0.51
" This combined with a plateau at higher doses is consistent with the lack of dose-response seen in the Phase III trials."( Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Harrington, CR; Jia, J; Kook, K; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM, 2019
)
0.51
" An MB dosage of 5 mg/kg IV administered at a CRI of 2 mg/kg/h exhibited the most protective effect against histopathological damage caused by intestinal ischemia-reperfusion."( Assessment of effects of methylene blue on intestinal ischemia and reperfusion in a rabbit model: hemodynamic, histological and immunohistochemical study.
Domínguez, JM; Fernández-Sarmiento, JA; Gómez-Villamandos, RJ; Granados, MDM; Molina, V; Morgaz, J; Muñoz-Rascón, P; Navarrete, R; Pérez, J; Ventura, S; Zafra, R, 2020
)
0.86
" Because of the variety of dosing strategies used and the incongruences between patient populations, it is also challenging to define finite recommendations."( Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock.
Sullivan, JB; Tchen, S, 2020
)
0.84
" The influences of initial dye concentration, dosage of PGP-DC, pH, ionic strength, and encapsulation mode on the encapsulation were systematically studied."( Facile synthesis of amphiphilic peach gum polysaccharide as a robust host for efficient encapsulation of methylene blue and methyl orange dyes from water.
Huang, X; Tan, J; Xu, X; Zeng, S; Zhou, L, 2020
)
0.77
"0); Biochar dosage (0."( Removal of methylene blue dye using rice husk, cow dung and sludge biochar: Characterization, application, and kinetic studies.
Ahmad, A; Chaturvedi, P; Chowdhary, P; Giri, BS; Khan, N, 2020
)
0.95
" Regardless of resistance phenotype, MB-aPDT presented species-specific dose-response kinetics."( Global priority multidrug-resistant pathogens do not resist photodynamic therapy.
Baptista, MDS; Dos Anjos, C; Lincopan, N; Ribeiro, MS; Sabino, CP; Sellera, FP; Wainwright, M, 2020
)
0.56
" The adverse effects associated with the use of MB and an approach to optimal dosing in septic shock are also addressed."( The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review.
Burns, SL; Saha, BK, 2020
)
0.83
"5 g natural and artificial zeolite dosage was sufficient."( Enhanced adsorption of methylene blue from textile wastewater by using natural and artificial zeolite.
Ekinci, N; Özdemir, S; Turp, GA; Turp, SM, 2020
)
0.87
"6%) experienced a ≥10% increase in mean arterial pressure (MAP) and a reduction in norepinephrine dosing in the one-to-two hour interval after MB administration."( Methylene Blue for Vasoplegia During Extracorporeal Membrane Oxygenation Support.
Chen, F; Dalia, AA; Devine, LT; French, A; Kawabori, M; Ortoleva, J; Roberts, RJ; Shelton, K, 2021
)
2.06
" We conclude that methylene blue may become a potential anti-tuberculosis agent due to its well-known side effects and dosing regimens."( In vitro activity of methylene blue on Mycobacterium tuberculosis complex isolates.
Gazel, D; Zanapalıoğlu Gazel, Ö, 2021
)
1.27
" Furthermore, the dosage of MDA revealed that the MB1h group showed lower values when compared with the control group (p=0."( Intradermal methylene blue administration on the progression of burn injuries.
Beldi, VF; Evora, PRB; Farina, JA; Moriguti, EK; Nunes, AA; Rosique, MJ; Tirapelli, LF, 2021
)
1
" In the adsorption studies, the effects of different parameters such as contact time (5-150 min), adsorbent dosage (0."( Methylene blue removal with ZnO coated montmorillonite: thermodynamic, kinetic, isotherm and artificial intelligence studies.
Altıntıg, E; Aydemır, Z; Balta, M; Balta, S, 2022
)
2.16
" Other advancements include individualized acetylcysteine dosing regimens for acetaminophen toxicity and carnitine supplementation in valproic acid toxicity."( The Roles of Antidotes in Emergency Situations.
Dart, RC; Kaiser, SK, 2022
)
0.72
"To compare the hemodynamic response of methylene blue dosing regimens (bolus v bolus plus infusion) for the treatment of vasoplegia."( Association of Methylene Blue Dosing With Hemodynamic Response for the Treatment of Vasoplegia.
Bauer, SR; Douglas, A; Hohlfelder, B; Wanek, M; Wang, L, 2022
)
1.34
" Bolus-only dosing of methylene blue may be sufficient for the treatment of vasoplegia after cardiac surgery."( Association of Methylene Blue Dosing With Hemodynamic Response for the Treatment of Vasoplegia.
Bauer, SR; Douglas, A; Hohlfelder, B; Wanek, M; Wang, L, 2022
)
1.39
" The obtained results suggest that initial dye concentration and composite dosage were the most influential parameters in dye removal among all the studied parameters."( One-pot synthesis of metal oxide-clay composite for the evaluation of dye removal studies: Taguchi optimization of parameters and environmental toxicity studies.
Gupta, S; K, AK; Panwar, J, 2023
)
0.91
" The effects of pH and catalyst dosage on the methylene blue (MB) dye degradation were carried out."( Green synthesis of AgNPs using Delonix regia bark for potential catalytic and antioxidant applications.
Bala, A; Rani, G, 2023
)
1.17
" However, there is a lack of evidence on MB as an adjuvant therapy, its' optimal timing, dosing and safety profile."( Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.
Aguilera-González, P; Aguirre-Avalos, G; Chávez-Peña, Q; Gómez-Partida, CA; Hernández, G; Ibarra-Estrada, M; Kattan, E; López-Pulgarín, JA; Mijangos-Méndez, JC; Ortiz-Macías, IX; Rico-Jauregui, U; Sandoval-Plascencia, L, 2023
)
1.25
" The introduction of less dosage of REC (1."( Chitosan-based composite hydrogel with a rigid-in-flexible network structure for pH-universal ultra-efficient removal of dye.
Ding, K; Guo, F; He, Q; Liu, X; Lu, H; Ma, W; Wang, W; Wang, X, 2023
)
0.91
"91) or vasopressor dosage (mean difference -0."( Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue.
Brokmeier, HM; Gerberi, DJ; Mara, KC; Nei, SD; Seelhammer, TG; Wieruszewski, PM; Wittwer, ED, 2023
)
1.12
" In addition, the adsorption increased rapidly with the plant dosage with high dependence on the initial MB concentration."( Potential use of dry powder of Vossia cuspidata (Roxb.) Griff. rhizomes and leaves in methylene blue dye remediation.
Awad, HEA; Farahat, EA; Mohammad, AM, 2023
)
1.13
" Under optimum adsorption conditions of pH 11, adsorbent dosage of 50 mg/L, and treatment time of 120 min, starch-impregnated MgAl-LDH exhibited maximum MB and AMX adsorption capacities of 114."( Simultaneous adsorption of methylene blue and amoxicillin by starch-impregnated MgAl layered double hydroxide: Parametric optimization, isothermal studies and thermo-kinetic analysis.
Ahmad, S; Ahmed, F; Alshahrani, T; Banat, F; Daud, M; Hai, A; Khattak, D; Mujtaba, G; Shah, MUH; Ullah, A, 2023
)
1.21
" The potential of the FSDSR to overcome fibrotic capsule formation and maintain constant drug dosing over time was demonstrated in silico and in vitro."( Soft robot-mediated autonomous adaptation to fibrotic capsule formation for improved drug delivery.
Beatty, R; Dockery, P; Dolan, EB; Duffy, GP; Fan, Y; Mendez, KL; O'Dwyer, J; Robinson, ST; Roche, ET; Schreiber, LHJ; Simpkin, AJ; Tannian, J; Tarpey, R; Whyte, W, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (13)

RoleDescription
EC 1.4.3.4 (monoamine oxidase) inhibitorAn EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4).
acid-base indicatorAn acid or base which exhibits a colour change on neutralization by the basic or acidic titrant at or near the equivalence point of a titration.
fluorochromeA fluorescent dye used to stain biological specimens.
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
cardioprotective agentAny protective agent that is able to prevent damage to the heart.
EC 3.1.1.8 (cholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).
histological dyeA dye used in microscopic or electron microscopic examination of cells and tissues to give contrast and to highlight particular features of interest, such as nuclei and cytoplasm.
EC 4.6.1.2 (guanylate cyclase) inhibitorAn EC 4.6.* (P-O lyase) inhibitor that interferes with the action of enzyme guanylate cyclase (EC 4.6.1.2).
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
physical tracerA physical tracer is one that is attached by physical means to the object being traced.
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic chloride salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Methylene Blue Pathway, Pharmacodynamics41

Protein Targets (130)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency22.38720.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency37.61880.004023.8416100.0000AID485290; AID489007
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency22.33420.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency23.73590.125919.1169125.8920AID2549; AID504841
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency17.49430.007215.758889.3584AID1224835; AID588342
T cell receptor, partialHomo sapiens (human)Potency6.28410.99603.64016.2841AID624298
acetylcholinesteraseHomo sapiens (human)Potency3.37660.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
luteinizing hormone receptorHomo sapiens (human)Potency84.921423.934130.632337.9330AID602293
glp-1 receptor, partialHomo sapiens (human)Potency6.30960.01846.806014.1254AID624417
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency22.38723.981127.764939.8107AID504842
phosphopantetheinyl transferaseBacillus subtilisPotency79.04200.141337.9142100.0000AID1490; AID2701; AID2707
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency42.27073.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.82300.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency6.74000.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency0.73050.004110.890331.5287AID504467
Fumarate hydrataseHomo sapiens (human)Potency17.78280.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency18.55690.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency6.74000.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency1.13640.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.73230.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency8.55390.180013.557439.8107AID1460; AID1468
TSHR proteinHomo sapiens (human)Potency15.50350.338119.046637.9330AID602292; AID602441
AR proteinHomo sapiens (human)Potency3.31170.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency31.62280.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency10.00000.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency10.87070.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259378
hypothetical protein, conservedTrypanosoma bruceiPotency19.95260.223911.245135.4813AID624173
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.66250.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency51.04060.000417.946075.1148AID1346795
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency52.11946.309627.099079.4328AID602179
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.48970.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency13.80610.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.70600.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency32.78590.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency1.63500.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency15.14220.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency1.88680.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.76090.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency0.69180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.38900.00108.379861.1304AID1645840
polyproteinZika virusPotency17.78280.00308.794948.0869AID1347053
luciferasePhoturis pensylvanica (Pennsylania firefly)Potency10.00000.891310.432820.5750AID1379
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency36.71950.001024.504861.6448AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency43.64120.001019.414170.9645AID743191
caspase-3Homo sapiens (human)Potency10.87070.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency7.30780.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency4.99570.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.93550.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency11.57590.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259393; AID1259395
activating transcription factor 6Homo sapiens (human)Potency0.43640.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency8.19660.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency11.53010.039147.5451146.8240AID1224845; AID1224896
serine-protein kinase ATM isoform aHomo sapiens (human)Potency13.02590.707925.111941.2351AID485349; AID493185; AID493192; AID493201
Bloom syndrome protein isoform 1Homo sapiens (human)Potency31.62280.540617.639296.1227AID2528
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency42.23950.010039.53711,122.0200AID1469; AID1479
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency11.58210.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency19.95263.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency18.20790.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency12.30660.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency58.29290.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency12.58930.000618.41981,122.0200AID1688
pyruvate kinase PKM isoform aHomo sapiens (human)Potency39.81070.04017.459031.6228AID1631; AID1634
DNA polymerase betaHomo sapiens (human)Potency25.11890.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency7.07950.039816.784239.8107AID1454
flap endonuclease 1Homo sapiens (human)Potency17.78280.133725.412989.1251AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency19.95260.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency2.57560.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency56.23410.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency56.23410.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.12540.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency2.31090.004611.374133.4983AID624297
VprHuman immunodeficiency virus 1Potency39.81071.584919.626463.0957AID651644
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency2.81840.00419.962528.1838AID2675
neuropeptide S receptor isoform AHomo sapiens (human)Potency3.18240.015812.3113615.5000AID1461; AID1491; AID2568
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency28.57770.001557.789015,848.9004AID1259244
Glycoprotein hormones alpha chainHomo sapiens (human)Potency0.50124.46688.344810.0000AID624291
Interferon betaHomo sapiens (human)Potency17.93130.00339.158239.8107AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.69180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency11.98950.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency28.57770.001551.739315,848.9004AID1259244
Alpha-synucleinHomo sapiens (human)Potency15.84890.56239.398525.1189AID652106
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Guanine nucleotide-binding protein GHomo sapiens (human)Potency10.00001.995325.532750.1187AID624288
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.99531.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency15.84891.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.69180.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency14.96010.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency14.96010.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.69180.01238.964839.8107AID1645842
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency17.78280.07578.474229.0628AID602233
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain E, Fibrin beta chainHomo sapiens (human)IC50 (µMol)46.26559.25309.29059.3280AID720729; AID720730
integrase, partialHuman immunodeficiency virus 1IC50 (µMol)19.24050.07953.52039.9390AID1053171; AID1053172
lens epithelium-derived growth factor p75Homo sapiens (human)IC50 (µMol)19.24050.07953.52039.9390AID1053171; AID1053172
Apoptotic peptidase activating factor 1Homo sapiens (human)IC50 (µMol)57.75000.037518.623253.2000AID588524; AID588538
neutrophil cytosol factor 1Homo sapiens (human)IC50 (µMol)0.39000.39006.544129.1200AID1275
caspase-9 isoform alpha precursorHomo sapiens (human)IC50 (µMol)17.00000.025616.507052.8000AID588574
caspase-3 isoform a preproproteinHomo sapiens (human)IC50 (µMol)17.00000.025620.323574.3000AID588574
Glutathione reductasePlasmodium falciparum 3D7IC50 (µMol)6.40006.40006.40006.4000AID242189
Glutathione reductase, mitochondrialHomo sapiens (human)IC50 (µMol)16.20001.00004.55008.1000AID241792; AID423559
Amyloid-beta precursor proteinHomo sapiens (human)IC50 (µMol)0.50000.00053.889510.0000AID1323641
Microtubule-associated protein tauHomo sapiens (human)IC50 (µMol)9.42500.06901.97693.5000AID1323642; AID1724078; AID748710; AID748713
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.50000.00021.874210.0000AID1323641
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)0.07000.00002.37899.7700AID1484646
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.50000.00021.270410.0000AID1323641
CruzipainTrypanosoma cruziIC50 (µMol)70.00000.00022.04508.0000AID484274; AID484275
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.50000.00001.819410.0000AID1323641
Thioredoxin reductase 1, cytoplasmicHomo sapiens (human)IC50 (µMol)30.00000.04322.26555.0000AID423706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)78.65000.018023.2882287.6000AID434968; AID435010
POsterior SegregationCaenorhabditis elegansEC50 (µMol)186.68102.201047.1808186.6810AID1964
Microtubule-associated protein tauHomo sapiens (human)EC50 (µMol)0.36000.13000.36000.5900AID1587215; AID1587216
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)113.88600.082031.0243168.9080AID1960
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)113.88600.082033.5679168.9080AID1960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC501.60000.063611.235844.9700AID720632
protein AF-9 isoform aHomo sapiens (human)AC504.08000.08008.380217.9800AID720495
replicative DNA helicaseMycobacterium tuberculosis H37RvAC5058.18000.057030.7482325.3000AID449749; AID449750
DNA repair protein RAD52 homolog isoform aHomo sapiens (human)AC500.93600.150012.066235.2100AID652116
Glutathione reductase, mitochondrialHomo sapiens (human)Km6.30006.30006.30006.3000AID423544
AlbuminBos taurus (cattle)Kdiss2.90002.90002.90002.9000AID423536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (411)

Processvia Protein(s)Taxonomy
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cellular response to starvationAlbuminBos taurus (cattle)
negative regulation of mitochondrial depolarizationAlbuminBos taurus (cattle)
cellular response to calcium ion starvationAlbuminBos taurus (cattle)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of autophagyMicrotubule-associated protein tauHomo sapiens (human)
microtubule cytoskeleton organizationMicrotubule-associated protein tauHomo sapiens (human)
microglial cell activationMicrotubule-associated protein tauHomo sapiens (human)
internal protein amino acid acetylationMicrotubule-associated protein tauHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processMicrotubule-associated protein tauHomo sapiens (human)
DNA damage responseMicrotubule-associated protein tauHomo sapiens (human)
cell-cell signalingMicrotubule-associated protein tauHomo sapiens (human)
memoryMicrotubule-associated protein tauHomo sapiens (human)
response to lead ionMicrotubule-associated protein tauHomo sapiens (human)
negative regulation of gene expressionMicrotubule-associated protein tauHomo sapiens (human)
negative regulation of mitochondrial membrane potentialMicrotubule-associated protein tauHomo sapiens (human)
rRNA metabolic processMicrotubule-associated protein tauHomo sapiens (human)
axonal transport of mitochondrionMicrotubule-associated protein tauHomo sapiens (human)
central nervous system neuron developmentMicrotubule-associated protein tauHomo sapiens (human)
regulation of microtubule polymerization or depolymerizationMicrotubule-associated protein tauHomo sapiens (human)
regulation of microtubule polymerizationMicrotubule-associated protein tauHomo sapiens (human)
positive regulation of microtubule polymerizationMicrotubule-associated protein tauHomo sapiens (human)
cytoplasmic microtubule organizationMicrotubule-associated protein tauHomo sapiens (human)
neuron projection developmentMicrotubule-associated protein tauHomo sapiens (human)
positive regulation of superoxide anion generationMicrotubule-associated protein tauHomo sapiens (human)
regulation of chromosome organizationMicrotubule-associated protein tauHomo sapiens (human)
negative regulation of kinase activityMicrotubule-associated protein tauHomo sapiens (human)
stress granule assemblyMicrotubule-associated protein tauHomo sapiens (human)
cellular response to heatMicrotubule-associated protein tauHomo sapiens (human)
cellular response to reactive oxygen speciesMicrotubule-associated protein tauHomo sapiens (human)
positive regulation of axon extensionMicrotubule-associated protein tauHomo sapiens (human)
microtubule polymerizationMicrotubule-associated protein tauHomo sapiens (human)
astrocyte activationMicrotubule-associated protein tauHomo sapiens (human)
regulation of synaptic plasticityMicrotubule-associated protein tauHomo sapiens (human)
intracellular distribution of mitochondriaMicrotubule-associated protein tauHomo sapiens (human)
generation of neuronsMicrotubule-associated protein tauHomo sapiens (human)
synapse organizationMicrotubule-associated protein tauHomo sapiens (human)
regulation of calcium-mediated signalingMicrotubule-associated protein tauHomo sapiens (human)
protein polymerizationMicrotubule-associated protein tauHomo sapiens (human)
axon developmentMicrotubule-associated protein tauHomo sapiens (human)
regulation of microtubule cytoskeleton organizationMicrotubule-associated protein tauHomo sapiens (human)
plus-end-directed organelle transport along microtubuleMicrotubule-associated protein tauHomo sapiens (human)
regulation of mitochondrial fissionMicrotubule-associated protein tauHomo sapiens (human)
negative regulation of mitochondrial fissionMicrotubule-associated protein tauHomo sapiens (human)
supramolecular fiber organizationMicrotubule-associated protein tauHomo sapiens (human)
axonal transportMicrotubule-associated protein tauHomo sapiens (human)
regulation of cellular response to heatMicrotubule-associated protein tauHomo sapiens (human)
regulation of long-term synaptic depressionMicrotubule-associated protein tauHomo sapiens (human)
positive regulation of protein localization to synapseMicrotubule-associated protein tauHomo sapiens (human)
neurofibrillary tangle assemblyMicrotubule-associated protein tauHomo sapiens (human)
negative regulation of establishment of protein localization to mitochondrionMicrotubule-associated protein tauHomo sapiens (human)
positive regulation of protein localizationMicrotubule-associated protein tauHomo sapiens (human)
negative regulation of tubulin deacetylationMicrotubule-associated protein tauHomo sapiens (human)
positive regulation of diacylglycerol kinase activityMicrotubule-associated protein tauHomo sapiens (human)
amyloid fibril formationMicrotubule-associated protein tauHomo sapiens (human)
cellular response to nerve growth factor stimulusMicrotubule-associated protein tauHomo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusMicrotubule-associated protein tauHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
mesoderm formationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
signal transductionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell population proliferationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell redox homeostasisThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (126)

Processvia Protein(s)Taxonomy
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
oxygen bindingAlbuminBos taurus (cattle)
DNA bindingAlbuminBos taurus (cattle)
fatty acid bindingAlbuminBos taurus (cattle)
protein bindingAlbuminBos taurus (cattle)
toxic substance bindingAlbuminBos taurus (cattle)
pyridoxal phosphate bindingAlbuminBos taurus (cattle)
metal ion bindingAlbuminBos taurus (cattle)
enterobactin bindingAlbuminBos taurus (cattle)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingMicrotubule-associated protein tauHomo sapiens (human)
minor groove of adenine-thymine-rich DNA bindingMicrotubule-associated protein tauHomo sapiens (human)
double-stranded DNA bindingMicrotubule-associated protein tauHomo sapiens (human)
single-stranded DNA bindingMicrotubule-associated protein tauHomo sapiens (human)
RNA bindingMicrotubule-associated protein tauHomo sapiens (human)
actin bindingMicrotubule-associated protein tauHomo sapiens (human)
protein bindingMicrotubule-associated protein tauHomo sapiens (human)
microtubule bindingMicrotubule-associated protein tauHomo sapiens (human)
SH3 domain bindingMicrotubule-associated protein tauHomo sapiens (human)
enzyme bindingMicrotubule-associated protein tauHomo sapiens (human)
protein kinase bindingMicrotubule-associated protein tauHomo sapiens (human)
protein-macromolecule adaptor activityMicrotubule-associated protein tauHomo sapiens (human)
apolipoprotein bindingMicrotubule-associated protein tauHomo sapiens (human)
dynactin bindingMicrotubule-associated protein tauHomo sapiens (human)
phosphatidylinositol bindingMicrotubule-associated protein tauHomo sapiens (human)
identical protein bindingMicrotubule-associated protein tauHomo sapiens (human)
sequence-specific DNA bindingMicrotubule-associated protein tauHomo sapiens (human)
protein-folding chaperone bindingMicrotubule-associated protein tauHomo sapiens (human)
protein phosphatase 2A bindingMicrotubule-associated protein tauHomo sapiens (human)
Hsp90 protein bindingMicrotubule-associated protein tauHomo sapiens (human)
lipoprotein particle bindingMicrotubule-associated protein tauHomo sapiens (human)
histone-dependent DNA bindingMicrotubule-associated protein tauHomo sapiens (human)
microtubule lateral bindingMicrotubule-associated protein tauHomo sapiens (human)
phosphatidylinositol bisphosphate bindingMicrotubule-associated protein tauHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
identical protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
NADPH peroxidase activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
FAD bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (104)

Processvia Protein(s)Taxonomy
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionAlbuminBos taurus (cattle)
extracellular spaceAlbuminBos taurus (cattle)
protein-containing complexAlbuminBos taurus (cattle)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
microtubuleMicrotubule-associated protein tauHomo sapiens (human)
membraneMicrotubule-associated protein tauHomo sapiens (human)
extracellular regionMicrotubule-associated protein tauHomo sapiens (human)
nucleusMicrotubule-associated protein tauHomo sapiens (human)
cytoplasmMicrotubule-associated protein tauHomo sapiens (human)
mitochondrionMicrotubule-associated protein tauHomo sapiens (human)
cytosolMicrotubule-associated protein tauHomo sapiens (human)
plasma membraneMicrotubule-associated protein tauHomo sapiens (human)
microtubule cytoskeletonMicrotubule-associated protein tauHomo sapiens (human)
nuclear speckMicrotubule-associated protein tauHomo sapiens (human)
axonMicrotubule-associated protein tauHomo sapiens (human)
dendriteMicrotubule-associated protein tauHomo sapiens (human)
growth coneMicrotubule-associated protein tauHomo sapiens (human)
axolemmaMicrotubule-associated protein tauHomo sapiens (human)
nuclear peripheryMicrotubule-associated protein tauHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleMicrotubule-associated protein tauHomo sapiens (human)
somatodendritic compartmentMicrotubule-associated protein tauHomo sapiens (human)
neuronal cell bodyMicrotubule-associated protein tauHomo sapiens (human)
dendritic spineMicrotubule-associated protein tauHomo sapiens (human)
cell bodyMicrotubule-associated protein tauHomo sapiens (human)
main axonMicrotubule-associated protein tauHomo sapiens (human)
membrane raftMicrotubule-associated protein tauHomo sapiens (human)
glial cell projectionMicrotubule-associated protein tauHomo sapiens (human)
neurofibrillary tangleMicrotubule-associated protein tauHomo sapiens (human)
axon cytoplasmMicrotubule-associated protein tauHomo sapiens (human)
tubulin complexMicrotubule-associated protein tauHomo sapiens (human)
neuron projectionMicrotubule-associated protein tauHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
nucleoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
extracellular exosomeThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
mitochondrionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (289)

Assay IDTitleYearJournalArticle
AID423556Ratio of kcat to Km for Plasmodium falciparum glutathione reductase at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423539Activity at human recombinant glutathione reductase C58A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423538Activity at pig recombinant dihydrolipoamide dehydrogenase at pH 7.32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID690244Cytotoxicity against CHO cells assessed as cell death at 0.1 to 100 uM after 3 hrs followed by photo/sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1323642Inhibition of recombinant human TAU three-repeat microtubule-binding domain aggregation expressed in Escherichia coli after 16 hrs by thioflavin T fluorescence assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors.
AID1393929Photodynamic antibacterial activity against wild type Escherichia coli K-12 assessed as bacterial killing at 10 uM incubated for 30 mins followed by 6 J/cm'2 irradiation with red light relative to control2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1484646Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cell microsomes using kynuramine as substrate after 20 mins by fluorescence spectroscopy2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID1496276Induction of inner mitochondrial membrane potential depolarization in human Friedreich's ataxia lymphocytes assessed as JC-1 aggregates at 1000 nM after 16 hrs by JC1-staining based flow cytometry (Rvb = 83%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1393946Dark toxicity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as bacterial load in shaved dorsal surfaces of mouse after 15 mins measured after 1 day by bioluminescence imag2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1609806Induction of singlet oxygen generation in TBS solution assessed as singlet oxygen quantum yield by measuring reduction in ADMA irradiated with 650 nanometer laser light2019European journal of medicinal chemistry, Dec-01, Volume: 183Novel water soluble BODIPY compounds: Synthesis, photochemical, DNA interaction, topoisomerases inhibition and photodynamic activity properties.
AID1725772Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID1393942Photodynamic antibacterial activity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followed 2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1496274Induction of inner mitochondrial membrane potential depolarization in human Friedreich's ataxia lymphocytes assessed as JC-1 aggregates at 250 nM after 16 hrs by JC1-staining based flow cytometry (Rvb = 83%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID1413792Increase in frataxin expression in human GM16216 cells at 50 to 250 nM after 24 to 48 hrs by ELISA2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID484397Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 150 uM by dynamic light scattering assay in presence of 0.75% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1393930Dark toxicity against TolC deficient Escherichia coli JW5503-1 assessed as reduction in bacterial load at 1 to 20 uM incubated for 30 mins2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1496275Induction of inner mitochondrial membrane potential depolarization in human Friedreich's ataxia lymphocytes assessed as JC-1 monomers at 250 nM after 16 hrs by JC1-staining based flow cytometry (Rvb = 17.3%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID484389Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 20 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1393947Photodynamic antibacterial activity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followed 2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID423552Ratio of kcat to Km for human recombinant glutathione reductase C63A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1365218Cytotoxicity in human Friedreich's ataxia lymphocytes assessed as reduction in cell viability at 2.5 uM incubated for 24 hrs by Live/Dead cell viability assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1413764Effect on mitochondrial membrane potential in human GM16216 cells assessed as intact mitochondrial membrane at 2.5 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 87%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1365221Induction of mitochondrial membrane potential preservation in human Friedreich's ataxia lymphocytes assessed as JC1 dye aggregates level at 1 uM pre-incubated for 24 hrs by JC1 staining based assay (Rvb = 69.8%)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1676949Antiplasmodial activity against synchronous gametocyte late stage of Plasmodium falciparum 3D7 harboring luc7 incubated for 72 hrs by ONE-Glo luciferase assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1871220Inhibition of human HSP70 ATPase activity at 10 uM incubated for 3 hrs by malachite green reagent based HTS analysis relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
AID1413770Effect on mitochondrial membrane potential in human GM15850 cells assessed as intact mitochondrial membrane at 0.25 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 87%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID484276Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID614073Displacement of Thioflavin S from Octadecyl sulfate-induced synthetic Tau 2N4R aggregate by fluorescence assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ligand polarizability contributes to tau fibril binding affinity.
AID423547Activity at Plasmodium falciparum glutathione reductase at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID690252Ratio of LD50 for sono-irradiated CHO cells to LD50 for photo-/sono-irradiated CHO cells2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID423551Ratio of kcat to Km for human recombinant glutathione reductase C58A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423537Activity at human recombinant TrxR1 at pH 7.42008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1393931Dark toxicity against wild type Escherichia coli K-12 assessed as reduction in bacterial load at 1 to 20 uM incubated for 30 mins2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1496268Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring live cells at 250 nM after 48 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 89.3%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID690247Cytotoxicity against CHO cells assessed as cell viability at 100 uM after 3 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID160054In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR32002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID423708Inhibition of Plasmodium falciparum glutathione reductase at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423545Activity at human recombinant glutathione reductase C63A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID323199Cytotoxicity against mouse L929 cells assessed as survival at 18 uM after 20 hrs by MTT method relative to control2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibitory property of the Piper betel phenolics against photosensitization-induced biological damages.
AID1496283Increase in total ATP levels in human Friedreich's ataxia lymphocytes at 100 nM after 24 hrs by bioluminescence assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID690259ROS-generating activity of the photo/sono-irradiated compound assessed as singlet oxygen generation measuring reduction in absorbance at 410 nm at 5 uM by DPBF oxidation method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID558776Antibacterial activity against acrB-deficient Salmonella enterica NKS175 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1496265Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring dead cells at 2500 nM after 24 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 11.2%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID768483Ratio of IC50 for trophozoite stage of Plasmodium falciparum 3D7 infected in RBC after 5 hrs in presence of 0.2 uM ALLN to IC50 for trophozoite stage of Plasmodium falciparum 3D7 infected in RBC after 5 hrs in absence of ALLN2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID1574999Antiplasmodial activity against chloroquine-sensitive final late stage of Plasmodium falciparum NF54-Mal8p1.16-GFP-Luc gametocytes after 24 hrs by BacTiter-Glo assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of Malaria.
AID1899517Antiproliferative activity against human MCF7 cells assessed as cell viability in light irradiation and measured after 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Biotinylated curcumin as a novel chemosensitizer enhances naphthalimide-induced autophagic cell death in breast cancer cells.
AID423536Binding affinity to bovine serum albumin by fluorescence spectroscopy2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1413780Effect on ATP production in human GM16216 cells at 0.1 uM after 24 hrs by Vialight reagent based luminescence assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID768482Ratio of IC50 for trophozoite stage of Plasmodium falciparum 3D7 infected in RBC after 5 hrs in presence of 5 uM ALLN to IC50 for trophozoite stage of Plasmodium falciparum 3D7 infected in RBC after 5 hrs in absence of ALLN2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID558775Antibacterial activity against Salmonella enterica ATCC 14028 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1413766Effect on mitochondrial membrane potential in human GM16216 cells assessed as intact mitochondrial membrane at 0.25 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 87%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID690243Cytotoxicity against CHO cells assessed as cell death at 0.1 to 100 uM after 3 hrs followed by sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1725770Inhibition of ferroptosis in human HepG2 cells assessed as increase in pAMPK/AMPK ratio at 1 uM incubated for 24 hrs by Western blot analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID1413777Inhibition of ATP production in human GM15850 cells after 24 hrs by Vialight reagent based luminescence assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID690251Ratio of LD50 for photo-irradiated CHO cells to LD50 for photo-/sono-irradiated CHO cells2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID558777Antibacterial activity against acrB-deficient Salmonella enterica NKS291 harboring hns gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1413778Inhibition of ATP production in human GM16216 cells after 24 hrs by Vialight reagent based luminescence assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID423549Activity at Plasmodium falciparum recombinant dihydrolipoamide dehydrogenase at pH 7.32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1899518Antiproliferative activity against mouse B16-F10 cells assessed as cell viability in dark incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Biotinylated curcumin as a novel chemosensitizer enhances naphthalimide-induced autophagic cell death in breast cancer cells.
AID1496273Cytoprotective activity against rotenone-induced cytotoxicity in human Friedreich's ataxia lymphocytes assessed as increase in cell viability at 250 to 2500 nM preincubated for 12 hrs followed by complex 1 inhibitor rotenone addition measured after 16 hrs2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1365227Effect on NADH-ubiquinone oxidoreductase in bovine heart submitochondrial particles assessed as induction of electron flow from complex-1 by measuring NADH oxidation at 5 uM in presence of 50 nM rotenone using NADH and coenzyme Q1 by spectrophotomery2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID423546Activity at human recombinant glutathione reductase C58A/C63A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID772515Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID1413791Increase in frataxin expression in human GM15850 cells at 50 to 250 nM after 24 to 48 hrs by ELISA2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1496271Cytoprotective activity against BSO-treated human Friedreich's ataxia fibroblasts assessed as increase in cell viability incubated overnight followed by BSO addition measured after 48 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytomet2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1309621Antibiofilm activity against Pseudomonas aeruginosa ATCC 9027 assessed as decrease in cell viability using laser illumination at 13.2 J2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Use of Photosensitizers in Semisolid Formulations for Microbial Photodynamic Inactivation.
AID1365226Cytoprotection against rotenone-induced cytotoxicity in human Friedreich's ataxia lymphocytes assessed as increase in cell viability at 0.25 and 2.5 uM pre-incubated for 12 hrs in glucose-free media followed by rotenone challenge for 24 hrs by Live/Dead c2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1496282Increase in total ATP levels in human Friedreich's ataxia lymphocytes at 0.5 to 2.5 uM after 24 hrs by bioluminescence assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1609805Induction of singlet oxygen generation in DMSO solution assessed as singlet oxygen quantum yield by measuring reduction in DPBF irradiated with 650 nanometer laser light2019European journal of medicinal chemistry, Dec-01, Volume: 183Novel water soluble BODIPY compounds: Synthesis, photochemical, DNA interaction, topoisomerases inhibition and photodynamic activity properties.
AID343391Inhibition of yeast glutathione reductase at 10 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID423557Ratio of kcat to Km for Plasmodium falciparum thioredoxin reductase at pH 7.42008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1776203Antiplasmodial activity against asexual stage (IV/V) Plasmodium falciparum NF54 late gametocytes transfected with GFP-Luc assessed as inhibition of exflagellation of male gametes incubated for 48 hrs by microscopy based luciferase reporter gene assay rela
AID1899516Antiproliferative activity against human MCF7 cells assessed as cell viability in dark incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Biotinylated curcumin as a novel chemosensitizer enhances naphthalimide-induced autophagic cell death in breast cancer cells.
AID423707Inhibition of pig recombinant dihydrolipoamide dehydrogenase at pH 7.32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1413779Effect on ATP production in human GM15850 cells at 0.1 uM after 24 hrs by Vialight reagent based luminescence assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID690242Cytotoxicity against CHO cells assessed as cell death at 0.1 to 100 uM after 3 hrs followed by photo-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID558781Antibacterial activity against acrB-deficient Salmonella enterica NKS422 harboring acrEF gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID317969Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
AID558779Antibacterial activity against tolC-deficient Salmonella enterica NKS419 harboring hns gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1496262Induction of inner mitochondrial membrane potential depolarization in human Friedreich's ataxia lymphocytes assessed as JC-1 aggregates at 2500 nM after 16 hrs by JC1-staining based flow cytometry (Rvb = 83%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID323203Prevention of 15 mins photoirradiation-induced damage in mouse L929 cells assessed as survival at 18 uM by MTT assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibitory property of the Piper betel phenolics against photosensitization-induced biological damages.
AID690257ROS-generating activity of the photo-irradiated compound assessed as singlet oxygen generation measuring reduction in absorbance at 410 nm at 5 uM by DPBF oxidation method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1413769Effect on mitochondrial membrane potential in human GM15850 cells assessed as loss of mitochondrial membrane potential at 0.25 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 13%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID242189Inhibitory concentration against Plasmodium falciparum glutathione reductase2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials.
AID1413793Induction of mitochondrial biogenesis in human GM15850 cells assessed as increase in ratio of COX1 to SDH-A protein levels at 50 to 250 nM after 24 to 48 hrs by ELISA2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1365219Cytotoxicity in human Friedreich's ataxia lymphocytes assessed as reduction in cell viability at 2.5 uM incubated for 48 hrs by Live/Dead cell viability assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1323641Inhibition of amyloid beta (1 to 42 residues) (unknown origin) aggregation after 24 hrs by thioflavin T fluorescence assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors.
AID1606803Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs in dark by MTT assay2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Pyridine-Embedded Phenothiazinium Dyes as Lysosome-Targeted Photosensitizers for Highly Efficient Photodynamic Antitumor Therapy.
AID614077Displacement of Thioflavin S from synthetic Tau 2N4R aggregate by fluorescence assay at 10 uM probe concentration2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ligand polarizability contributes to tau fibril binding affinity.
AID484292Colloidal aggregation in fed state simulated intestinal fluid at 200 uM by transmission electron microscopy in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1399533Permeability of the compound at 100 ug/ml after 10 hrs by artificial membrane permeability assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation.
AID423535Antiplasmodial activity after 42 hrs against chloroquine-resistant Plasmodium falciparum K1 treated for 6 hrs by Giemsa stain2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1724075Displacement of Bis-ANS from solvent exposed hydrophobic site of non-aggregated human full length recombinant tau-441 expressed in Escherichia coli assessed as reduction in fluorescence intensity at 120 uM incubated for 72 hrs by Bis-ANS fluorescence assa
AID1725771Induction of mitochondria membrane potential depolarization in FRDA patient-derived lymphocyte at 2.5 uM incubated for 16 hrs by JC-1 probe based flow cytometry analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID1393926Photodynamic antibacterial activity against TolC deficient Escherichia coli JW5503-1 assessed as bacterial killing at 20 uM incubated for 30 mins followed by 6 J/cm'2 irradiation with red light relative to control2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID690245Cytotoxicity against CHO cells assessed as cell death at 100 uM after 3 hrs followed by photo/sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay relative to photo-irradiated cells2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1894200Inhibition of tau aggregation (unknown origin) at 20 uM relative to control2021European journal of medicinal chemistry, Mar-15, Volume: 214Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
AID1496277Induction of inner mitochondrial membrane potential depolarization in human Friedreich's ataxia lymphocytes assessed as JC-1 monomers at 1000 nM after 16 hrs by JC1-staining based flow cytometry (Rvb = 17.3%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1393935Photodynamic antibacterial activity against enteropathogenic Escherichia coli WS2572 infected in BALB/c mouse full-thickness third-degree burn infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followe2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID768491Antimalarial activity against Plasmodium falciparum 3D7 infected in RBC assessed as growth inhibition after 48 hrs by SYBR Green-I fluorescence assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID1724077Inhibition of human full length recombinant tau-441 expressed in Escherichia coli assessed as inhibition of heparin-induced beta-sheet formation and protein aggregation by measuring fluorescence intensity at 120 uM incubated for 72 hrs by Proteo-stat fluo
AID1725773Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID690253Cytotoxicity against CHO cells after 3 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID484284Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 0.75% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID423561Inhibition of human recombinant glutathione reductase C63A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1399532Inhibition of recombinant full length tau 0N4R (unknown origin) aggregation expressed in Escherichia coli at 20 uM after 72 hrs by thioflavin S assay relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation.
AID72013Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID558778Antibacterial activity against tolC-deficient Salmonella enterica NKS174 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1724080Inhibition of human full length recombinant tau-441 expressed in Escherichia coli assessed as inhibition of heparin-induced protein aggregation by measuring reduction in fibrillization by measuring reduction in short and long filaments and fibrillar netwo
AID558780Antibacterial activity against acrEF-deficient Salmonella enterica NKS176 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1365223Induction of mitochondrial membrane potential preservation in human Friedreich's ataxia lymphocytes assessed as JC1 dye aggregates level at 5 uM pre-incubated for 24 hrs by JC1 staining based assay (Rvb = 69.8%)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1393933Photodynamic antibacterial activity against wild type Acinetobacter baumannii AB007 assessed as bacterial killing at 20 uM incubated for 30 mins followed by 6 J/cm'2 irradiation with red light relative to control2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1413762Cytoprotection against DEM-induced toxicity in human GM15850 cells assessed as increase in cell viability at 0.5 to 2.5 uM pretreated for 16 hrs followed by DEM addition and measured after 5 hrs by live/dead staining based flow cytometry2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1413761Cytoprotection against DEM-induced toxicity in human GM16216 cells assessed as increase in cell viability at 0.5 to 2.5 uM pretreated for 16 hrs followed by DEM addition and measured after 5 hrs by live/dead staining based flow cytometry2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1394970Gametocytocidal activity against Plasmodium falciparum NF54 HGL gametocytes assessed as inhibition of parasite viability after 72 hrs by ONE-Glo reagent based luminescence assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analog
AID423543Solubility at neutral pH at 25 degC2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423542Stability at pH 5.02008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1496266Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring live cells at 2500 nM after 24 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 88.2%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1725774Induction of ATP production in FRDA patient-derived lymphocyte at 0.1 uM incubated for 24 hrs by luciferase-linked ATPase enzymatic assay2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID423710Inhibition of Plasmodium falciparum recombinant dihydrolipoamide dehydrogenase at pH 7.32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1413765Effect on mitochondrial membrane potential in human GM16216 cells assessed as loss of mitochondrial membrane potential at 0.25 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 13%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID423559Inhibition of human recombinant glutathione reductase at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1725779Cytotoxicity against FRDA patient-derived lymphocyte at 2.5 uM incubated for 24 to 48 hrs by flow cytometry analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID1724078Inhibition of human full length recombinant tau-441 expressed in Escherichia coli assessed as inhibition of heparin-induced protein aggregation by measuring reduction in fluorescence intensity incubated for 72 hrs by Proteo-stat fluorescence aggregation a
AID1496278Induction of inner mitochondrial membrane potential depolarization in human Friedreich's ataxia lymphocytes assessed as JC-1 monomers at 2500 nM after 16 hrs by JC1-staining based flow cytometry (Rvb = 17.3%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID323202Prevention of 10 mins photoirradiation-induced damage in mouse L929 cells assessed as survival at 18 uM by MTT assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibitory property of the Piper betel phenolics against photosensitization-induced biological damages.
AID423706Inhibition of human recombinant TrxR1 at pH 7.42008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1776178Antiplasmodial activity against asexual stage (I/III) Plasmodium falciparum NF54 early gametocytes transfected with GFP-Luc assessed as inhibition of exflagellation of male gametes at 1 uM incubated for 48 hrs by microscopy based luciferase reporter gene
AID423540Dissociation constant, pKa of the compound2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID614076Displacement of Thioflavin T from synthetic Tau 2N4R aggregate by fluorescence assay at 1 uM probe concentration2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ligand polarizability contributes to tau fibril binding affinity.
AID1776181Antiplasmodial activity against asexual stage (IV/V) Plasmodium falciparum NF54 late gametocytes transfected with GFP-Luc assessed as inhibition of exflagellation of male gametes at 1 uM incubated for 48 hrs by microscopy based luciferase reporter gene as
AID323198Cytotoxicity against mouse L929 cells assessed as survival at 9 uM after 20 hrs by MTT method relative to control2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibitory property of the Piper betel phenolics against photosensitization-induced biological damages.
AID614074Displacement of Thioflavin S from arachidonic acid-induced synthetic Tau 2N4R aggregate by fluorescence assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ligand polarizability contributes to tau fibril binding affinity.
AID1541837Antimalarial activity against Plasmodium falciparum NF54 early gametocytes transfected with luciferase gene incubated for 48 hrs by luciferase reporter gene assay
AID423560Inhibition of human recombinant glutathione reductase C58A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID614075Displacement of Thioflavin S from heparin-induced synthetic Tau 2N4R aggregate by fluorescence assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ligand polarizability contributes to tau fibril binding affinity.
AID1393945Dark toxicity against enteropathogenic Escherichia coli WS2572 infected in BALB/c mouse full-thickness third-degree burn infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins measured after 1 day by biolu2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1724076Inhibition of human full length recombinant tau-441 expressed in Escherichia coli assessed as inhibition of heparin-induced protein aggregation by measuring reduction in fluorescence intensity at 5 to 120 uM incubated for 72 hrs by Proteo-stat fluorescenc
AID1393934Dark toxicity against enteropathogenic Escherichia coli WS2572 infected in BALB/c mouse full-thickness third-degree burn infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse measured after 15 mins by bioluminescence i2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID690248Cytotoxicity against CHO cells after 3 hrs followed by photo/sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID748713Inhibition of human recombinant brain tau protein (412 amino acid residues) filament assembly expressed in Escherichia coli BL21(DE3) by electron microscopic analysis in presence of heparin2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID423553Ratio of kcat to Km for human recombinant glutathione reductase C58A/C63A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1421918Gametocytocidal activity against synchronized Plasmodium falciparum NF54 mature stage 5 gametocytes after 48 hrs by ATP bioluminescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1394968Gametocytocidal activity against Plasmodium falciparum 3D7 elo1-pfs16-CBG99 late-stage (4 to 5) gametocytes assessed as inhibition of parasite viability after 72 hrs by luciferase reporter assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analog
AID1309617Antibacterial activity against methicillin-resistant Staphylococcus aureus 180 assessed as planktonic cell killing at 50 ug/ml after 15 mins followed by irradiation with paterson lamp at 100 J/cm'2 by serial ten fold dilution method2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Use of Photosensitizers in Semisolid Formulations for Microbial Photodynamic Inactivation.
AID1399531Inhibition of self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 20 uM after 72 hrs by thioflavin T assay relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation.
AID1496264Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring live cells at 250 nM after 24 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 88.2%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1676920Antiplasmodial activity against synchronous gametocyte early stage of Plasmodium falciparum 3D7 harboring luc7 incubated for 72 hrs by ONE-Glo luciferase assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID232807Selective toxicity- EC50 value of FM3A / EC50 value of Plasmodium falciparum2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID1587215Inhibition of tau aggregation (unknown origin)2019European journal of medicinal chemistry, May-01, Volume: 169Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.
AID241792Inhibitory concentration against human glutathione reductase2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials.
AID1899519Antiproliferative activity against mouse B16-F10 cells assessed as cell viability in light irradiation and measured for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Biotinylated curcumin as a novel chemosensitizer enhances naphthalimide-induced autophagic cell death in breast cancer cells.
AID484274Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1393939Photodynamic antibacterial activity against enteropathogenic Escherichia coli WS2572 infected in BALB/c mouse full-thickness third-degree burn infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followe2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID423709Inhibition of Plasmodium falciparum thioredoxin reductase at pH 7.42008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID484390Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering-based beads autocorrelation assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1323649In vivo inhibition of human tau aggregation in JNPL3 human tau P301L transgenic mouse model assessed as reduction in amount of sarkosyl-insoluble tau in brain at 40 mg/kg/day, po for 4 weeks by ELISA2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors.
AID1413768Effect on mitochondrial membrane potential in human GM15850 cells assessed as intact mitochondrial membrane at 2.5 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 87%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1399538Binding affinity to recombinant full length tau 0N4R (unknown origin) expressed in Escherichia coli by surface plasmon resonance assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation.
AID423544Activity at human recombinant glutathione reductase at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID484275Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1413794Induction of mitochondrial biogenesis in human GM16216 cells assessed as increase in ratio of COX1 to SDH-A protein levels at 50 to 250 nM after 24 to 48 hrs by ELISA2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1496290Induction of mitochondrial biogenesis in FRDA patient derived Friedreich's ataxia lymphocytes assessed as increase in COX-1/SDH-A protein levels at 250 nM after 24 to 48 hrs by ELISA2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID323201Prevention of 5 mins photoirradiation-induced damage in mouse L929 cells assessed as survival at 18 uM by MTT assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibitory property of the Piper betel phenolics against photosensitization-induced biological damages.
AID1496270Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring live cells at 2500 nM after 48 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 89.3%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1365228Reduction in ATP level in human Friedreich's ataxia lymphocytes at 0.5 to 5 uM incubated for 24 hrs by luminescence based assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1393927Photodynamic antibacterial activity against TolC deficient Escherichia coli JW5503-1 assessed as bacterial killing at 10 uM incubated for 30 mins followed by 6 J/cm'2 irradiation with red light relative to control2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID768490Antimalarial activity against Plasmodium falciparum K1 infected in RBC assessed as growth inhibition after 48 hrs by SYBR Green-I fluorescence assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID690246Cytotoxicity against CHO cells assessed as cell death at 100 uM after 3 hrs followed by photo/sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay relative to sono-irradiated cells2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1496269Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring dead cells at 2500 nM after 48 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 10.6%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID423548Activity at Plasmodium falciparum thioredoxin reductase at pH 7.42008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1393928Photodynamic antibacterial activity against wild type Escherichia coli K-12 assessed as bacterial killing at 20 uM incubated for 30 mins followed by 6 J/cm'2 irradiation with red light relative to control2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1496281Substrate activity at NADH-ubiquinone oxidoreductase in mouse liver mitochondrial membrane fractions assessed as induction of electron flow from complex-1 by measuring NADH oxidation at 5 uM after 5 mins in presence of complex 1 blocker rotenone at 0.1 uM2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1353398Induction of singlet oxygen production in DMSO assessed as DPBF absorption intensity (Rvb = 100%)2018European journal of medicinal chemistry, Mar-10, Volume: 147Synthesis of novel Chlorin e6-curcumin conjugates as photosensitizers for photodynamic therapy against pancreatic carcinoma.
AID1393943Photodynamic antibacterial activity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followed 2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID1393932Dark toxicity against wild type Acinetobacter baumannii AB007 assessed as reduction in bacterial load at 1 to 20 uM incubated for 30 mins2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID768455Ratio of IC50 for trophozoite stage of Plasmodium falciparum 3D7 infected in RBC after 5 hrs to IC50 for Plasmodium falciparum 3D7 infected in RBC after 48 hrs2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID1776179Antiplasmodial activity against asexual stage (I/III) Plasmodium falciparum NF54 early gametocytes transfected with GFP-Luc assessed as inhibition of exflagellation of male gametes incubated for 48 hrs by microscopy based luciferase reporter gene assay re
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID423558Ratio kcat to Km for Plasmodium falciparum recombinant dihydrolipoamide dehydrogenase at pH 7.32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423705Inhibition of human recombinant glutathione reductase C58A/C63A mutant expressed in Escherichia coli SG5 at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1393949Photodynamic antibacterial activity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followed 2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID375602Inhibition of His-tagged human recombinant 2N4R tau protein aggregation assessed as inhibition octadecyl sulphate-induced fibrillation by filter trap assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structure-activity relationship of cyanine tau aggregation inhibitors.
AID1541838Antimalarial activity against Plasmodium falciparum NF54 late gametocytes transfected with luciferase gene incubated for 48 hrs by luciferase reporter gene assay
AID1496287Increase in frataxin protein expression levels in FRDA patient derived Friedreich's ataxia lymphocytes at 50 nM after 24 to 48 hrs by ELISA relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID423550Ratio of kcat to Km for human recombinant glutathione reductase at pH 6.92008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1496263Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring dead cells at 250 nM after 24 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 11.2%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1365222Induction of mitochondrial membrane potential preservation in human Friedreich's ataxia lymphocytes assessed as JC1 dye monomer level at 5 uM pre-incubated for 24 hrs by JC1 staining based assay (Rvb = 10.1%)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1724079Inhibition of human full length recombinant tau-441 expressed in Escherichia coli assessed as inhibition of heparin-induced protein aggregation by measuring fluorescence intensity at 120 uM incubated for 72 hrs by Bis-ANS fluorescence assay (Rvb = 2800 au
AID1393948Dark toxicity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins measured after 12 days by biolu2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID772516Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID772517Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID323200Prevention of 15 mins photoirradiation-induced damage in mouse L929 cells assessed as survival at 9 uM by MTT assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibitory property of the Piper betel phenolics against photosensitization-induced biological damages.
AID1606811Drug uptake in nucleus of human HT-29 cells at 0.5 uM incubated for 5 hrs by Hoechst 33342 staining based fluorescence microscopy2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Pyridine-Embedded Phenothiazinium Dyes as Lysosome-Targeted Photosensitizers for Highly Efficient Photodynamic Antitumor Therapy.
AID1496288Induction of mitochondrial biogenesis in FRDA patient derived Friedreich's ataxia lymphocytes assessed as increase in COX-1/SDH-A protein levels at 50 nM after 24 to 48 hrs by ELISA relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID768487Antimalarial activity against trophozoite stage of Plasmodium falciparum 3D7 infected in RBC assessed as growth inhibition after 5 hrs by SYBR Green-I fluorescence assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID1365220Induction of mitochondrial membrane potential preservation in human Friedreich's ataxia lymphocytes assessed as JC1 dye monomer level at 1 uM pre-incubated for 24 hrs by JC1 staining based assay (Rvb = 10.1%)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1309619Antibacterial activity against Burkholderia cepacia assessed as cell killing at 250 ug/ml after 15 mins followed by irradiation with paterson lamp at 100 J/cm'2 by serial ten fold dilution method2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Use of Photosensitizers in Semisolid Formulations for Microbial Photodynamic Inactivation.
AID1606802Cytotoxicity against human HT-29 cells assessed as reduction in cell viability preincubated for 1 hr followed by light irradiation at 3.2 J/cm2 for 30 sec and measured after 24 hrs by MTT assay2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Pyridine-Embedded Phenothiazinium Dyes as Lysosome-Targeted Photosensitizers for Highly Efficient Photodynamic Antitumor Therapy.
AID1429839Anti-plasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 late 4/5 stage gametocytes assessed as reduction in ATP levels after 24 hrs by BacTiter-Glo reagent based bioluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.
AID1496289Increase in frataxin protein expression levels in FRDA patient derived Friedreich's ataxia lymphocytes at 250 nM after 24 to 48 hrs by ELISA2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID748712Terminal half life in rat at 100 mg, iv2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID1871221Inhibition of human HSP70 ATPase activity at incubated for 3 hrs by malachite green reagent based HTS analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
AID1393941Dark toxicity against Acinetobacter baumannii AB Iraqi 007 infected in BALB/c mouse needle back-scratch wound abrasion infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse measured after 15 mins by bioluminescence ima2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID748710Inhibition of tau protein aggregation (unknown origin) by Western blot analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID1365229Effect on ATP level in human Friedreich's ataxia lymphocytes at 100 nM incubated for 24 hrs by luminescence based assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction.
AID1413767Effect on mitochondrial membrane potential in human GM15850 cells assessed as loss of mitochondrial membrane potential at 2.5 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 13%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID558782Antibacterial activity against acrB-deficient Salmonella enterica NKS416 harboring acrEF, hns gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1496267Cytotoxicity against human Friedreich's ataxia lymphocytes assessed as cell viability by measuring dead cells at 250 nM after 48 hrs by calceinAM ester/ethidium homodimer-1 staining based flow cytometry (Rvb = 10.6%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1725769Induction of ATP production in FRDA patient-derived lymphocyte incubated for 24 hrs by luciferase-linked ATPase enzymatic assay2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
AID484293Colloidal aggregation in phosphate buffer at 100 uM by transmission electron microscopy in presence of 0.2% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1496279Inhibition of DEM-induced ROS production in human Friedreich's ataxia lymphocytes incubated for 16 hrs followed by DEM treatment for 80 mins by DCFH-DA dye based flow cytometry2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID690250Cytotoxicity against CHO cells after 3 hrs followed by sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1393938Photodynamic antibacterial activity against enteropathogenic Escherichia coli WS2572 infected in BALB/c mouse full-thickness third-degree burn infection model assessed as reduction in bacterial load in shaved dorsal surfaces of mouse after 15 mins followe2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.
AID423555Ratio of kcat to Km for pig recombinant dihydrolipoamide dehydrogenase at pH 7.32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1496291Restoration of total aconitase activity in FRDA patient derived Friedreich's ataxia lymphocytes at 50 to 250 nM after 5 days by colorimetric assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
AID1587216Inhibition of tau-tau binding (unknown origin) assessed as increase in dissolved paired helical filaments2019European journal of medicinal chemistry, May-01, Volume: 169Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.
AID1413763Effect on mitochondrial membrane potential in human GM16216 cells assessed as loss of mitochondrial membrane potential at 2.5 uM after 16 hrs by JC1 staining based flow cytometry (Rvb = 13%)2018MedChemComm, Sep-01, Volume: 9, Issue:9
Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells.
AID1416210Inhibition of PTP1B (1 to 298 residues) (unknown origin) using DifMUP as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence assay2017MedChemComm, Jun-01, Volume: 8, Issue:6
PAIN-less identification and evaluation of small molecule inhibitors against protein tyrosine phosphatase 1B.
AID423554Ratio of kcat to Km for human recombinant TrxR1 at pH 7.42008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1309620Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 assessed as planktonic cell killing using laser illumination at 15.5 J/cm'22016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Use of Photosensitizers in Semisolid Formulations for Microbial Photodynamic Inactivation.
AID690258ROS-generating activity of the sono-irradiated compound assessed as singlet oxygen generation measuring reduction in absorbance at 410 nm at 5 uM by DPBF oxidation method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID690249Cytotoxicity against CHO cells after 3 hrs followed by photo-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10,378)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902654 (25.57)18.7374
1990's1449 (13.96)18.2507
2000's1763 (16.99)29.6817
2010's3008 (28.98)24.3611
2020's1504 (14.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.29 (24.57)
Research Supply Index9.35 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index203.83 (26.88)
Search Engine Supply Index3.89 (0.95)

This Compound (58.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials394 (3.56%)5.53%
Reviews370 (3.34%)6.00%
Case Studies834 (7.54%)4.05%
Observational18 (0.16%)0.25%
Other9,451 (85.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (102)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Role of Methylene Blue Dye in Identification of Facial Nerve in Parotid Surgery [NCT05401370]20 participants (Anticipated)Interventional2022-06-30Not yet recruiting
A Non-Randomized, Prospective, Open Label, Single-site Feasibility Trial for Real-time Identification of the Ureters With a Methylene-blue fluoroPhore [NCT05111808]10 participants (Anticipated)Interventional2020-06-22Recruiting
Comparative Study Between High and Low Dose Methylene Blue Infusion in Septic Cancer Patients. A Randomized Blinded Controlled Study [NCT06005558]Phase 2/Phase 390 participants (Anticipated)Interventional2023-08-01Recruiting
Lymphatic Mapping and Sentinel Node Identification in Patients With Stage1B1 Cervical Carcinoma [NCT00070317]102 participants (Actual)Interventional2004-06-30Terminated
Efficacy and Safety of Methylene Blue -Mediated Photodynamic Therapy for Diabetic Lower Limb Ulcer : a Randomized Controlled Study [NCT03222544]60 participants (Anticipated)Interventional2019-04-29Recruiting
Investigating the Use of Fluorescent Imaging and Methylene Blue to Identify and Prevent Ureteric Injuries During Laparoscopic and Open Colorectal Surgery [NCT03177070]Phase 250 participants (Actual)Interventional2016-05-09Completed
Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX® Modified Release Tablets Administered to Patients Undergoing Colonoscopy [NCT03287219]Phase 2114 participants (Actual)Interventional2011-05-02Completed
Efficacy of Thoracic Paravertebral Block With Methylene Blue Visual Confirmation in the Management of Postoperative Pain After Video-assisted Thoracoscopic Lobectomy [NCT05812521]120 participants (Actual)Interventional2020-01-15Completed
Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis [NCT03379389]Phase 4284 participants (Actual)Interventional2018-03-31Completed
The Effect of Red Light Photobiomodulation and Topical Disinfectants on the Nasal Microbiome [NCT05797818]Phase 1/Phase 228 participants (Actual)Interventional2023-01-10Completed
A Phase 1 Study to Assess Safety and Feasibility of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities [NCT02240498]Phase 121 participants (Anticipated)Interventional2014-09-30Recruiting
Three-dimensionally Printed Navigational Template for Localizing Small Pulmonary Nodules [NCT04056923]47 participants (Actual)Interventional2018-01-01Completed
The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients [NCT04054999]Phase 420 participants (Anticipated)Interventional2019-11-30Recruiting
Study of Surgical Navigation System in Detection of Sentinel Lymph Node of Early Breast Cancer Patients [NCT02084784]98 participants (Actual)Interventional2014-01-31Completed
Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery [NCT02089542]Phase 1/Phase 241 participants (Actual)Interventional2014-10-31Completed
Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract [NCT04615936]45 participants (Actual)Interventional2020-10-13Completed
The Effect of Early Use of Methylene Blue on Hemodynamics in Septic Shock [NCT04970602]106 participants (Anticipated)Interventional2021-06-20Active, not recruiting
The Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected Patients [NCT04933864]Phase 160 participants (Actual)Interventional2020-04-24Completed
Methylene Blue Mouthwash for Oral Mucositis Pain in Cancer: An Open-Label, Non-Randomized, Controlled Study [NCT05878405]Phase 3100 participants (Anticipated)Interventional2023-05-30Recruiting
Efficacy of Some Different Photosensitizers in Photodynamic Inactivation of Periodontal Pathogens:A Randomized Clinical Trial [NCT05162417]18 participants (Actual)Interventional2021-11-15Completed
Evaluation of the Effects of Methylene Blue on Neuropathic Pain and Protein Biomarkers [NCT02303886]10 participants (Actual)Interventional2009-03-31Completed
The Effect of Methylene Blue on Microcirculation in Patients With Septic Shock: a Randomized Controlled Trial [NCT04295993]Phase 332 participants (Anticipated)Interventional2020-03-10Not yet recruiting
Pilot Clinical Evaluation to Characterize the in Vivo Effects of Topically Applied ZuraPrep and ZuraPrep Vehicle [NCT02578771]Phase 3123 participants (Actual)Interventional2015-10-31Completed
To Evaluate the Safety and Efficacy of Near-infarred Fluorescence Molecular Imaging in the Prospective, Multi-center and Self-controlled Clinical Trial of Sentinel Lymph Node Biopsy in Breast Cancer Surgery [NCT03579979]130 participants (Actual)Interventional2017-08-24Completed
Methylene Blue Spray for Identification of Recurrent Laryngeal Nerve and Parathyroid Glands During Thyroidectomy: A Randomized Controlled Trial [NCT05113628]80 participants (Actual)Interventional2020-01-15Completed
Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment in Asians [NCT03098342]42 participants (Anticipated)Interventional2017-06-01Not yet recruiting
Evaluation of Parameters of Tissue Dosimetry in Photodynamic Therapy for the Treatment of Periodontal Disease - Clinical Study [NCT03262077]30 participants (Actual)Interventional2016-10-11Completed
The Impact of ex Vivo Intra-arterial Methylene Blue Injection on Nodal Staging Accuracy and Survival in Colorectal Cancer. [NCT04842968]200 participants (Anticipated)Interventional2021-04-15Not yet recruiting
Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV2- Affected Patients: a Phase 2, Randomized, Placebo- Controlled, Single Blind Clinical Trial [NCT04635605]Phase 264 participants (Anticipated)Interventional2020-11-05Active, not recruiting
Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy in Reducing the Microbial Flora of the Canal While Root Retreatment in Patients With Periradicular Lesions [NCT02555488]Phase 220 participants (Anticipated)Interventional2015-01-31Recruiting
Effect of Methylene Blue on Perioperative Organ Function in Patients With Obstructive Jaundice [NCT04109859]Phase 164 participants (Anticipated)Interventional2019-04-01Enrolling by invitation
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Using the Navigation of the Combination of Indocyanine and Blue Dye in Patients With Breast Cancer [NCT02869815]150 participants (Anticipated)Observational2016-08-31Recruiting
Use of Methylene Blue in Acquired Methemoglobinemia: Prospective Observational Registry (metHb) [NCT03542760]24 participants (Actual)Observational [Patient Registry]2018-05-31Completed
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease [NCT01689246]Phase 3891 participants (Actual)Interventional2013-01-31Completed
Evaluation of Microaspiration and Efficacy of Above the Cuff Suctioning During General Anesthesia: A Comparison of Two Endotracheal Tubes With Suction Above Cuff With a Standard Endotracheal Tube [NCT01386879]Phase 450 participants (Actual)Interventional2011-07-31Terminated(stopped due to The study was terminated because of slower than anticipated enrollment)
Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children [NCT01407887]Phase 2180 participants (Actual)Interventional2011-08-31Completed
In Vivo Evaluation of Tumor Neurogenesis in Gastrointestinal Diseases by Topical Submucosal Chromoendoscopy [NCT05232357]Early Phase 1100 participants (Anticipated)Interventional2022-03-01Recruiting
Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate [NCT04110418]Phase 236 participants (Anticipated)Interventional2019-02-19Recruiting
Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study [NCT03068208]15 participants (Anticipated)Interventional2017-05-01Not yet recruiting
Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder [NCT00214877]Phase 340 participants (Anticipated)Interventional2003-11-30Completed
PhotoDynamic Therapy for Line Infection Prevention (PLIP): Pilot Study on Normal Volunteers [NCT01981460]10 participants (Actual)Interventional2013-05-31Completed
Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical Treatment of Peri-implant Disease [NCT04187053]Phase 456 participants (Actual)Interventional2020-02-14Completed
PHOTODYNAMIC THERAPY USING METHYLENE BLUE AND INTENSE PULSED LIGHT VERSUS INTENSE PULSED LIGHT ALONE IN TREATMENT OF VERRUCA :A RANDOMIZED CONTROLLED STUDY [NCT04620785]80 participants (Anticipated)Interventional2020-01-01Recruiting
Photodynamic Therapy Associated With Full-mouth Ultrasonic Debridement in the Treatment of Severe Chronic Periodontitis: a Randomized-controlled Clinical Trial Running Title: Photodynamic Therapy Associated With Periodontal Debridement [NCT01535690]22 participants (Actual)Interventional2008-03-31Completed
Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali [NCT02831023]Phase 280 participants (Actual)Interventional2016-07-31Completed
Evaluation of Indocyanine Green Fluorescent Cholangiography Versus Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy: Randomized Controlled Study [NCT01847612]Phase 3132 participants (Anticipated)Interventional2013-07-08Recruiting
Intermittent Bolus Infusion of Methylene Blue to Reduce Norepinephrine Requirements in Sepsis: A Randomized Controlled Trial [NCT00486174]0 participants (Actual)Interventional2007-06-30Withdrawn(stopped due to primary site withdrew due to competing study: never enrolled any subjects.)
French, Prospective, Post-marketing Study to Describe the Use, Detection Performance and Safety Profile of Infracyanine® (Indocyanine Green) for Breast Cancer Patients Undergoing a Sentinel Lymph Node (SLN) Biopsy. [NCT06024213]100 participants (Anticipated)Observational2023-06-06Recruiting
Full-mouth Antimicrobial Photodynamic Therapy as an Adjunct to Non-surgical Periodontal Disease Treatment in Down's Syndrome Patients [NCT02938988]33 participants (Actual)Interventional2013-10-31Completed
Methylene Blue and Ozone in Early Sepsis , a Randomized Double Blind Trial [NCT02910765]Phase 440 participants (Anticipated)Interventional2016-10-31Not yet recruiting
Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy [NCT05367869]40 participants (Anticipated)Interventional2022-06-01Not yet recruiting
[NCT01725477]30 participants (Actual)Interventional2012-09-30Completed
The Preventive Value of Continuous Perineural Methylene Blue Infusion in Patients Undergoing Lower Limb Amputation Surgery [NCT05830630]72 participants (Anticipated)Interventional2023-05-01Recruiting
A Controlled Prospective Randomized Open-Label Study of Methylene Blue and Inhaled Nitric Oxide in Patients With Septic Shock and Acute Lung Injury [NCT00159510]Phase 128 participants (Actual)Interventional2004-04-30Terminated(stopped due to Inability to recruit the patients due to the short supply and changed local hospital protocol)
Infusion of Methylene Blue in Severe Sepsis and Septic Shock: Randomized, Single Blinded [NCT01797978]Phase 3354 participants (Anticipated)Interventional2013-02-28Recruiting
Early Use of Methylene Blue in Patients With Septic Shock: a Pilot Randomized Controlled Trial [NCT04446871]Phase 2/Phase 391 participants (Actual)Interventional2017-03-17Completed
Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic [NCT04619290]Phase 146 participants (Anticipated)Interventional2020-10-12Recruiting
[NCT00354380]Phase 20 participants Interventional2006-09-30Completed
Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery [NCT00513032]22 participants (Actual)Observational2005-01-31Completed
Evaluation of Photodynamic Therapy in Pericoronitis: a Randomized, Controlled, Double-blind Clinical Study [NCT03576105]34 participants (Anticipated)Interventional2019-12-01Enrolling by invitation
Problem of Safety of Anastomosis in Colorectal Surgery and Search for the Solutions [NCT03958500]60 participants (Actual)Interventional2019-04-01Completed
A Prospective, Single-center, Clinical Trial to Evaluate the Efficacy of Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors (Seminoma/Nonseminoma)(PITERLAND). [NCT06133699]44 participants (Anticipated)Interventional2023-11-08Recruiting
Pilot Trial to Determine the Feasibility of a One Step Sentinel Lymph Node Biopsy Procedure Using Radiolabeled Methylene Blue (IND 70,627) [NCT00784849]Phase 262 participants (Actual)Interventional2004-11-30Completed
Identification of Sentinel Lymph Node (SLN) in Breast Cancer Care: Clinical and Economical Evaluation of a Double Method Using Isotope and Methylene Blue Dye Injection. [NCT00314405]100 participants (Anticipated)Interventional2006-04-30Completed
Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria [NCT01657448]Phase 3316 participants (Actual)Interventional2016-06-27Completed
Open Label Randomized Controlled Trial Pharmacokinetic and Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency [NCT01668433]Phase 120 participants (Actual)Interventional2013-07-31Completed
Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 [NCT04376788]Phase 215 participants (Anticipated)Interventional2020-05-20Recruiting
Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue [NCT01823172]21 participants (Actual)Interventional2013-04-30Completed
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy [NCT01694966]Phase 31,249 participants (Actual)Interventional2013-09-30Completed
Effect of Oral Administration of Methylene Blue MMX Tablets on Double-stranded DNA Damage Assessed by GammaH2AX Analysis of Colon Biopsy Samples [NCT02295774]Phase 210 participants (Actual)Interventional2013-02-28Completed
Open Label Clinical Study to Evaluate the Safety and Efficacy of ProvayBlueTM (Methylene Blue) for the Treatment of Acquired Methemoglobinemia [NCT03395223]Phase 47 participants (Actual)Interventional2018-07-06Completed
Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial [NCT02851108]Phase 2100 participants (Actual)Interventional2016-10-31Completed
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease [NCT02380573]Phase 2117 participants (Actual)Interventional2015-07-31Active, not recruiting
A Phase 2 Study to Assess Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses [NCT06052956]Phase 260 participants (Anticipated)Interventional2024-05-31Not yet recruiting
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment [NCT03446001]Phase 3598 participants (Actual)Interventional2018-01-10Completed
The Influence of Endotracheal Tube Cuff Design on Intraoperative Microaspiration and Postoperative Respiratory Complications [NCT01539135]80 participants (Actual)Interventional2012-04-30Completed
Methylene Blue as a Third-line Vasopressor in Septic Shock to Maintain Hemodynamics [NCT04089072]Phase 2250 participants (Anticipated)Interventional2019-12-01Recruiting
What Should be the Next Vasopressor for Severe Septic Shock Patients? Methylene Blue or Terlipressin [NCT03038503]Phase 360 participants (Anticipated)Interventional2016-12-31Recruiting
Harmonic Generation Microscopy Observation of Intradermal Injection Nerve Fibers by Methylene Blue Intra-vital Staining [NCT05547685]5 participants (Anticipated)Interventional2020-04-10Recruiting
Evaluation of the Efficacy of Mixed Methylene Blue Compound Injection for the Treatment of Nonneoplastic Epithelial Disorders of Vulva. [NCT03200808]Phase 1118 participants (Actual)Interventional2013-10-01Completed
Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD) [NCT01188694]Phase 242 participants (Actual)Interventional2009-09-30Completed
Intraoperative Infusion of Methylene Blue for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac and Nonneurosurgical Surgery [NCT04341844]248 participants (Actual)Interventional2019-01-14Completed
COVID-19 Methylene Blue Antiviral Treatment [NCT05004805]Phase 224 participants (Actual)Interventional2021-08-06Completed
Bacterial Eradication of the Nasal Epithelium From Infectious Toxins With PDT (BENEFIT-PDT) [NCT05090657]Phase 2322 participants (Actual)Interventional2022-02-04Completed
Randomized Controlled Trial Comparing 4 Intervention Arms, Including 3 Different Concentrations of Methylene Blue Oral Rinse Combined With Conventional Therapy and Conventional Therapy, in Patients With Intractable Pain Associated With Oral Mucositis [NCT03469284]Phase 269 participants (Actual)Interventional2019-02-28Completed
A One-Period, Single-Dose, Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Injection USP Following a 1 mg/kg Intravenous Dose in Healthy Adult Volunteers [NCT02478281]Phase 112 participants (Actual)Interventional2012-10-31Completed
Gastric Cancer Sentinel Lymph Node Sampling: Refining Patient Selection for Organ Sparing Resection of Early Gastric Cancer in a North American Context [NCT03049345]40 participants (Anticipated)Interventional2016-07-01Recruiting
Effectiveness and Safety of Methylene Blue for Prevention of Postoperative Neurocognitive Disorders in Patients Undergoing Pancreatic Tumor Surgery: A Prospective Randomized Controlled Clinical Trial [NCT04529265]314 participants (Anticipated)Interventional2021-05-01Recruiting
A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections [NCT03178747]Phase 3150 participants (Anticipated)Interventional2017-03-07Recruiting
The Preventive Effects of Pre-treatment With Methylene Blue for Vascular Paralysis of the Patients With Obstructive Jaundice During Operation [NCT03406676]70 participants (Anticipated)Interventional2017-08-01Recruiting
The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients [NCT04370288]Phase 120 participants (Anticipated)Interventional2020-04-19Recruiting
Infrared Lymphangiography as a Method of Sentinel Node Identification [NCT02057393]89 participants (Actual)Interventional2014-06-30Completed
Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program [NCT01276054]Phase 24 participants (Actual)Interventional2010-12-31Terminated(stopped due to P.I. left)
Beneficial Effects of Methylene Blue on Human Cognitive and fMRI Measures [NCT01836094]Early Phase 136 participants (Actual)Interventional2013-08-31Completed
Comparison Between Intradermal Injection and Subcutaneous Injection With Methylene Blue for Sentinel Lymph Node Biopsy for Breast Cancer Patients [NCT02982148]Phase 4352 participants (Anticipated)Interventional2015-05-31Recruiting
Methylene Blue for the Prevention of Hypotension During Hemodialysis: a Randomized Open Label Trial [NCT05092165]Phase 2260 participants (Anticipated)Interventional2021-10-25Not yet recruiting
The Effect of Combination Therapy of Oral Methylene Blue and Platelet-rich Plasma-fibrin Glue in Patients With Non-healing Diabetic Foot Ulcer: a Pilot Study [NCT05850611]Early Phase 120 participants (Anticipated)Interventional2023-04-30Recruiting
Impact of Photodynamic Therapy as an Adjunct to Non-surgical Periodontal Treatment on Clinical and Biochemical Parameters Among Patients Having Mild Rheumatoid Arthritis With Periodontitis [NCT05122117]50 participants (Actual)Interventional2019-03-04Completed
Prospective Case Series on a Combination Methylene Blue, Gentian Violet, and Ovine Forestomach-derived Extracellular Matrix Dressing for Hidradenitis Suppurativa [NCT04354012]Phase 25 participants (Actual)Interventional2021-02-04Active, not recruiting
A Randomized, Placebo-controlled Single-center Pilot Study of the Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia Undergoing Cardiac Surgery With Cardiopulmonary Bypass [NCT03446599]Phase 20 participants (Actual)Interventional2019-11-30Withdrawn(stopped due to Lack of funding)
FLuorescence Cholangiography Using Methylene Blue [NCT03386201]40 participants (Anticipated)Interventional2018-01-01Recruiting
Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial [NCT03120637]Phase 4111 participants (Actual)Interventional2017-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00070317 (2) [back to overview]False Negative Predictive Value (FNPV)
NCT00070317 (2) [back to overview]Sensitivity
NCT00784849 (3) [back to overview]Superficial Skin Necrosis
NCT00784849 (3) [back to overview]The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel Node(s)
NCT00784849 (3) [back to overview]Safety (Allergic Reaction to Blue Dye)
NCT01188694 (1) [back to overview]PTSD Symptom Severity-Interview (PSS-I)
NCT01386879 (6) [back to overview]Evaluation the Trachea and Vocal Cords at the Time of ETT Extubation to Determine Whether There is a Difference in the Amount of Mucosal Injury Between the 3 Types of ETT.
NCT01386879 (6) [back to overview]Evaluation of Bacterial Load of Secretions Collected Above Endotracheal Tube Cuff During Surgery
NCT01386879 (6) [back to overview]Evaluation of pH of Secretions Collected Above Endotracheal Tube Cuff During Surgery
NCT01386879 (6) [back to overview]Evaluation of Volume of Secretions Collected Above Endotracheal Tube Cuff During Surgery
NCT01386879 (6) [back to overview]Prevention of the Movement of Test Dye (Methylene Blue) From the Pharynx Into Patients' Trachea During Surgery
NCT01386879 (6) [back to overview]the Ease of Tracheal Intubation Following the Induction of General Anesthesia Among the 3 Types of ETT
NCT01539135 (4) [back to overview]Number of Participants With Dye Leakage
NCT01539135 (4) [back to overview]Length of Hospital Stay
NCT01539135 (4) [back to overview]Number of Participants With Unanticipated Intensive Care Unit Admission
NCT01539135 (4) [back to overview]Number of Participants With Postoperative Pneumonia
NCT01694966 (1) [back to overview]To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.
NCT02057393 (1) [back to overview]Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes
NCT02295774 (2) [back to overview]Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy
NCT02295774 (2) [back to overview]To Evaluate the Staining Quality Obtained With Oral Methylene Blue MMX® Tablets.
NCT02851108 (1) [back to overview]Change in Haemoglobin Compared to the Baseline
NCT03287219 (7) [back to overview]Bowel Cleansing Quality-Boston Bowel Preparation Score
NCT03287219 (7) [back to overview]Evaluation of Mucosal Staining Efficacy
NCT03287219 (7) [back to overview]Safety and Tolerability of Methylene Blue MMX as Determined Body Weight.
NCT03287219 (7) [back to overview]Safety and Tolerability of Methylene Blue MMX as Determined by AEs
NCT03287219 (7) [back to overview]Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Oxygen Saturation in Peripheral Blood)
NCT03287219 (7) [back to overview]Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Blood Pressure)
NCT03287219 (7) [back to overview]Safety and Tolerability of Methylene Blue MMX as Determined by Heart Rate
NCT03395223 (1) [back to overview]Number of Participants With and Without Concomitant Normalization of Blood Pressure
NCT03469284 (5) [back to overview]Change in Oral Function Burden (OFB) Scores
NCT03469284 (5) [back to overview]Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool
NCT03469284 (5) [back to overview]Morphine Equivalent Daily Doses (MEDD)
NCT03469284 (5) [back to overview]Pain Duration
NCT03469284 (5) [back to overview]World Health Organization Oral Mucositis Severity Grades
NCT04187053 (14) [back to overview]Number of Sites With Plaque Per Participant
NCT04187053 (14) [back to overview]Number of Sites With Plaque Per Participant
NCT04187053 (14) [back to overview]Levels of Immunologic Biomarkers in Peri-implant Sulcular Fluid (PISF) Sample as Assessed by Multiplexed Fluorescent Bead-based Immunoassay
NCT04187053 (14) [back to overview]Levels of Immunologic Biomarkers in Peri-implant Sulcular Fluid (PISF) Sample as Assessed by Multiplexed Fluorescent Bead-based Immunoassay
NCT04187053 (14) [back to overview]Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing
NCT04187053 (14) [back to overview]Number of Sites With Plaque Per Participant
NCT04187053 (14) [back to overview]Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing
NCT04187053 (14) [back to overview]Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing
NCT04187053 (14) [back to overview]Mean Probing Pocket Depth
NCT04187053 (14) [back to overview]Mean Probing Pocket Depth
NCT04187053 (14) [back to overview]Max Probing Pocket Depth
NCT04187053 (14) [back to overview]Max Probing Pocket Depth
NCT04187053 (14) [back to overview]Max Probing Pocket Depth
NCT04187053 (14) [back to overview]Mean Probing Pocket Depth

False Negative Predictive Value (FNPV)

The proportion of patients with FNPV among patients who tests as negative sentinel node, where FNPV is defined as a person who tests as negative sentinel node but who actually has lymph node metastases (NCT00070317)
Timeframe: At the time of Surgery

InterventionPercentage of participants (Number)
Diagnostic5.9

[back to top]

Sensitivity

Sensitivity is defined as the proportion of patients who test as positive sentinel node among the patients who have lymph node metastases. (NCT00070317)
Timeframe: At the time of surgery

InterventionPercentage of participants (Number)
Diagnostic85.7

[back to top]

Superficial Skin Necrosis

the number of participants who developed post-operative skin necrosis within 2 weeks of surgery (NCT00784849)
Timeframe: 2 weeks postoperatively

Interventionparticipants (Number)
Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue2

[back to top]

The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel Node(s)

(NCT00784849)
Timeframe: intraoperatively; up to 6 hours

Interventionparticipants (Number)
RadioactiveBlueRadioactive and BlueEfferent blue lymphatics leading up to the SLN
Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue5855550

[back to top]

Safety (Allergic Reaction to Blue Dye)

number of participants who had a systemic allergic reaction such as hives, shortness of breath, hypotension (NCT00784849)
Timeframe: intraoperatively up to 6 hours

Interventionparticipants (Number)
Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue0

[back to top]

PTSD Symptom Severity-Interview (PSS-I)

PTSD Symptom Scale - Interview Version, higher scores represent higher PTSD severity (range 0 - 51) (NCT01188694)
Timeframe: Pre-treatment, post-treatment (4 weeks from pre-), 1-month follow-up (from post-), and 3-month follow-ups (from post-)

,,
Interventionunits on a scale (Mean)
Pre-TreatmentPost-Treatment1 Month Follow-up3 Month Follow-up
Delayed Psychotherapy32.7329.6028.337.25
Psychotherapy Plus Methylene Blue, USP32.0717.1010.337.63
Psychotherapy Plus Placebo31.3814.6713.3310.93

[back to top]

Evaluation the Trachea and Vocal Cords at the Time of ETT Extubation to Determine Whether There is a Difference in the Amount of Mucosal Injury Between the 3 Types of ETT.

number of patients with mucosal injury and blood below the vocal cords (NCT01386879)
Timeframe: 4 hours

InterventionParticipants (Count of Participants)
TaperGuard Evac ETT10
Teleflex ISIS ETT11
Standard ETT7

[back to top]

Evaluation of Bacterial Load of Secretions Collected Above Endotracheal Tube Cuff During Surgery

Secretions will be continuously suctioned from the suction port of the two ETT with suction above the cuff port (TaperGard Evac ETT and Teleflex ISIS ETT) into a Luken's trap. The number of patients with a bacterial load of the aspirate between two ETT with suction above the cuff port was measured by gram stain of the aspirated secretions. (NCT01386879)
Timeframe: 4 hours

InterventionParticipants (Count of Participants)
TaperGuard Evac ETT13
Teleflex ISIS ETT13

[back to top]

Evaluation of pH of Secretions Collected Above Endotracheal Tube Cuff During Surgery

Secretions will be continuously suctioned from the suction port of the two ETT with suction above the cuff port (TaperGard Evac ETT and Teleflex ISIS ETT) into a Luken's trap. We will evaluate whether there is a difference in the pH of the aspirate between two ETT with suction above the cuff port. (NCT01386879)
Timeframe: 4 hours

InterventionpH (Mean)
TaperGuard Evac ETT7.38
Teleflex ISIS ETT7.29

[back to top]

Evaluation of Volume of Secretions Collected Above Endotracheal Tube Cuff During Surgery

Secretions will be continuously suctioned from the suction port of the two ETT with suction above the cuff port (TaperGard Evac ETT and Teleflex ISIS ETT) into a Luken's trap. (NCT01386879)
Timeframe: 4 hours

InterventionmL (Mean)
TaperGuard Evac ETT13.00
Teleflex ISIS ETT26.00

[back to top]

Prevention of the Movement of Test Dye (Methylene Blue) From the Pharynx Into Patients' Trachea During Surgery

The primary objective of the pilot study is to evaluate whether there is a difference between the 3 types of ETT in preventing the movement of test dye (methylene blue) from the pharynx into the trachea, past the inflated cuff. After tracheal intubation a small amount of methylene blue will be instilled into patients' pharynx every 60 minutes. The presence or absence of blue dye above and below the ETT cuff will be evaluated every 20 minutes using a video recording fiberoptic bronchoscope. (NCT01386879)
Timeframe: 4 hours

Interventionnumber of participants with dye (Number)
TaperGuard Evac ETT0
Teleflex ISIS ETT0
Standard ETT2

[back to top]

the Ease of Tracheal Intubation Following the Induction of General Anesthesia Among the 3 Types of ETT

Time to intubate trachea (NCT01386879)
Timeframe: 1 hour

Interventionminutes (Mean)
TaperGuard Evac ETT7.53
Teleflex ISIS ETT7.59
Standard ETT7.41

[back to top]

Number of Participants With Dye Leakage

Blue dye will be instilled above the endotracheal tube cuff immediately after intubation where it will remain for the duration of the surgery. The presence of dye leakage past the endotracheal tube cuff will be determined via analysis of bronchoscopic images taken at the end of the surgical procedure when surgical closure has begun. (NCT01539135)
Timeframe: Duration of surgical procedure - from 2 to 12 hours

Interventionparticipants (Number)
Hi-Lo Endotracheal Tube3
TaperGuard Endotracheal Tube2

[back to top]

Length of Hospital Stay

Time of readiness for discharge from PACU, defined as when an Aldrete score of greater than or equal to 8 is given, to the time at which discharge (from the hospital) orders are written. The inpatient period may extend up to 72 hours. (NCT01539135)
Timeframe: Time from discharge from PACU to discharge from hospital up to 72 hours

Interventionhours (Mean)
Hi-Lo Endotracheal Tube42.4
TaperGuard Endotracheal Tube34.9

[back to top]

Number of Participants With Unanticipated Intensive Care Unit Admission

Incidence of unscheduled Intensive Care Unit admission after surgery and length of ICU stay if applicable. (NCT01539135)
Timeframe: Time from discharge from PACU to discharge from hospital up to 72 hours

Interventionparticipants (Number)
Hi-Lo Endotracheal Tube3
TaperGuard Endotracheal Tube3

[back to top]

Number of Participants With Postoperative Pneumonia

Diagnosis of postoperative pneumonia during the 30 day follow up period after surgery (NCT01539135)
Timeframe: Up to 30 days after surgery

Interventionparticipants (Number)
Hi-Lo Endotracheal Tube1
TaperGuard Endotracheal Tube0

[back to top]

To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.

Adenoma Detection Rate (NCT01694966)
Timeframe: +7 days

Interventionpercentage of participants (Number)
Methylene Blue MMX® 200mg56.3
Methylene Blue MMX® 100mg51.5
Placebo47.8

[back to top]

Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes

The primary outcome measure is the accuracy of indocyanine green (ICG) and real time lymphangiography to identify sentinel nodes (SLN) in patients with melanoma, compared to tech99 and methylene blue. Tech99 is considered the standard, for comparison. Accuracy is being determined by the number of sentinel nodes that are identified with ICG, compared to tech99 or methylene blue. (NCT02057393)
Timeframe: 2 weeks

Interventionnumber of sentinel nodes per patient (Mean)
Indocyanine Green1.87

[back to top]

Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy

Assay of gamma H2AX histone phosphorylation in biopsy samples collected during colonoscopy. (NCT02295774)
Timeframe: 2 weeks

Interventionsubject biopsies that tested + for γH2AX (Number)
MB MMX 200mg0

[back to top]

To Evaluate the Staining Quality Obtained With Oral Methylene Blue MMX® Tablets.

"Staining quality (SC) observed in each colonic region, in the FAS set (N=10); mean (±SD) is reported for SC.~SC is ranked as follows:~0 no staining~traces (poor traces in colon mucosa)~detectable (at least the 25% of colon mucosa is stained)~acceptable (at least the 50% of colon mucosa is stained)~good (at least the 75% of colon mucosa is stained)~overstained ( the 100% of the colon mucosa is over stained)" (NCT02295774)
Timeframe: During the colonoscopy

InterventionUnits on a 6 point scale (Mean)
Ascending colonTransverse colonDescending colonRectosigmoid
MB MMX 200mg2.93.22.72.2

[back to top]

Change in Haemoglobin Compared to the Baseline

Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden) (NCT02851108)
Timeframe: 7 days

Interventiong/dl (Mean)
AS-AQ-MB0.18
AS-AQ-PQ0.54

[back to top]

Bowel Cleansing Quality-Boston Bowel Preparation Score

"Bowel cleansing quality evaluated according to the validated Boston Bowel Preparation Scale (BBPS).~Colon was divided into 4 target regions: ascending colon (AC), transverse colon (TC), descending colon (DC) and rectosigmoid (RES). Methylene blue staining efficacy was assessed scoring the observed staining percentage as reported below for each colon region:~0 - no staining~- traces (poor traces in colon mucosa)~- detectable (at least the 25% of colon mucosa is stained)~- acceptable (at least the 50% of colon mucosa is stained)~- good (at least the 75% of colon mucosa is stained)~- over stained ( the 100% of the colon mucosa is over stained)" (NCT03287219)
Timeframe: One day- bowel cleansing quality is assessed during the colonoscopy procedure

InterventionColon cleansing score (Mean)
150 mg Methylene Blue-MMX Tablets5.4
200 mg Methylene Blue-MMX Tablets5.4
Overall5.4

[back to top]

Evaluation of Mucosal Staining Efficacy

"Mucosal staining efficacy of Methylene Blue MMX tablets after total oral doses of 150 or 200 mg.~Methylene blue staining efficacy was assessed by scoring the observed percentage of staining as reported below for each colon region (AC, TC, DC, RES) 0 - no staining~- traces (poor traces in colon mucosa)~- detectable (at least the 25% of colon mucosa is stained)~- acceptable (at least the 50% of colon mucosa is stained)~- good (at least the 75% of colon mucosa is stained)~- over stained ( the 100% of the colon mucosa is over stained) After scoring (SC) separately each colonic segment, the total staining score (TSC) was also calculated and the number of regions with an SC>2 (NSA) was determined.~For each patient, the best effective TSC was set at 16, when SC=4 was detected in all 4 regions. SC=5 detected in any region and TSC>16, both denoting an overstaining of the mucosa, were defined as suboptimal results in colon staining." (NCT03287219)
Timeframe: One day- mucosal staining efficacy is assessed during the colonoscopy procedure

Interventionscores on a scale (Mean)
A (Dose:150mg)6.8
B (Dose:150mg)2.3
C (Dose:150mg)8.1
D (Dose:200mg)7.0
E (Dose:200mg)9.8
F (Dose:200mg)10.5
G (Dose 200mg)10.5
H (Dose:200mg)10.0
I (Dose:200mg)11.4
J (Dose:200mg)11.6

[back to top]

Safety and Tolerability of Methylene Blue MMX as Determined Body Weight.

safety and tolerability of Methylene Blue MMX in relation to incidence of treatment emergent by body weight. (NCT03287219)
Timeframe: until study completion (until 2 days after dose)

InterventionKg (Mean)
Visit 1-Screening 150mL67.2
Visit 1-Screening 200mL71.3
Visit 2-Final 150mL67.4
Visit 2-Final 200mL71.2

[back to top]

Safety and Tolerability of Methylene Blue MMX as Determined by AEs

Safety and tolerability of Methylene Blue MMX® tablets after administration of total oral doses of 150 or 200 mg.AEs were assessed throughout the study. (NCT03287219)
Timeframe: Until study completion (until 2 days after dose)

InterventionParticipants (Count of Participants)
Pre Colonoscopy - 150mg Dose3
Pre Colonoscopy- 200mg Dose3
During Colonoscopy- 150mg Dose0
During Colonoscopy- 200mg Dose0
Post Colonoscopy- 150mg Dose0
Post Colonoscopy- 200mg Dose0

[back to top]

Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Oxygen Saturation in Peripheral Blood)

safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (Oxygen Saturation in peripheral blood) (NCT03287219)
Timeframe: until study completion (until 2 days after dose)

Interventionpercentage of saturation (Mean)
Pre Colonoscopy - 150mg Dose98.4
Pre Colonoscopy- 200mg Dose98.7
During Colonoscopy- 150mg Dose98.4
During Colonoscopy- 200mg Dose98.8
Post Colonoscopy- 150mg Dose98.4
Post Colonoscopy- 200mg Dose98.8

[back to top]

Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Blood Pressure)

safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (blood pressure) (NCT03287219)
Timeframe: until study completion (until 2 days after dose)

,,,,,
InterventionmmHg (Mean)
Systolic Blood Pressure (mmHg)Diastolic Blood Pressure(mmHg)
During Colonoscopy- 150mg Dose122.674.9
During Colonoscopy- 200mg Dose124.374.0
Post Colonoscopy- 150mg Dose122.775
Post Colonoscopy- 200mg Dose124.274.0
Pre Colonoscopy - 150mg Dose122.674.7
Pre Colonoscopy- 200mg Dose124.374.0

[back to top]

Safety and Tolerability of Methylene Blue MMX as Determined by Heart Rate

incidence of treatment emergent by measurement of vital signs (heart rate) to determine Safety and Tolerability of Methylene Blue MMX (NCT03287219)
Timeframe: until study completion (until 2 days after dose)

Interventionbeats per minute (BPM) (Mean)
Pre Colonoscopy - 150mg Dose73.9
Pre Colonoscopy- 200mg Dose75.2
During Colonoscopy - 150mg Dose74.3
During Colonoscopy- 200mg Dose75.3
Post Colonoscopy- 150mg Dose74.2
Post Colonoscopy- 200mg Dose7.1

[back to top]

Number of Participants With and Without Concomitant Normalization of Blood Pressure

Normalization of blood pressure standard values within 2 hours of the first dose of ProvayBlue. The normal range used for systolic blood pressure was was 90-140 mm HG and the normal range used for diastolic blood pressure was 60-90 mm HG. (NCT03395223)
Timeframe: 2 hours

InterventionParticipants (Count of Participants)
Systolic BP72172164Diastolic BP72172164
normalized within 2 hours of the first dose of ProN/A (Normal at baseline or no measurement within 2
ProvayBlue (Methylene Blue) Arm2
ProvayBlue (Methylene Blue) Arm0
ProvayBlue (Methylene Blue) Arm5
ProvayBlue (Methylene Blue) Arm1
ProvayBlue (Methylene Blue) Arm6

[back to top]

Change in Oral Function Burden (OFB) Scores

Oral functioning (eat, swallow, talk: unable=2, difficulty=1, able=0. Oral functioning score is the total score of 3 categories, ranged 0-6). Scale is included in the Modified Harris mucositis-related pain assessment tool. Measurements are obtained at day 0, 1, 2, and 7. Modified Harris mucositis-related pain assessment tool. Lowest value=0 representing normal. Highest value =6 representing worst outcome. (NCT03469284)
Timeframe: Baseline up to day 7

Interventionscore on a scale (Mean)
Conventional Therapy (Controlled Arm)0.81
Conventional Therapy + Methylene Blue (MB) 0.025%2.47
Conventional Therapy + Methylene Blue (MB) 0.05%2.79
Conventional Therapy + Methylene Blue (MB) 0.1%2.87

[back to top] [back to top]

Morphine Equivalent Daily Doses (MEDD)

"Morphine equivalent daily dose (MEDD) used for oral mucositis pain at 2 post MB administration.~Before the study was implemented, it was observed that many patients had pain resolved just within a few doses. Therefore, the study aimed to cover only 100 cc of MB, which typically last about 2 days. Some patients requested more MB after the two days which had to be provided by the pharmacy and ordered by the primary team and paid by patient insurance. This was considered out of the study, but the patients were still followed. Also, there was no average, only self-reported level of pain from the patient at point of data collection." (NCT03469284)
Timeframe: Baseline to Day 2

Interventionmg (Median)
Conventional Therapy (Controlled Arm)117.5
Conventional Therapy + Methylene Blue (MB) 0.025%115
Conventional Therapy + Methylene Blue (MB) 0.05%107
Conventional Therapy + Methylene Blue (MB) 0.1%120

[back to top]

Pain Duration

Measured the days the patient was in pain. The study aimed to cover only 100 cc of MB, which typically last about 2 days. Some patients requested more MB after the two days which had to be provided by the pharmacy and ordered by the primary team and paid by patient insurance. This was considered out of the study, but the patients were still followed. We followed for 30-90 days (no treatment for 30-90 days), only to observe for AEs. Also, there was no average, only self-reported level of pain from the patient at point of data collection. (NCT03469284)
Timeframe: Up to 30-90 days

Interventiondays (Median)
Conventional Therapy (Controlled Arm)5.5
Conventional Therapy + Methylene Blue (MB) 0.025%8
Conventional Therapy + Methylene Blue (MB) 0.05%6
Conventional Therapy + Methylene Blue (MB) 0.1%5

[back to top]

World Health Organization Oral Mucositis Severity Grades

"Used the WHO grading system (0= no mucositis, 3=severe mucositis) The clinical severity of the OM was documented only at enrollment point to the study. Most of the patients had the grade 3 mucositis (Soreness/erythema + ulceration + ability to use a liquid diet only), per World Health Organization criteria. See table below which indicates the description of the various grades.~Grade Description 0 No changes~Soreness/erythema~Soreness/erythema + ulceration + ability to eat solid foods~Soreness/erythema + ulceration + ability to use a liquid diet only~Secondary endpoint included oral functioning burden (0=normal, 6= worse oral function) (OFB; measured on a scale of 0, representing normal, to 6, meaning total inability, reflecting a total score of three categories: the ability to eat, swallow, and talk, each scored as unable = 2, difficult = 1, able = 0)." (NCT03469284)
Timeframe: Up to day 2

,,,
InterventionParticipants (Count of Participants)
Grade 2Grade 3
Conventional Therapy (Controlled Arm)115
Conventional Therapy + Methylene Blue (MB) 0.025%015
Conventional Therapy + Methylene Blue (MB) 0.05%113
Conventional Therapy + Methylene Blue (MB) 0.1%411

[back to top]

Number of Sites With Plaque Per Participant

Presence of plaque was evaluated at six sites (mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual) around the implant surface and the presence of plaque will be recorded. (NCT04187053)
Timeframe: 6 weeks post treatment

Interventionsites with plaque (Mean)
Conventional Mechanical Therapy With aPDT Adjunct3.19
Conventional Mechanical Therapy With Sham aPDT Treatment2.86

[back to top]

Number of Sites With Plaque Per Participant

Presence of plaque was evaluated at six sites (mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual) around the implant surface and the presence of plaque will be recorded. (NCT04187053)
Timeframe: Baseline

Interventionsites with plaque (Mean)
Conventional Mechanical Therapy With aPDT Adjunct4.06
Conventional Mechanical Therapy With Sham aPDT Treatment4.07

[back to top]

Levels of Immunologic Biomarkers in Peri-implant Sulcular Fluid (PISF) Sample as Assessed by Multiplexed Fluorescent Bead-based Immunoassay

PISF samples will be taken from six sites of each implant at baseline and 12 weeks after aPDT. The levels of interleukin IL-1a, IL-1b, IL-6, IL-8, IL-10, IL-12, IL-7A, tumor necrosis factor (TNF)-a, C-reactive protein, osteoprotegerin, leptin, and adiponectin will be determined using multiplex proteomic immunoassays. (NCT04187053)
Timeframe: 12 weeks

,
Interventionpicograms per milliliter (Mean)
IL-1alphaIL-1betaIL-6IL-8IL-10IL-12tumor necrosis factor (TNF)-alpha
Conventional Mechanical Therapy With aPDT Adjunct97.91444.1124.431691.3410.651.334.53
Conventional Mechanical Therapy With Sham aPDT Treatment94.97177.1325.331478.703.171.303.52

[back to top]

Levels of Immunologic Biomarkers in Peri-implant Sulcular Fluid (PISF) Sample as Assessed by Multiplexed Fluorescent Bead-based Immunoassay

PISF samples will be taken from six sites of each implant at baseline and 12 weeks after aPDT. The levels of interleukin IL-1a, IL-1b, IL-6, IL-8, IL-10, IL-12, IL-7A, tumor necrosis factor (TNF)-a, C-reactive protein, osteoprotegerin, leptin, and adiponectin will be determined using multiplex proteomic immunoassays. (NCT04187053)
Timeframe: Baseline

,
Interventionpicograms per milliliter (Mean)
IL-1alphaIL-1betaIL-6IL-8IL-10IL-12tumor necrosis factor (TNF)-alpha
Conventional Mechanical Therapy With aPDT Adjunct74.13391.2426.051283.363.201.304.06
Conventional Mechanical Therapy With Sham aPDT Treatment42.49324.8739.881134.662.371.373.82

[back to top]

Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing

Bleeding on probing (BOP) will be assessed, where each of 6 gingival areas (mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual) around each tooth will be gently swept by the periodontal probe just within the gingival sulcus of the implant and the presence or absence of bleeding will be recorded. (NCT04187053)
Timeframe: Baseline

InterventionBleeding sites (Mean)
Conventional Mechanical Therapy With aPDT Adjunct4.42
Conventional Mechanical Therapy With Sham aPDT Treatment3.53

[back to top]

Number of Sites With Plaque Per Participant

Presence of plaque was evaluated at six sites (mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual) around the implant surface and the presence of plaque will be recorded. (NCT04187053)
Timeframe: 12 weeks post treatment

Interventionsites with plaque (Mean)
Conventional Mechanical Therapy With aPDT Adjunct3.13
Conventional Mechanical Therapy With Sham aPDT Treatment3.12

[back to top]

Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing

Bleeding on probing (BOP) will be assessed, where each of 6 gingival areas (mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual) around each tooth will be gently swept by the periodontal probe just within the gingival sulcus of the implant and the presence or absence of bleeding will be recorded. (NCT04187053)
Timeframe: 6 weeks post treatment

InterventionBleeding sites (Mean)
Conventional Mechanical Therapy With aPDT Adjunct3.11
Conventional Mechanical Therapy With Sham aPDT Treatment2.13

[back to top]

Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing

Bleeding on probing (BOP) will be assessed, where each of 6 gingival areas (mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual) around each tooth will be gently swept by the periodontal probe just within the gingival sulcus of the implant and the presence or absence of bleeding will be recorded. (NCT04187053)
Timeframe: 12 weeks post treatment

InterventionBleeding sites (Mean)
Conventional Mechanical Therapy With aPDT Adjunct3.2
Conventional Mechanical Therapy With Sham aPDT Treatment2.51

[back to top]

Mean Probing Pocket Depth

Periodontal pocket depth was measured from the free gingival margin to the base of the pocket, with a UNC periodontal probe with 1mm measurement units. It was assessed at 6 sites per implant: mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual. For each participant, an average of the depths of the 6 sites is reported. (NCT04187053)
Timeframe: Baseline

Interventionmillimeters (Mean)
Conventional Mechanical Therapy With aPDT Adjunct4.62
Conventional Mechanical Therapy With Sham aPDT Treatment4.45

[back to top]

Mean Probing Pocket Depth

Periodontal pocket depth was measured from the free gingival margin to the base of the pocket, with a UNC periodontal probe with 1mm measurement units. It was assessed at 6 sites per implant: mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual. For each participant, an average of the depths of the 6 sites is reported. (NCT04187053)
Timeframe: 6 weeks post treatment

Interventionmillimeters (Mean)
Conventional Mechanical Therapy With aPDT Adjunct3.92
Conventional Mechanical Therapy With Sham aPDT Treatment3.54

[back to top]

Max Probing Pocket Depth

Periodontal pocket depth was measured from the free gingival margin to the base of the pocket, with a UNC periodontal probe with 1mm measurement units. It was assessed at 6 sites per implant: mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual. For each participant, the depth of the deepest of the 6 sites is reported. (NCT04187053)
Timeframe: Baseline

Interventionmillimeters (Mean)
Conventional Mechanical Therapy With aPDT Adjunct6.16
Conventional Mechanical Therapy With Sham aPDT Treatment6.34

[back to top]

Max Probing Pocket Depth

Periodontal pocket depth was measured from the free gingival margin to the base of the pocket, with a UNC periodontal probe with 1mm measurement units. It was assessed at 6 sites per implant: mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual. For each participant, the depth of the deepest of the 6 sites is reported. (NCT04187053)
Timeframe: 6 weeks post treatment

Interventionmillimeters (Mean)
Conventional Mechanical Therapy With aPDT Adjunct5.23
Conventional Mechanical Therapy With Sham aPDT Treatment4.16

[back to top]

Max Probing Pocket Depth

Periodontal pocket depth was measured from the free gingival margin to the base of the pocket, with a UNC periodontal probe with 1mm measurement units. It was assessed at 6 sites per implant: mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual. For each participant, the depth of the deepest of the 6 sites is reported. (NCT04187053)
Timeframe: 12 weeks post treatment

Interventionmillimeters (Mean)
Conventional Mechanical Therapy With aPDT Adjunct5.53
Conventional Mechanical Therapy With Sham aPDT Treatment4.76

[back to top]

Mean Probing Pocket Depth

Periodontal pocket depth was measured from the free gingival margin to the base of the pocket, with a UNC periodontal probe with 1mm measurement units. It was assessed at 6 sites per implant: mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual, and mesiolingual. For each participant, an average of the depths of the 6 sites is reported. (NCT04187053)
Timeframe: 12 weeks post treatment

Interventionmillimeters (Mean)
Conventional Mechanical Therapy With aPDT Adjunct4.02
Conventional Mechanical Therapy With Sham aPDT Treatment3.63

[back to top]